

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83729 A2

(51) International Patent Classification⁷: C12N 15/00

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).

(21) International Application Number: PCT/EP01/04863

(22) International Filing Date: 30 April 2001 (30.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/562,934 1 May 2000 (01.05.2000) US

(71) Applicants: NOVARTIS AG [CH/CH]; Schwarzwalldallee 215, CH-4058 Basel (CH). THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicants and

(72) Inventors: NEMEROW, Glen, R. [US/US]; 462 Cerro Street, Encinitas, CA 92024 (US). VON SEGGERN, Daniel, J. [US/US]; Apartment 30, 5175 Luigi Terrace, San Diego, CA 92122 (US). FRIEDLANDER, Marty [US/US]; 1720 Zapo Street, Del Mar, CA 92014 (US).



WO 01/83729 A2

(54) Title: VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

(57) Abstract: Adenovirus vector-based gene therapy methods for treating ocular disorders are provided. Adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene therapy are provided.

VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

Work described herein was supported by NIH grants EY11431 and HL54352. The government has certain rights in such subject matter.

5 RELATED APPLICATIONS

This application claims the benefit of priority to U.S. application Serial No. 09/562,934, filed May 1, 2000, to Glen R. Nemerow, Daniel Von Seggern,; Martin Friedlander, entitled "VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY".

- 10 This application is related to copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000)), to Daniel Von Seggern, Glen R. Nemerow, Paul Hallenbeck, Susan Stevenson, Yelena Skripchenko, filed January 14, 2000, entitled "Adenovirus Vectors, Packaging Cell Lines, Compositions, and
- 15 Methods for Preparation and Use," which is a continuation-in-part of U.S. Application 09/423,783 filed November 12, 1999 and claims the benefit of the filing date of U.S. Provisional Application 60/115,920 filed January 14, 1999. Where permitted, the contents and subject matter of each application and of the provisional application are incorporated in their entirety herein by reference.

20 FIELD OF INVENTION

- The present invention relates to gene therapy, especially to adenovirus vector-based gene therapy. In particular, adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene
- 25 therapy are provided.

BACKGROUND OF THE INVENTION

Retinal dystrophies

- The eye is susceptible to a number of hereditary and/or age related degenerative disorders. In the United States, common causes of irreversible
- 30 blindness or severe loss of vision are retinal dystrophies (see, *e.g.*, Cotlier *et al.* (1995) *Surv. Ophthalmology* 40:51-61; Bird (1995) *Am. J. Ophthalm.* 119: 543-562; and Adler (1996) *Arch Ophthalm* 114:79-83). The retina is the sensory

-2-

tunic of the eye, containing light sensitive receptors, a complex of neurons, and pigmented epithelium, arranged in discrete layers. In humans, the macula is the portion of the retina that lies directly behind the lens. Cones, the photoreceptor cells responsible for central vision, are heavily concentrated in the macula.

- 5 Central dystrophies, which affect the macula, include Best's disease, age-related macular degeneration, and Stargardt's macular dystrophy. The peripheral retina is composed mainly of rods, which are responsible for side and night vision. Peripheral degenerative retinal diseases include retinitis pigmentosa, choroidemia and Bietti's crystalline dystrophy.

- 10 Macular degenerations are a heterogenous group of diseases, characterized by progressive central vision loss and degeneration of the macula and underlying retinal pigmented epithelium. Age-related macular degeneration (ARMD) is the most common form of the disease, affecting an estimated 20% of persons over 75 years of age. ARMD is poorly understood in terms of etiology and pathogenesis. The very late onset of the disease has made genetic mapping particularly difficult. Certain macular degenerative conditions with a clear genetic basis, such as Stargardt's and Best's diseases, share many features with ARMD, but have been more amenable to molecular and genetic analysis.

- Hereditary peripheral retinopathies are also relatively common. Retinitis pigmentosa (RP), for example, affects approximately 1.5 million people worldwide. Substantial genetic heterogeneity has been observed in this condition, with over 20 chromosomal loci identified. A predisposition to retinitis pigmentosa can be inherited by autosomal dominant, autosomal recessive, X-linked or digenic mode. Mutations have been identified in seven genes, four of which encode proteins in the rod phototransduction cascade: rhodopsin, alpha and beta subunits of rod cGMP phosphodiesterase, and rod cGMP-cation-gated channel protein .alpha. subunit. Mutations in the peripherin/RDS gene have been linked to retinitis pigmentosa and macular degeneration. A single peripherin/RDS mutation apparently caused retinitis pigmentosa, pattern dystrophy and fundus flavimaculatus, in different family members.
- 20
25
30

In spite of causal heterogeneity, there is significant clinical similarity among RP subtypes. Common signs and symptoms include early electroretinographic abnormalities, ophthalmoscopic findings, and protracted, contiguous expansion of the ring-like scotoma toward the macula, leading to progressively worsening tunnel vision. A recent hypothesis is that active photoreceptor cell death, which is characteristic of these genetically distinct disorders, is mediated by a common induction of apoptosis. It may be possible to treat these conditions by the administration of agents that block induction of apoptosis in photoreceptors, such as neurotrophic factors.

10 Adenovirus delivery vectors

Adenovirus, which is a DNA virus with a 36 kilobase (kb) genome, is very well-characterized and its genetics and genetic organization are understood. The genetic organization of adenoviruses permits substitution of large fragments of viral DNA with foreign DNA. In addition, recombinant adenoviruses are structurally stable and no rearranged viruses are observed after extensive amplification.

Adenoviruses have been employed as delivery vehicles for introducing desired genes into eukaryotic cells. The adenovirus delivers such genes to eukaryotic cells by binding to cellular receptors followed by internalization. The adenovirus fiber protein is responsible for binding to cells. The fiber protein has two domains, a rod-like shaft portion and a globular head portion that contains the receptor binding region. The fiber spike is a homotrimer, and there are 12 spikes per virion. Human adenoviruses bind to and infect a broad range of cultured cell lines and primary tissues from different species.

The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described (see, *e.g.*, Neumann *et al.*, *Gene* 69: 153-157 (1988); Herisse *et al.*, *Nuc. Acids Res.* 9: 4023-4041 (1981); Roberts *et al.*, *J. Biol. Chem.* 259: 13968-13975 (1984); Kinloch *et al.*, *J. Biol. Chem.* 259: 6431-6436 (1984); and Chroboczek *et al.*, *Viol.* 161: 549-554, 1987).

-4-

The 35,935 bp sequence of Ad5 DNA is also known and portions of many other adenovirus genomes have been sequenced. The upper packaging limit for adenovirus virions is about 105% of the wild-type genome length (see, *e.g.*, Bett, *et al.*, *J. Virol.* 67(10): 5911-21, 1993). Thus, for Ad2 and Ad5, this would be an upper packaging limit of about 38kb of DNA.

Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats permit single strands of viral DNA to circularize by base-pairing of their terminal sequences to form base-paired "panhandle" structures that are required for replication of the viral DNA.

For efficient packaging, the ITRs and the packaging signal (a few hundred bp in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential *cis* elements (the ITRs and contiguous packaging sequence) have been constructed.

Ad vectors have several distinct advantages as gene delivery vehicles. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins. Adenovirus (Ad)-based gene delivery vectors efficiently infect many different cells and tissues. This broad tropism, however, means that gene delivery cannot be directed to a specific target cell. A large fraction of intravenously administered adenovirus is retained by the liver, which could lead to undesirable side-effects. Adenovirus may potentiate immune responses. For example, Adenovirus type 5 (Ad5) also transduces dendritic cells, which present antigens very efficiently, thereby possibly exacerbating the immune response against the vector. It has been proposed that vectors with different targeting efficiencies might eliminate these problems, permitting a lower total particle dose and more specific targeting (see, *e.g.*, U.S. application Serial No. 09/482,682).

The wealth of information on adenovirus structure and mechanism of infection, its efficient infection of nondividing cells, and its large genetic capacity make adenovirus a popular gene therapy vector. The wide expression of receptors to which adenovirus binds makes targeting adenovirus vectors
5 difficult.

Hence there is a need to improve delivery and targeting of adenoviral vectors and also to provide treatments for ocular disorders. Therefore, it is an object herein to provide adenoviral vectors that specifically or selectively target cells in the eye. It is also an object herein to provide these vectors for treatment
10 of ocular disorders.

SUMMARY OF THE INVENTION

Degenerative ocular diseases, such as, but not limited to, retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, and others (see, *e.g.*, Table below), have a genetic basis. Genes expressed in
15 the photoreceptor cells at the back of the retina are implicated in these diseases. Provided herein are recombinant viral vectors for targeting therapeutic products to these cells.

Recombinant adenoviral vectors that include nucleic acid that permits specific binding to these photoreceptors are provided. In particular, the vector
20 particles contain a fiber protein of Ad37 or a modified form thereof. As shown herein, fiber protein from Ad37 permits efficient infection of photoreceptor cells. Fiber proteins from other adenovirus D serotypes may also be used. In addition, the portions of the fiber protein, particularly those that interact with other viral structural proteins, such as penton, may be modified to resemble the viral source
25 of the other structural proteins. As exemplified herein, the recombinant virus provided herein include Ad5 structural components. The N-terminus of the Ad37 fiber protein, which interacts with the penton protein, is modified to resemble the Ad5 fiber protein N-terminus to ensure production of viral particles.

The recombinant adenoviral vectors are intended for gene therapy of
30 diseases in which genes expressed in the photoreceptors are implicated. Such diseases include, but are not limited to, degenerative ocular diseases, such as retinitis pigmentosa and Stargardt's disease. These vectors are also useful for

-6-

targeting to other ocular cells, such as conjunctival cells, which also bear receptors to which fiber from Ad37 and related serotypes bind.

The vectors will deliver therapeutic agents to the targeted cells for treatment of a variety of disorders (see *e.g.*, Tables 3 and 4, below)). The therapeutic agents are intended for expression in the photoreceptors and for secretion from the photoreceptor cells, which are surrounded on one side by choroidal vasculature, and on the other side by retinal vasculature, thereby providing a means for delivery of products. In addition, expression of growth factors, such as VEGF and others, can be used to enhance blood flow to the retina and prevent or slow the degeneration.

Therapeutic agents encoded by the recombinant adenoviral vectors include, but are not limited to, nucleic acid molecules encoding genes that are defective in certain hereditary disorders, nucleic acid molecules that encode antiangiogenics and antitumor agents for treatment of retinal disorders, such as retinoblastomas; nucleic acid molecules encoding trophic factors, such as glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF), growth factors and growth factor inhibitors, antiapoptotic factors, such as Bcl-2 (CNTF), antitumor agents, anti-angiogenics, and genes or portions thereof for gene replacement or repair of defective genes. Hence, methods for treatment of inherited and acquired retinal diseases, including diseases involving neovascular and vascular degeneration are provided.

Methods for treating diseases involving genes expressed in photoreceptor cells are provided herein. The methods provided herein are practiced by administration of the recombinant viral vectors by any means suitable for delivery to the photoreceptors. A preferred mode of administration is intraocular injection including intravitreal and subretinal injection. Other modes of administration include, but are not limited to, intrascleral, periorbital and intravenous administration. The vectors also can include photoreceptor-specific promoters thereby providing a means, not only for specific targeting of expression in these cells, but also for photoreceptor-restricted transgene expression.

DETAILED DESCRIPTION OF THE INVENTION**A. DEFINITIONS**

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, applications, published applications and other publications and sequences from GenBank and other data bases referred to anywhere in the disclosure herein are incorporated by reference in their entirety.

As used herein, the amino acids, which occur in the various amino acid sequences appearing herein, are identified according to their three-letter or one-letter abbreviations. The nucleotides, which occur in the various DNA fragments, are designated with the standard single-letter designations used routinely in the art (see, Table 1).

As used herein, amino acid residue refers to an amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. In keeping with standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 C.F.R. § 1.821 - 1.822, abbreviations for amino acid residues are shown in the following Table:

25

Table 1
Table of Correspondence

SYMBOL		
1-Letter	3-Letter	AMINO ACID
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine

30

-8-

SYMBOL		
A	Ala	alanine
S	Ser	serine
I	Ile	isoleucine
L	Leu	leucine
T	Thr	threonine
V	Val	valine
P	Pro	proline
K	Lys	lysine
H	His	histidine
Q	Gln	glutamine
E	Glu	glutamic acid
Z	Glx	Glu and/or Gln
W	Trp	tryptophan
R	Arg	arginine
D	Asp	aspartic acid
N	Asn	asparagine
B	Asx	Asn and/or Asp
C	Cys	cysteine
X	Xaa	Unknown or other

It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of Correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. § § 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or

-9-

more amino acid residues or to an amino-terminal group such as NH₂ or to a carboxyl-terminal group such as COOH.

In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. *Molecular Biology of the Gene*, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p.224).

Such substitutions are preferably made in accordance with those set forth in TABLE 2 as follows:

TABLE 2		
	Original residue	Conservative substitution
15	Ala (A)	Gly; Ser
	Arg (R)	Lys
	Asn (N)	Gln; His
	Cys (C)	Ser
	Gln (Q)	Asn
20	Glu (E)	Asp
	Gly (G)	Ala; Pro
	His (H)	Asn; Gln
	Ile (I)	Leu; Val
	Leu (L)	Ile; Val
25	Lys (K)	Arg; Gln; Glu
	Met (M)	Leu; Tyr; Ile
	Phe (F)	Met; Leu; Tyr
	Ser (S)	Thr
	Thr (T)	Ser
30	Trp (W)	Tyr
	Tyr (Y)	Trp; Phe
	Val (V)	Ile; Leu

Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions.

As used herein, a complementing plasmid describes plasmid vectors that deliver nucleic acids into a packaging cell line for stable integration into a chromosome in the cellular genome.

As used herein, a delivery plasmid is a plasmid vector that carries or delivers nucleic acids encoding a therapeutic gene or gene that encodes a

-10-

therapeutic product or a precursor thereof or a regulatory gene or other factor that results in a therapeutic effect when delivered *in vivo* in or into a cell line, such as, but not limited to a packaging cell line, to propagate therapeutic viral vectors.

5 As used herein, a variety of vectors with different requirements are described. For example, one vector is used to deliver particular nucleic acid molecules into a packaging cell line for stable integration into a chromosome. These types of vectors are generally identified herein as complementing plasmids. A further type of vector described herein carries or delivers nucleic
10 acid molecules in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating therapeutic viral vectors; hence, these vectors are generally referred to herein as delivery plasmids. A third "type" of vector described herein is used to carry nucleic acid molecules encoding therapeutic proteins or polypeptides or regulatory proteins or are regulatory sequences to specific cells or cell types in a
15 subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or recombinant adenoviral vectors or viral Ad-derived vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette for expressing the therapeutic gene.

As used herein, a DNA or nucleic acid homolog refers to a nucleic acid
20 that includes a preselected conserved nucleotide sequence, such as a sequence encoding a therapeutic polypeptide. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith or a lesser percentage of homology or identity and conserved biological activity or function.

25 The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443 (1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482
30 (1981)). Briefly, the GAP program defines similarity as the number of aligned symbols (*i.e.*, nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default

-11-

parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE*
5 *AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

Whether any two nucleic acid molecules have nucleotide sequences that
10 are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988). Alternatively the BLAST function of the
15 National Center for Biotechnology Information database may be used to determine identity.

In general, sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics*
20 *and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).
25 While there exist a number of methods to measure identity between two polynucleotides or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge
30 Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred

-12-

computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(II):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., *et al.*, *J Molec Biol* 215:403 (1990)).

5 Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the
10 reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons may be made between a test and
15 reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or
20 deletions.

As used herein, genetic therapy involves the transfer of heterologous DNA to the certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The DNA is introduced into the selected target cells in a manner such that the heterologous DNA is
25 expressed and a therapeutic product encoded thereby is produced. Alternatively, the heterologous DNA may in some manner mediate expression of DNA that encodes the therapeutic product, it may encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy may also be used to deliver nucleic
30 acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid may encode a therapeutic compound, such as a growth

-13-

factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding the therapeutic product may be modified
5 prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, heterologous DNA is DNA that encodes RNA and proteins that are not normally produced *in vivo* by the cell in which it is expressed or that mediates or encodes mediators that alter expression of endogenous DNA by
10 affecting transcription, translation, or other regulatable biochemical processes. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which it is expressed is herein encompassed by heterologous DNA. Examples of heterologous DNA include, but are not limited to, DNA that encodes
15 traceable marker proteins, such as a protein that confers drug resistance, DNA that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and DNA that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous DNA may be secreted or expressed on the surface of the cell in which the heterologous DNA has been
20 introduced.

Hence, herein heterologous DNA or foreign DNA, refers to a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in the corresponding wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (*i.e.*, exogenous) or
25 from another Ad serotype.

As used herein, a therapeutically effective product is a product that is encoded by heterologous DNA that, upon introduction of the DNA into a host, a product is expressed that effectively ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures said disease.
30 Typically, DNA encoding the desired heterologous DNA is cloned into a plasmid vector and introduced by routine methods, such as calcium-phosphate mediated DNA uptake (see, (1981) Somat. Cell. Mol. Genet. 7:603-616) or

-14-

microinjection, into producer cells, such as packaging cells. After amplification in producer cells, the vectors that contain the heterologous DNA are introduced into selected target cells.

As used herein, an expression or delivery vector refers to any plasmid or virus into which a foreign or heterologous DNA may be inserted for expression in a suitable host cell — *i.e.*, the protein or polypeptide encoded by the DNA is synthesized in the host cell's system. Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors that allow cloning of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.

As used herein, a gene is a nucleic acid molecule whose nucleotide sequence encodes RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

As used herein, tropism with reference to an adenovirus refers to the selective infectivity or binding that is conferred on the particle by the fiber protein, such as by the C-terminus portion that comprises the knob.

As used herein, isolated with reference to a nucleic acid molecule or polypeptide or other biomolecule means that the nucleic acid or polypeptide has separated from the genetic environment from which the polypeptide or nucleic acid were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compound can be substantially purified by the one-step method described in

-15-

Smith and Johnson, *Gene* 67:31-40 (1988). The terms *isolated* and *purified* are sometimes used interchangeably.

Thus, by "isolated" is meant that the nucleic acid is free of the coding sequences of those genes that, in the naturally-occurring genome of the organism (if any) immediately flank the gene encoding the nucleic acid of interest. Isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.

Isolated or purified as it refers to preparations made from biological cells or hosts means any cell extract containing the indicated DNA or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.

A preparation of DNA or protein that is "substantially pure" or "isolated" should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure" should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.

A cell extract that contains the DNA or protein of interest should be understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term "cell extract" is intended to include culture media, especially spent culture media from which the cells have been removed.

As used herein, a packaging cell line is a cell line that provides a missing gene product or its equivalent.

As used herein, an adenovirus viral particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of

-16-

particles or a viral genome. The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures.

As used herein, "penton" or "penton complex" are preferentially used herein to designate a complex of penton base and fiber. The term "penton" may
5 also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

As used herein, a plasmid refers to an autonomous self-replicating extrachromosomal circular nucleic acid molecule, typically DNA.

10 As used herein, a post-transcription regulatory element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages. Examples include, but are not limited to, human hepatitis virus, woodchuck hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA
15 sequence.

As used herein, pseudotyping describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing an Ad37 fiber protein. This may be
20 accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.

As used herein, promoters of interest herein may be inducible or constitutive. Inducible promoters will initiate transcription only in the presence of an additional molecule; constitutive promoters do not require the presence of
25 any additional molecule to regulate gene expression. a regulatable or inducible promoter may also be described as a promoter where the rate or extent of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include, but are not limited to various compounds or compositions, light, heat, stress and chemical energy sources. Inducible, suppressible and repressible
30 promoters are considered regulatable promoters. Preferred promoters herein, are promoters that are selectively expressed in ocular cells, particularly photoreceptor cells.

-17-

As used herein, receptor refers to a biologically active molecule that specifically or selectively binds to (or with) other molecules. The term "receptor protein" may be used to more specifically indicate the proteinaceous nature of a specific receptor.

5 As used herein, recombinant refers to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.

As used herein, a transgene or therapeutic nucleic acid molecule includes DNA and RNA molecules encoding an RNA or polypeptide. Such molecules may
10 be "native" or naturally-derived sequences; they may also be "non-native" or "foreign" that are naturally- or recombinantly-derived. The term "transgene," which may be used interchangeably herein with the term "therapeutic nucleic acid molecule," is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.

15 Therefore, therapeutic nucleotide nucleic acid molecules include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) all include nucleic acid molecules that function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic
20 nucleic acid molecule can include a sequence of nucleotides that encodes a functional protein intended for delivery into a cell which is unable to produce that functional protein.

As used herein, the vitreous of the eye refers to material that fills the chamber behind the lens of the eye (i.e., vitreous humor or vitreous body).

25 As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of the DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region
30 includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be *cis* acting or

-18-

may be responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.

Thus, promoters are nucleic acid fragments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the promoter. The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter. A promoter also includes DNA sequences that direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance efficiency of expression.

A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. (see, e.g., U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Regulatable promoters may also include tissue-specific promoters. Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then it is expressed appropriately in the correct cell types (see, e.g., Palmiter et al. (1986) Ann. Rev. Genet. 20: 465-499).

As used herein, the phrase "operatively linked" generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form, whereby control sequences on one segment control expression or replication or other such control of other segments. The two segments are not necessarily contiguous.

-19-

As used herein, exogenous encompasses any therapeutic composition that is administered by the therapeutic methods provided herein. Thus, exogenous may also be referred to herein as foreign, or non-native or other equivalent expression.

5 B. Ad37 fiber tropism

The adenovirus fiber protein is a major determinant of adenovirus tropism (Gall *et al.* (1996) *J. Virol.* 70:2116-2123; Stevenson *et al.* (1995) *J. Virol.* 69:2850-2857). The fiber protein extends from the capsid and mediates viral binding to the cell surface by binding to specific cell receptors (Philipson *et al.* 10 (1968) *J. Virol.* 2:1064-1075). The fiber is a trimeric protein that includes an N-terminal tail domain that interacts with the adenovirus penton base, a central shaft domain of varying length, and a C-terminal knob domain that contains the cell receptor binding site (Chroboczek *et al.* (1995) *Curr.Top.Microbiol.Immunol.* 199:163-200; Riurok *et al.* (1990) *J.Mol.Biol.* 215:589-596; Stevenson *et al.* 15 (1995) *J. Virol.* 69:2850-2857). Fiber proteins of most adenovirus subgroups have been shown to bind specifically or selectively to the 46 kDa coxsackievirus-adenovirus receptor (CAR), (Bergelson *et al.* (1997) *Science* 275:1320-1323; Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). CAR appears to be expressed in a variety of human tissues, including the lung, at various levels (Bergelson *et al.* 20 (1997) *Science* 275:1320-1323), but Ad37 binds poorly to lung epithelial cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). This suggests that the tropism of this serotype may be influenced by factors independent of CAR expression.

Structural and biochemical data also suggest that distinct receptor binding sites are located on different regions of the Ad5 and Ad37 fiber knobs.

25 Adopting the nomenclature of Xia *et al.* (Xia *et al.* (1994) *Structure* 2:1259-1270), the receptor binding site for Ad5 is located at the AB-loop on the side of the fiber knob (Bewley *et al.* (1999) *Science* 286:1579-1583; Roelvink *et al.* (1999) *Science* 286:1568-1571). It is known that a lysine residue at position 240 of the Ad37 fiber, located in the CD-loop, is important for receptor binding 30 (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). The co-crystal structure of the Ad12 knob and the N-terminal domain of CAR (Bewley *et al.* (1999) *Science* 286:1579-1583) show that the CD-loop does not contact CAR. It thus appears

-20-

that different regions of the Ad5 and Ad37 fiber knobs recognize distinct cell receptors.

A 46 kDa receptor for coxsackieviruses and adenoviruses (CAR) mediates attachment for many adenovirus serotypes. The wide distribution of CAR fails to explain why certain adenovirus serotypes (i.e. Ad37) are highly associated with severe ocular infections such as epidemic keratoconjunctivitis (EKC). Ad37 does not use CAR, but instead uses a glycoprotein that contains sialic acid as its primary receptor (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). The modest number of Ad37 binding sites per cell (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) also suggests that Ad37 recognizes a specific glycoprotein as its primary receptor for binding to conjunctival cells.

Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract. The tropism of Ad37 derives from the binding preference of its fiber protein, which binds to a receptor located on the surface of cells including Chang C, conjunctival epithelial cell line (Huang *et al.* (1999) *J. Virology* 73:2798-2802).

A protein receptor that is preferentially expressed on conjunctival cells to which Ad37 fiber binds is shown herein. The preferential expression of the Ad37 receptor protein on conjunctival cells suggests that this receptor likely influences Ad37 tropism and should play a key role in ocular pathogenesis. It is shown herein that Ad37 uses a distinct protein receptor that is selectively expressed on conjunctival cells. It is shown that Ad37 binds well to conjunctival cells (Chang C), but poorly to lung carcinoma cells (A549). To determine if infection correlated with cell binding, an Ad5 vector containing the Ad37 fiber protein was constructed. The 'pseudotyped' vector delivered transgenes to Chang C cells better than to A549 cells. Ad37 binding was abolished by protease treatment of Chang C cells, indicating the receptor is a membrane protein. Ad37 binding to conjunctival cells is shown herein to be calcium-dependent. It is also shown that Ad37 infection was not inhibited by a function-blocking anti-CAR monoclonal antibody, which is a feature distinct from Ad5 fiber interaction with CAR. Using a virus overlay protein blot assay (VOPBA), calcium-dependent Ad37 binding to a 50 KDa membrane protein on Chang C

-21-

cells, but not A549 cells was detected. Ad19p a closely related serotype that fails to bind to conjunctival cells, does not recognize the 50 kDa protein. Together, these data indicate that the 50 kDa protein is a candidate receptor for Ad37 on conjunctival cells.

- 5 Significantly, it is also shown herein that, upon administration of the vector to the vitreous humor, the recombinant adenovirus with the Ad37 fiber preferentially and selectively binds to photoreceptor cells. Hence, a recombinant adenoviral delivery vehicle that has an Ad37 fiber protein can serve as a vector for delivery of therapeutic agents to the eye for treatment of ocular disorders,
- 10 including genetic and acquired disorders. The identification of the receptor for Ad37 and the resulting recognition of Ad37 tropism allows targeting of adenovirus vectors to specific human ocular cells.

- As noted, fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on a cell surface. Hexon, penton and fiber
- 15 capsomeres are the major components on the surface of the virion. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber includes three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that
- 20 forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus (see, *e.g.*, Hong and Engler,
- 25 *Virology* 185: 758-761, 1991). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery.

- As shown herein, alteration of fiber in recombinant Ad vectors such that the fiber is derived from Ad37 or another adenovirus serotype D, provides a means for selective delivery of a recombinant virus to particular cells in the eye,
- 30 including conjunctival cells, and most significantly photoreceptors, thereby providing a means for targeted delivery to photoreceptor cells.

-22-

Photoreceptor cells are implicated in a number of hereditary and acquired retinal degenerative disorders. In addition, photoreceptor cells are located such that products produced therein can be delivered to other areas of the eye by virtue of the blood flow in the vicinity of the photoreceptor cells and also by virtue of the proximity of the photoreceptors to the retinal pigmented epithelium (RPE) and other retinal cells.

Hence it is contemplated herein that the recombinant viral vector will include a packaged recombinant adenovirus genome containing at least the minimal elements for replication and packaging; heterologous DNA encoding a desired gene product, typically a therapeutic product or plurality of products, such as several trophic factors, whose combined activity is effective for treating a disorder, such as a retinal degenerative disorder; and the resulting virion particles will include a fiber that has a sufficient portion to confer specific targeting to photoreceptor cells when the recombinant viral particles are introduced into the aqueous humor of a mammalian, preferably a human, eye, or otherwise contacted with the photoreceptor cells. The fiber may be a chimeric protein that has been modified for effective interaction with other coat structural proteins, such as penton. In addition, the fiber may be modified to include other elements that alter its tropism to permit binding to other cells as well (see, e.g., U.S. Patent Nos. 5,756,086 and 5,543,328, International PCT application No. WO 95/26412 and WO 98/44121 and Krasnykh, *et al.* (*J. Virol.* 70: 6839-46, 1996).

C. Construction of the viral particles

1. Selection of viral genome and fiber protein

Methods for preparing recombinant adenoviral vectors for gene product delivery are well known. Preferred among those are the methods exemplified herein (see EXAMPLES) and also described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265, filed January 14, 2000, which claims priority to U.S. provisional application Serial No. 60/115,920, as does U.S. application Serial No. 09/482,682)).

-23-

As noted, any desired recombinant adenovirus is contemplated for use in the methods herein as long as the viral genome is packaged in a capsid that includes at least the portion of a fiber protein that provides selective binding to photoreceptor cells. This fiber protein is preferably from an adenovirus type D serotype and is preferably an Ad37 fiber. The fiber protein should retain the knob region at the C-terminus ("head domain") from the Ad virus of subgroup D that contains the type-specific antigen and is responsible for binding to the cell surface receptor. Hence the fiber protein can be a chimeric fiber protein as long as it retains a sufficient portion of the type D serotype to specifically or selectively bind to photoreceptor cells. Generally the portion retained will be all or a portion of the knob region. The precise amount of knob region required can be determined empirically by including portions thereof and identifying the minimum residues from an Ad type D serotype, preferably Ad37, to effect selective targeting of a virion packaged with such fiber to photoreceptors in the eye upon introduction of the packaged virion into the aqueous humor.

Recombinant adenovirus containing heterologous nucleic acids that encode a desired product, such as a gene to correct a genetic defect, may be made by any methods known to those of skill in the art. The viruses must be packaged in a cell line that results in expression of fiber on the particles that specifically, electively or preferentially targets (binds and results in internalization) the viral particle to cells in the eye. The fiber protein from Ad37 and other Adenoviruses of serotype D that infect the eye effects such targeting. The resulting adenovirus particles that express such fiber is administered by intraocular injection, subretinal injection, particularly intravitreal injection, or any means that results in preferential accumulation in photoreceptor cells.

The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) as well as members of the genus Mastadenovirus including human, simian, bovine, equine, porcine, ovine, canine and opossum viruses and members of the Aviadenovirus genus, including bird viruses, such as CELO.

-24-

Thus it is contemplated that the methods herein can be applied to any recombinant viral vectors derived from any adenovirus species. One of skill in the art would have knowledge of the different adenoviruses (see, *e.g.*, Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) and can construct recombinant viruses containing portions of the genome of any such virus.

In the exemplified embodiment, viral particles with Ad37 fiber were prepared. Site-directed mutations were made to the Ad37 fiber gene to make the tail sequence more closely match that of Ad5 to facilitate Ad37 fiber binding to the Ad5 penton base. The plasmid for the expression of the Ad37 fiber protein, pDV80, contains the CMV promoter, the adenovirus type 5 tripartite leader (TPL), and the modified Ad37 fiber gene sequence. Genes of interest, such as nucleic acid encoding the β subunit of cGMP phosphodiesterase (β PDE), β -glucuronidase, rhodopsin, growth factors, anti-cancer agents, growth factor receptors and other anti-angiogenic agents, and anti-apoptotic agents, can be incorporated into these vectors using the methods known to those of skill in the art and exemplified herein.

Known adenovirus vectors, previously constructed for intraocular therapy (see, *e.g.*, Bennett *et al.* (1996) *Nature Medicine* 2:649-654, which provides an Ad virus encoding β PDE for treatment of retinitis pigmentosa; Cayouette *et al.* (1998) *Human Gene Therapy* 8:423-430, which provides an Ad vector that expresses CNTF for treatment of retinitis pigmentosa and other retinal degenerative diseases; and Li *et al.* (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92:7700-7704, which provides an Ad virus vector that encodes a human β -glucuronidase for treatment of lysosomal storage disease caused by β -glucuronidase deficiency) can be modified by repackaging the recombinant genome using a packaging line that expresses an Ad37 fiber or other D serotype fiber.

For exemplification, nucleic acid encoding GFP was incorporated into these vectors as a means to visualize their localization. Other genes, such as genes that encode therapeutic products, may be included in place of or in addition to GFP.

-25-

Plasmid pDV80 was electroporated into E1-2a S8 cells and stable lines were selected. The fiber-deleted vectors Ad5. β gal. Δ F and Ad5.GFP. Δ F were grown in cells in a resulting cell line, designated 705, to produce virions, which express the Ad37 fiber (Ad5. β gal. Δ F/37F and Ad5.GFP. Δ F/37F) and CsCl-
5 purified. These virions selectively transduce photoreceptor cells when injected intraocularly into the vitreous humor.

2. Packaging

Recombinant adenoviral vectors generally have at least a deletion in the first viral early gene region, referred to as E1, which includes the E1a and E1b
10 regions. Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of
15 complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1
20 gene region products to "support" the growth of E1-deleted virus in the cell line (see, e.g., Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378).

Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106).

Copending U.S. application Serial No. 09/482,682 (also filed as
25 International PCT application No. PCT/US00/00265, filed January 14, 2000)) provides packaging cell lines that support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses and also provides cell lines and helper viruses for use with helper-dependent vectors. The packaging cell line has heterologous DNA stably integrated into the
30 chromosomes of the cellular genome. The heterologous DNA sequence encodes one or more adenovirus regulatory and/or structural polypeptides that complement the genes deleted or mutated in the adenovirus vector genome to

-26-

be replicated and packaged. The packaging cell line express, for example, one or more adenovirus structural proteins, polypeptides, or fragments thereof, such as penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof. The
5 expression can be constitutive or under the control of a regulatable promoter. These cell lines are designed for expression of recombinant adenoviruses intended for delivery of therapeutic products.

Particular packaging cell lines complement viral vectors having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein,
10 regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

The packaging cell lines are produced by introducing each DNA molecule into the cells and then into the genome via a separate complementing plasmid or plurality of DNA molecules encoding the complementing proteins can be
15 introduced via a single complementing plasmid. Of interest herein, is a variation in which the complementing plasmid includes DNA encoding adenovirus fiber protein (or a chimeric or modified variant thereof), from Ad virus of subgroup D, such as Ad 37, polypeptide or fragment thereof.

For therapeutic applications, the delivery plasmid further includes a
20 nucleotide sequence encoding a foreign polypeptide. Exemplary delivery plasmids include, but are not limited to, pDV44, p Δ E1B β -gal and p Δ E1sp1B. In a similar or analogous manner, therapeutic genes may be introduced.

The cell further includes a complementing plasmid encoding a fiber as contemplated herein; the plasmid or portion thereof is integrated into a
25 chromosome(s) of the cellular genome of the cell.

In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second
30 delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.

-27-

In a variation, the packaging cell line expresses fiber protein or chimeric variant thereof from an Ad virus of subgroup D, preferably Ad37, serotype or it can be any fiber protein but one that has been modified to include the portion of the Ad virus of subgroup D, such as Ad37, responsible for selective targeting to photoreceptors upon introduction into the vitreous humor of the eye of a mammal, preferably a human. The fiber protein can be further modified to include a non-native amino acid residue sequence that targets additional specific receptors. In all instances, the modification should not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. The structural protein is fiber can include amino acid residue sequences from more than one adenovirus serotype. The nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein, may be modified "internally" as well as at the termini.

Additional nucleic acid fragments can encode polypeptides that are added to the fiber protein. In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In another, the non-native amino acid residue sequence further includes a linker sequence.

Alternatively, the fiber protein further comprises a ligand coupled to the linker. Suitable ligands include, but are not limited to, ligands that specifically or selectively bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, the packaging cell lines will contain nucleic acid encoding the fiber protein or modified protein stably integrated into a chromosome or chromosomes in the cellular genome.

The packaging cell line can be derived from a procaryotic cell line or from a eukaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from among the 293, A549, W162, HeLa, Vero, 211, and 211A cell lines, and any other cell lines suitable for such use are likewise contemplated herein.

3. Components of the nucleic acid molecule included in the particle

-28-

A recombinant viral vector or therapeutic viral vector for use in the methods herein, typically includes a nucleic acid fragment that encodes a protein or polypeptide molecule, or a biologically active fragment thereof, or other regulatory sequence, that is intended for use in therapeutic applications.

5 The nucleic acid molecule to be packaged in the viral particle also may include an enhancer element and/or a promoter located 3' or 5' to and controlling the expression of the therapeutic product-encoding nucleic acid molecule if the product is a protein. Further, for purposes herein, the promoter and/or other transcriptional and translational regulatory sequences controlling
10 expression of the product is preferably one that is expressed specifically in the targeted cells, such as the a photoreceptor-specific promoter, such as a rhodopsin gene promoter.

The nucleic acid molecule to be packaged in viral capsid includes at least 2 different operatively linked DNA segments. The DNA can be manipulated and
15 amplified by PCR as described herein and by using standard techniques, such as those described in *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, Sambrook *et al.*, eds., Cold Spring Harbor, New York (1989). Typically, to produce such molecule, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous
20 replication in a cell either *in vivo* or *in vitro*. By operatively linking the enhancer element or promoter and nucleic acid molecule to the vector, the attached segments are replicated along with the vector sequences.

Thus, the recombinant DNA molecule (rDNA) is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in
25 nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof. The nucleic acid molecule intended to be packaged is from about 20 base pairs to about 40,000 base pairs in length, preferably about 50 bp to about 38,000 bp in length. In various embodiments, the nucleic acid molecule is of sufficient length
30 to encode one or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, encoding nucleic acid molecules

-29-

from about 50 bp up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic product-encoding nucleic acid molecules.

- Preferably the molecule includes an adenovirus tripartite leader (TPL)
- 5 nucleic acid sequence operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line. Most preferably the intron contains a splice donor site and a splice acceptor site. Alternatively, the TPL nucleotide sequence may not comprise an intron. The intron includes any sequence of
- 10 nucleotides that function in the packaging cell line to provide RNA processing signals, including splicing signals. Introns have been well characterized from a large number of structural genes, and include but are not limited to a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP intron; the rabbit beta-globin intron, and synthetic intron constructs (see,
- 15 *e.g.*, Petitclerc *et al.* (1995) *J. Biotechnol.*, 40:169; and Choi *et al.* (1991) *Mol. Cell. Biol.*, 11:3070).

- The nucleic acid molecule encoding the TPL includes either (a) first and second TPL exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from among the complete TPL exon 1, partial TPL
- 20 exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, Ad5, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples.
- 25 The use of a TPL with a partial exon 1 has been reported (International PCT application No. WO 98/13499).

- The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence. An intron may not be a part of the construct. For example, the intron can be positioned
- 30 between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment,

-30-

complete TPL exon 1 is operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral

5 systems such as rabiesvirus.

A preferred "complete" TPL nucleic acid molecule containing complete TPL exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an adenovirus TPL nucleotide sequence as described herein.

4. Complementing Plasmids

Also contemplated are the use of nucleic acid molecules, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein. Because these expression plasmids are used to complement the defective genes of a recombinant adenovirus vector genome, the plasmids are referred to as complementing or complementation plasmids.

The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product encoded by the nucleic acid molecule. Expression cassettes typically contain a promoter and a structural gene operatively linked to the promoter. The complementing plasmid can further include a sequence of nucleotides encoding TPL nucleotide to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.

30 A complementing plasmid can include a promoter operatively linked to a sequence of nucleotides encoding an adenovirus structural polypeptide, such as, but are not limited to, penton base; hexon; fiber; polypeptide IIIa; polypeptide V;

-31-

polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid may also include a sequence of nucleotides encoding a first adenovirus regulatory polypeptide, a second regulatory polypeptide, and/or a third regulatory polypeptide, and any combination of the foregoing.

Plasmid pDV80 is a preferred plasmid herein. Other plasmids constructed in an analogous manner to encode modified fiber proteins and chimeric fiber proteins are also contemplated herein.

5. Nucleic Acid Molecule Synthesis

A nucleic acid molecule comprising synthetic oligonucleotides can be prepared using any suitable method, such as the phosphotriester or phosphodiester methods (see, *e.g.*, Narang (1979) *et al.*, *Meth. Enzymol.*, 68:90; U.S. Patent No. 4,356,270; and Brown *et al.*, (1979) *Meth. Enzymol.*, 68:109). For oligonucleotides, the synthesis of the family members can be conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer. The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected nucleotide precursors to the solid phase oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants (see, *e.g.*, Ausubel *et al.* (*Current Protocols in Molecular Biology*, Suppl. 8. p.2.11.7, John Wiley & Sons, Inc., New York, 1991).

-32-

Nucleotide bases other than the common four nucleotides (A,T,G or C), or the RNA equivalent nucleotide uracil (U), can also be used. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be found referred to in 37 C.F.R. §1.822.

Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures are contemplated. The composition can contain four members, where a preselected position contains A,T,G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity to hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides in a manner similar to inosine.

Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and ligation, as is well known.

D. Adenovirus Expression Vector Systems

The adenovirus vector genome that is encapsulated in the virus particle and that expresses exogenous genes in a gene therapy setting is a key component of the system. Thus, the components of a recombinant adenovirus vector genome include the ability to express selected adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat containing an adenovirus origin of replication, as is well known and described herein.

-33-

Although adenovirus include many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector). Thus, deletion of the appropriate genes from a recombinant Ad vector permits accommodation of even larger "foreign" DNA segments.

5 A preferred recombinant adenovirus vector genome is "helper independent" so that genome can replicate and be packaged without the help of a second, complementing helper virus. Complementation is provided by a packaging cell.

10 In a preferred embodiment, the adenovirus vector genome does not encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is
15 referred to as a "fiberless" genome, not to be confused with a fiberless particle. Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.

 Thus, contemplated for use are helper-independent fiberless recombinant adenovirus vector genomes that include genes that (a) express all adenovirus
20 structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contain an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.

25 The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.

30 A vector herein includes a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, *e.g.*, a gene or polynucleotide, can be operatively linked to bring about replication of the

-34-

attached segment. For purposes herein, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule. As noted above, therapeutic nucleic acid molecules include those encoding proteins and also those that encode regulatory factors that can lead to expression or inhibition or alteration of expression of a gene product in a targeted cell.

1. Nucleic Acid Gene Expression Cassettes

In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized. Another preferred therapeutic viral vector includes a nucleotide sequence encoding at least a portion of a therapeutic nucleotide sequence operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.

The choice of viral vector into which a therapeutic nucleic acid molecule is operatively linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, vector replication and protein expression, and the host cell to be transformed -- these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the use of *any* adenovirus serotype, including hybrids and derivatives thereof are contemplated.

A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the nucleic acid material and any polypeptides that are to be inserted into the cell.

2. Promoters

As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector may also include a promoter, particularly a tissue or cell specific promoter, preferably one expressed in ocular cells, particularly photoreceptors.

5 Promoters contemplated for use herein include regulatable (inducible) as well as constitutive promoters, which may be used, either on separate vectors or on the same vector. Some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, *e.g.*, International PCT application No. WO
10 96/14061). Preferably the promoter selected is from a photoreceptor-specific gene, such as a rhodopsin gene or gene that encodes a protein that regulates rhodopsin expression.

E. Formulation and administration

Compositions containing therapeutically effective concentrations of
15 recombinant adenovirus delivery vectors are provided. These are for delivery of therapeutic gene products to cells, particularly cells express a particular 50 kDa receptor or other receptor with which the vectors interact. These cells include cells of the eye and genital tract. Of particular interest are photoreceptor cells of the eye. Administration is effected by any means through which contacting with
20 the photoreceptors is effected. Preferable modes of administration include, but are not limited to, subretinal injection, particularly intravitreal injection, to provide access to photoreceptor cells.

The recombinant viral compositions may also be formulated for
implantation into the anterior or posterior chamber of the eye, preferably the
25 vitreous cavity, in sustained released formulations, such as those adsorbed to biodegradable supports, including collagen sponges, or in liposomes. Sustained release formulations may be formulated for multiple dosage administration, so that during a selected period of time, such as a month or up to about a year, several dosages are administered. Thus, for example, liposomes may be
30 prepared such that a total of about two to up to about five or more times the single dosage is administered in one injection.

-36-

The vectors are formulated in an ophthalmologically acceptable carrier for intraocular, preferably intravitreal, administration in a volume of between about 0.05 ml and 0.150 ml, preferably about 0.05 and 0.100 ml.

The composition can be provided in a sealed sterile vial containing an amount of a compound of formula I, that upon intraocular administration will deliver a sufficient amount of viral particles to the photoreceptors in a volume of about 50 to 150 μ l, containing at least about 10^7 , more preferably at least about 10^8 plaque forming units in such volume. Typically, the vials will, thus, contain about 0.150 ml of the composition.

To prepare compositions the viral particles are dialyzed into a suitable ophthalmologically acceptable carrier or viral particles, for example, may be concentrated and/or mixed therewith. The resulting mixture may be a solution, suspension or emulsion. In addition, the viral particles may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active agents for the particular disorder treated.

For administration by intraocular injection or via eyedrops, suitable carriers include, but are not limited to, physiological saline, phosphate buffered saline (PBS), balanced salt solution (BSS), lactate Ringers solution, and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. Suitable ophthalmologically acceptable carriers are known. Solutions or mixtures intended for ophthalmic use may be formulated as 0.01% - 10% isotonic solutions, pH about 5-7, with appropriate salts [see, e.g., U.S. Patent No. 5,116,868, which describes typical compositions of ophthalmic irrigation solutions and solutions for local application]. Such solutions, which have a pH adjusted to about 7.4, contain, for example, 90-100 mM sodium chloride, 4-6 mM dibasic potassium phosphate, 4-6 mM dibasic sodium phosphate, 8-12 mM sodium citrate, 0.5-1.5 mM magnesium chloride, 1.5-2.5 mM calcium chloride, 15-25 mM sodium acetate, 10-20 mM D.L.-sodium β -hydroxybutyrate and 5-5.5 mM glucose.

-37-

The compositions may be prepared with carriers that protect them from rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and other types of implants that may be placed directly into the anterior or posterior chamber or vitreous cavity of the eye. The compositions may also be administered in pellets, such as Elvax pellets (ethylene-vinyl acetate copolymer resin).

10 Liposomal suspensions, including tissue-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. For example, liposome formulations may be prepared by methods known to those of skill in the art [see, e.g., Kimm *et al.* (1983) *Bioch. Bioph. Acta* 728:339-398; Assil *et al.* (1987) *Arch Ophthalmol.* 105:400; and U.S. Patent No. 4,522,811]. The viral particles
15 may be encapsulated into the aqueous phase of liposome systems.

The active materials can also be mixed with other active materials, that do not impair the desired action, or with materials that supplement the desired action or have other action, including viscoelastic materials, such as hyaluronic acid, which is sold under the trademark HEALON, which is a solution of a high
20 molecular weight (MW) of about 3 millions fraction of sodium hyaluronate [manufactured by Pharmacia, Inc; see, e.g., U.S. Patent Nos. 5,292,362, 5,282,851, 5,273,056, 5,229,127, 4,517,295 and 4,328,803], VISCOAT [fluorine-containing (meth)acrylates, such as, 1H,1H,2H,2H-hepta-decafluorodecylmethacrylate; see, e.g., U.S. Patent Nos. 5,278,126, 5,273,751
25 and 5,214,080; commercially available from Alcon Surgical, Inc.], ORCOLON [see, e.g., U.S. Patent No. 5,273,056; commercially available from Optical Radiation Corporation], methylcellulose, methyl hyaluronate, polyacrylamide and polymethacrylamide [see, e.g., U.S. Patent No. 5,273,751]. The viscoelastic materials are present generally in amounts ranging from about 0.5 to 5.0%,
30 preferably 1 to 3% by weight of the conjugate material and serve to coat and protect the treated tissues. The compositions may also include a dye, such as

-38-

methylene blue or other inert dye, so that the composition can be seen when injected into the eye. Additional active agents may be included.

The compositions can be enclosed in ampules, disposable syringes or multiple or single dose vials made of glass, plastic or other suitable material.

- 5 Such enclosed compositions can be provided in kits. In particular, kits containing vials, ampules or other containers, preferably disposable vials with sufficient amount of the composition to deliver about 0.100 ml thereof, and disposable needles, preferably self sealing 25-30 gauge needles, are provided herein.

- 10 Finally, the compounds may be packaged as articles of manufacture containing packaging material, typically a vial, an ophthalmologically acceptable composition containing the viral particles and a label that indicates the therapeutic use of the composition.

- Also provided are kits for practice of the methods herein. The kits
15 contain one or more containers, such as sealed vials, with sufficient composition for single dosage administration, and one or more needles, such as self sealing 25-33 gauge needles, preferably 33 gauge or smaller needles, precisely calibrated syringes or other precisely calibrated delivery device, suitable for intravitreal injection.

- 20 Administration of the composition is preferably by intraocular injection, although other modes of administration may be effective, if the sufficient amount of the compound achieves contact with the vitreous cavity. Intraocular injection may be effected by intravitreal injection, aqueous humor injection or injection into the external layers of the eye, such as subconjunctival injection or
25 subtenon injection, or by topical application to the cornea, if a penetrating formulation is used.

Administration

- The compositions containing the compounds are administered intraocularly or by other means, such as topically in the form of penetrating
30 eyedrops, whereby contact of the recombinant vectors with the aqueous humor is effected. Intraocular administration may be effected by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as

-39-

subconjunctival injection or subtenon injection, preferably in free form, but, alternatively, in liposomes or other sustained drug delivery device.

Administration is preferably by intravitreal injection, preferably through self sealing, 25-30 gauge needles or other suitably calibrated delivery device.

- 5 Injection into the eye may be through the pars plana via the self-sealing needle.

It is further understood that, for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the recombinant viruses, and that the concentration ranges set

- 10 forth herein are exemplary only and are not intended to limit the scope or practice of the claimed methods

F. Diseases, Disorders and therapeutic products

1. Disease and disorders

Retinitis pigmentosa

- 15 Methods for specifically or selectively targeting recombinant adenovirus vectors for delivery of gene products, particularly therapeutic products are provided herein. These methods are particularly suitable for targeting cells that express receptors that are selectively recognized by Ad virus of subgroup D viruses, particularly Ad37. It is shown herein that these viruses selectively
- 20 recognize receptors on cells, such as conjunctival cells and photoreceptors, that are not recognized by other adenoviruses. Hence, methods for targeting to these cell types by providing vectors that are packaged in viral particles that contain a sufficient portion of a fiber protein from one of these Ad serotypes to bind to these receptors. These methods are useful for targeting to
- 25 photoreceptors and for treating ocular disorders, including, but are not limited to, inherited and acquired retinal, neovascular degenerative diseases (see table below).

- It is estimated that 1 in 3,500 individuals in the United States suffer from one of the pigmented retinopathies. This group of retinal diseases, commonly
- 30 called retinitis pigmentosa, is characterized by progressive loss of peripheral and night vision. Patients may be affected at almost any age and it is not uncommon to experience symptoms in early childhood in certain inherited forms.

-40-

It has been shown that there are a variety of mutations in genes expressed in the photoreceptors, including genes in the rhodopsin gene and pathway that appear to be responsible for these diseases. In addition to mutations in rhodopsin, changes in the retinal pigmented epithelial (RPE) cells, also undergo
5 degenerative changes and can form clumps of pigment that give rise to the characteristic pigmentary changes seen in patients with RP.

Angiogenesis and ocular diseases and disorders

The vast majority of diseases that cause catastrophic loss of vision do so as a result of ocular neovascularization; age related macular degeneration
10 (ARMD) affects 12-15 million American over the age of 65 and causes visual loss in 10-15% of them as a direct effect of choroidal (sub-retinal) neovascularization. The leading cause of visual loss for Americans under the age of 65 is diabetes; 16 million individuals in the United States are diabetic and 40,000 per year suffer from ocular complications of the disease, which often are
15 a result of retinal neovascularization. Laser photocoagulation has been effective in preventing severe visual loss in subgroups of high risk diabetic patients, but the overall 10 year incidence of retinopathy remains essentially unchanged. For patients with choroidal neovascularization due to ARMD or inflammatory eye disease, such as ocular histoplasmosis, photocoagulation, with few exceptions,
20 is ineffective in preventing visual loss. While recently developed, non-destructive photodynamic therapies hold promise for temporarily reducing individual loss in patients with previously untreatable choroidal neovascularization, only 61.4% of patients treated every 3-4 months had improved or stabilized vision compared to 45.9% of the placebo-treated group.
25 In the normal adult, angiogenesis is tightly regulated and limited to wound healing, pregnancy and uterine cycling. Angiogenesis is turned on by specific angiogenic molecules such as basic and acidic fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiogenin, transforming growth factor (TGF), tumor necrosis factor- α (TNF- α) and platelet derived growth factor
30 (PDGF). Angiogenesis can be suppressed by inhibitory molecules such as interferon- α , thrombospondin-1, angiostatin and endostatin. It is the balance of these naturally occurring stimulators and inhibitors that controls the normally

-41-

quiescent capillary vasculature. When this balance is upset, as in certain disease states, capillary endothelial cells are induced to proliferate, migrate and ultimately differentiate.

Angiogenesis plays a central role in a variety of diseases, including, but
5 are not limited to, cancer and ocular neovascularization. Sustained growth and metastasis of a variety of tumors has also been shown to be dependent on the growth of new host blood vessels into the tumor in response to tumor derived angiogenic factors. Proliferation of new blood vessels in response to a variety of stimuli occurs as the dominant finding in the majority of eye diseases that blind,
10 such as, but are not limited to, proliferative diabetic retinopathy (PDR), ARMD, rubeotic glaucoma, interstitial keratitis and retinopathy of prematurity. In these diseases, tissue damage can stimulate release of angiogenic factors resulting in capillary proliferation. VEGF plays a dominant role in iris neovascularization and neovascular retinopathies. While reports clearly show a correlation between
15 intraocular VEGF levels and ischemic retinopathic ocular neovascularization, FGF likely plays a role. Basic and acidic FGF are known to be present in the normal adult retina, even though detectable levels are not consistently correlated with neovascularization. This may be largely due to the fact that FGF binds very tightly to charged components of the extracellular matrix and may not be readily
20 available in a freely diffusible form that would be detected by standard assays of intraocular fluids.

A final common pathway in the angiogenic response involves integrin-mediated information exchange between a proliferating vascular endothelial cell and the extracellular matrix. This class of adhesion receptors, called integrins,
25 are expressed as heterodimers having an α and β subunit on all cells. One such integrin, $\alpha_v\beta_3$, is the most promiscuous member of this family and allows endothelial cells to interact with a wide variety of extracellular matrix components. Peptide and antibody antagonists of this integrin inhibit angiogenesis by selectively inducing apoptosis of the proliferating vascular
30 endothelial cells. Two cytokine-dependent pathways of angiogenesis exist and may be defined by their dependency on distinct vascular cell integrins, $\alpha_v\beta_3$ and $\alpha_v\beta_5$. Specifically, basic FGF- and VEGF-induced angiogenesis depend on integrin

-42-

$\alpha_v\beta_3$ and $\alpha_v\beta_5$, respectively, since antibody antagonists of each integrin selectively block one of these angiogenic pathways in the rabbit corneal and chick chorioallantoic membrane (CAM) models. Peptide antagonists that block all α_v integrins inhibit FGF- and VEGF-stimulated angiogenesis. While normal human ocular blood vessels do not display either integrin, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins are selectively displayed on blood vessels in tissues from patients with active neovascular eye disease. While only $\alpha_v\beta_3$ was consistently observed in tissue from patients with ARMD, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ were present in tissues from patients with PDR. Systemically administered peptide antagonists of integrins blocked new blood vessel formation in a mouse model of retinal vasculogenesis.

In addition to adhesion events described above, cell migration through the extracellular matrix also depends on proteolysis. Matrix metalloproteinases are a family of zinc-requiring matrix-degrading enzymes that include the collagenases, gelatinases and stromelysins, all of which have been implicated in invasive cell behavior. Invasive cell processes such as tumor metastasis and angiogenesis have been found to be associated with the expression of integrins and MMP-2, MMP-2 are all found throughout the eye where they may interact to maintain a quiescent vasculature until the balance is upset, resulting in pathological angiogenesis. A non-catalytic C-terminal hemopexin-like domain of MMP-2 (PEX) can block cell surface collagenolytic activity and inhibit angiogenesis in the CAM model by preventing localization of MMP-2 to the surface of invasive cells through interaction with the integrin $\alpha_v\beta_3$.

Hence, anti-angiogenic agents have a role in treating retinal degeneration to prevent the damaging effects of these trophic and growth factors. Angiogenic agents, also have a role in promoting desirable vascularization to retard retinal degeneration by enhancing blood flow to cells.

Members of adenovirus subgroup D, Ad8, 19A, and 37, are infectious agents that cause particularly severe cases of epidemic keratoconjunctivitis (EKC) (Arnberg *et al.* (1998) *Virology* 227:239-244; Curtis *et al.* (1998) *J. Med. Microbiol.* 47:91-94; Ritterband *et al.* (1998) *Rev. Med. Virol.* 8:187-201; and Takeuchi *et al.* (1999) *J. Clin. Microbiol.* 37:3392-3394). There is no effective treatment for this debilitating and contagious disease and EKC

-43-

continues to be a problem in ophthalmology clinics worldwide (Curtis *et al.* (1998) *J. Med. Microbiol.* 47:91-94, Lukashok *et al.* (1998) *Curr. Clin. Top. Infec. Dis.* 18:286-304). Hence the vectors herein may be used for treating the disease.

5

Table 3
Candidate targets for ocular disease therapy

CANDIDATE TARGETS FOR OCULAR DISEASE THERAPY	
Disease	Candidate target(s)
Retinitis pigmentosa	Rhodopsin gene, and genes that regulate expression thereof <i>rds/peripherin</i>
10 Stargardt's disease	rim protein (ARC protein)
Choroideremia	rab geranylgeranyl transferase CHM, TCD, CHML *
Gyrate Atrophy	ornithine aminotransferase
15 Macular dystrophy	<i>rds/peripherin</i>

15

* see, "MSR6-yeast homologue of the choroideraemia gene," *Nature Genetics* 3: 193-4 (1993)

TABLE 4

Other Diseases	
20	Exudative Choroidal Diseases
	ICSC, fluorescein angiogram
	ICSC with large serous detachment of RPE (retinal pigmented epithelium)
	ICSC with bullous retinal detachment
	Macular drusen, exudative, confluent
25	Drusen, sub-RPE choroidal neovascularization
	Drusen, notched serous detachment of RPE

Other Diseases	
	Drusen, notched serous and hemorrhagic detachment of RPE
	Drusen, serous and hemorrhagic detachment of RPE and retina
	Drusen, organized RPE detachment causing bullous retinal detachment
	Drusen, geographic atrophy of RPE
5	Drusen, exudative and cuticular, vitelliform macular detachment
	Drusen, cuticular, large vitelliform macular detachment
	North Carolina dystrophy with macular staphyloma
	North Carolina dystrophy with macular staphyloma
	Angioid streaks, pseudoxanthoma elasticum (PXE), CNVM
10	Angioid streaks, PXE, large notched retinal detachment
	Myopic degeneration, Foerster-Fuchs spot
	Presumed ocular histoplasmosis syndrome (POHS)
	Submacular bacterial abscess
	<i>Toxocara canis</i> , subretinal granuloma
15	Serpiginous (geographic) choroiditis
	Posterior scleritis
	Harada's disease
	Posterior sympathetic uveitis
	Benign reactive lymphoid hyperplasia of uveal tract
20	Choroidal ruptures and CNVM
	Cavernous hemangioma of choroid
	Choroidal osteoma
	Choroidal nevus, serous macular detachment
	Choroidal nevus with CNVM
25	Diffuse sclerochoroidal melanocytic nevus
	Choroidal melanoma with serous detachment of RPE
	Metastatic lung carcinoma to choroid
	Sub-RPE reticulum cell sarcoma

-45-

Other Diseases	
	RPE tear, idiopathic choroidal neovascularization
Heredodystrophic Disorders Affecting RPE & Retina	
	Best's vitelliform macular dystrophy
	Best's vitelliform macular dystrophy with CNVM
5	Best's vitelliform macular dystrophy, multiple lesions
	Adult-onset vitelliform foveomacular dystrophy
	Pattern dystrophy simulating fundus flavimaculatus
	Stargardt's disease (fundus flavimaculatus)
	Asteroid macular dystrophy
10	Sjögren-Larssen syndrome
	Oguchi's disease, light-adapted state
	Oguchi's disease, dark-adapted state
	Fundus albipunctatus
	Retinitis pigmentosa, cystoid macular edema
15	Crystalline tapetoretinal dystrophy
	Choroideremia
	Goldmann-Favre syndrome
	Sex-linked juvenile retinoschisis
	Perivenous retinitis pigmentosa
20	Retinal Vascular Disorders
	Retinal arteriovenous aneurysm
	Central retinal artery occlusion
	Cilioretinal artery obstruction
	Ischemic retinopathy in systemic lupus erythematosus
25	Ischemic retinopathy in scleroderma
	Hemorrhagic detachment of internal limiting membrane, hypertensive retinopathy
	Acquired retinal arterial macroaneurysm

-46-

Other Diseases	
	Cystoid macular edema, aphakic
	Cystoid macular edema, nicotinic acid maculopathy
	Congenital retinal telangiectasis
	Acquired bilateral juxtafoveal telangiectasis
5	Acquired bilateral juxtafoveal obliterative telangiectasis
	Diabetic optic neuropathy
	X-ray radiation exudative retinopathy
	Sickle cell SC disease, macular hemorrhage
	Retinal arterial aneurysms, arteritis, neuroretinitis
10	Branch retinal vein obstruction (BRVO)
	BRVO, exudative maculopathy
	BRVO, optic disc new vessels, photocoagulation
	Waldenström's macroglobulinemia
Inflammatory Diseases of the Retina and Choroid	
15	Luetic retinal vasculitis
	Focal <i>Candida</i> retinal abscess
	Toxoplasmosis, atrophic chorioretinal scar
	Toxoplasmosis retinitis and macular detachment
	Toxoplasmosis scar, CNVM, macular detachment
20	Diffuse unilateral subacute neuroretinitis, small worm
	Diffuse unilateral subacute neuroretinitis, large worm
	Cytomegalic inclusion disease, papillitis
	Acute posterior multifocal placoid pigment epitheliopathy
	Acute macular neuroretinitis
25	Sarcoid retinitis
	Sarcoid papillitis
	Behcet's disease
	Vitiliginous (bird-shot) chorioretinitis

-47-

	Other Diseases
	Multifocal choroiditis and panuveitis (pseudo-POHS)
	Retinal and Pigment Epithelial Hamartomas
	Congenital grouped albinotic RPE spots
	Congenital hyperplasia of RPE
5	Combined RPE and retinal hamartoma, juxtapapillary
	Combined RPE and retinal hamartoma, peripheral
	Cystic astrocytoma, juxtapapillary
	Astrocytoma, macula
	Astrocytoma, juxtapapillary
10	Cavernous hemangioma of retina
	Juxtapapillary sessile retinal capillary hemangioma
	Juxtapapillary endophytic retinal capillary hemangioma
	Other Tumors of the Choroid
	Choroidal metastasis
15	Choroidal osteoma
	Choroidal hemangioma
	Miscellaneous uveal tumors
	Intraocular Lymphoid Tumors
	The leukemias and lymphomas
20	Tumors of the Vitreous
	Non-Hodgkins ("reticulum cell") lymphoma
	Tumor involvement of the vitreous cavity
	Macular Disease
	Age-related macular degeneration -- atrophic form
25	Exudative age-related macular degeneration
	Choroidal neovascular membrane in degenerative myopia
	Central serous retinopathy
	Macular hole

-48-

	Other Diseases
	Macular dystrophies
	Retinal Vascular Disease
	Etiologic mechanisms in diabetic retinopathy
	Background diabetic retinopathy
5	Proliferative diabetic retinopathy
	Retinal arterial obstructive disease
	Central retinal vein occlusion
	Retinal branch vein occlusion
	Pregnancy and retinal disease
10	Pregnancy-induced hypertension
	Hypertension
	The rheumatic disease
	Parafoveal telangiectasis
	Coats disease
15	Disseminated intravascular systemic coagulopathy and related vasculopathies
	Hemoglobinopathies
	Retinopathy of prematurity
	Acquired retinal macroaneurysms
	Eales disease
20	Radiation retinopathy
	The ocular ischemic syndrome
	Inflammatory Disease
	Ocular toxoplasmosis
	Ocular toxocariasis
25	Ocular cysticercosis
	Cytomegalovirus infections of the retina
	Retinal and ophthalmologic manifestations of AIDS
	Acute retinal necrosis syndrome

Other Diseases	
	Endogenous fungal infections of the retina and choroid
	Pars planitis
	Syphilis and tuberculosis
	Diffuse unilateral subacute neuroretinitis
5	Scleritis
	Birdshot retinochoroidopathy
	Punctate inner choroidopathy
	Sarcoidosis
	Acute multifocal placoid pigment epitheliopathy
10	Geographic helicoid peripapillary choroidopathy (GHPC): serpiginous choroiditis
	Sympathetic ophthalmia
	Vogt-Koyanagi-Harada syndrome (uveomeningitic syndrome)
15	Ciliochoroidal (uveal) effusion

Reproduced from: Stereoscopic Atlas of Ocular Diseases Diagnosis and Treatment, 2nd Edition, J. Donald O. Gass, Vol. 1 & 2, C.V. Mosley Co. (1987); and Retina Vol. II, Editor, Stephen J. Ryan, Medical Retina, C.V. Mosley Co. (1989).

20 2. Therapeutic products

Therapeutic products include but are not limited to, wild-type genes that are defective in ocular disorders, such as rhodopsin, or fragments thereof sufficient to correct the genetic defect, trophic factors, including growth factors, inhibitors and agonists of trophic factors, anti-apoptosis factors and other
 25 products described herein or known to those of skill in the art to be useful for treatment of disorders of the eye or that can be treated by a product expressed by a photoreceptor.

OCULAR GENE THERAPY STRATEGIES		
GENERAL DISEASE	EXAMPLES	STRATEGY

OCULAR GENE THERAPY STRATEGIES		
Hereditary retinal and macular degeneration	<ul style="list-style-type: none"> • Retinitis pigmentosa • Stargardt's disease • Other macular dystrophies 	Growth factors (e.g., GDNF) anti-apoptotic factors (e.g., bcl2 gene) Stargardt Disease Gene (ABCR) [†]
Neovascular	<ul style="list-style-type: none"> • Diabetes • Choroidal neovascularization 	Anti-angiogenesis factors
Anti-tumor	Retinoblastoma	Antiproliferant
5 Glaucoma	Nerve fiber layer atrophy	Neuroprotective agent

[†] See Allikmets *et al.* (1997) *Science* 277:1805-1807.

For example, for treatment of retinitis pigmentosa the adenovirus vector can deliver a wild-type rhodopsin gene or a growth factor or trophic factor, such as ciliary neurotrophic factor CNTF; for treatment of Stargardt's disease, the
 10 vector can deliver a wild type ABCR (also called STGD1) or a growth factor or anti-angiogenic agent; for diabetic retinopathies, retinal vascularization the vector can deliver growth factors, such as a TGF (TGF β), to prevent degeneration.

15 The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of Adenovirus Packaging Cell Lines

Cell lines that are commonly used for growing adenovirus are useful as
 20 host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and other
 25 epithelial-derived cell lines. As a result of the adenovirus transformation, the

-51-

293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.

These cell lines allow the production and propagation of adenovirus-based gene delivery vectors that have deletions in preselected gene regions and that are obtained by cellular complementation of adenoviral genes. To provide the desired complementation of such deleted adenoviral genomes in order to generate a viral vector, plasmid vectors that contain preselected functional units have been designed. Such units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such complementation, thereby being "complementary plasmids or constructs," that are stably inserted into host cell chromosomes are described below.

A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses

The viral E4 regulatory region contains a single transcription unit that is alternately spliced to produce several different mRNA products. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcription unit. A DNA fragment extending from 175 nucleotides upstream of the E4 transcription start site including the natural E4 promoter to 153 nucleotides downstream of the E4 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek *et al.* (*Virol.*, 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of the primers used were 5'CGGTACACAGAATTTCAGGAGACACAACCTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGGAAAAC3' (SEQ ID NO: 2) (backward or 3' primer referred to as E4R). To facilitate cloning of the PCR fragment, these oligonucleotides were designed to create new sites for the restriction enzymes EcoRI and BamHI, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minute,

-52-

50 C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.

The amplified DNA E4 products were then digested with EcoRI and BamHI for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid pBS/E4. A 2603 base pair (bp) cassette including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with FspI followed by addition of BamHI linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHI to isolate the hygromycin-containing fragment.

The isolated BamHI-modified fragment was then cloned into the BamHI site of pBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 bp. The pE4/Hygro plasmid has been deposited with the ATCC under accession number 97739. The complete nucleotide sequence of pE4/Hygro is set forth in SEQ ID NO: 4. Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone. The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses

To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHI and NotI sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACGCGGCCGCTTCTTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHI and NotI sites are indicated by underlining. The 5' primer also

-53-

contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon (C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.

The amplified DNA fragment was inserted into the BamHI and NotI sites
5 of pcDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.

10 The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO: 7 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.

To enhance expression of fiber protein by the constitutive CMV promoter
15 provided by the pcDNA vector, a BglII fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay *et al.*, *BioTechniques*, 15:856-862 (1993) and inserted into the BamHI site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral
20 mRNAs as described by Logan *et al.*, *Proc. Natl. Acad. Sci., USA*, 81:3655-3659 (1984) and Berkner, *BioTechniques*, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-
25 7182 (the entire second leader segment), and 9644-9845 (the third leader segment and sequence downstream of that segment). The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is included in SEQ ID NO: 8 bordered by BamHI/BglII 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial
30 TPL is also listed separately as SEQ ID No. 22 with the noted 5' and 3' restriction sites and with the following nucleotide regions identified: 1-6 nt BglII site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1);

-54-

28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt BglII site.

The pCLF plasmid has been deposited with the ATCC as described in Example 4. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3' ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA.

C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins

The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham *et al.*, *J. Gen. Virol.*, 36:59-74 (1977) and as further characterized by Spector, *Virol.*, 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10% fetal calf serum. Four x 10⁶ cells were electroporated with 20 µg each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25 µF. DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond, CA).

Following electroporation, cells were split into fresh complete DMEM + 10% fetal calf serum containing 200 µg/ml Hygromycin B (Sigma, St. Louis, MO).

From expanded colonies, genomic DNA was isolated using the "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions. The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO: 9), the latter of which is a 5' forward primer near adenovirus open reading frame 6.

One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the product, indicating the presence of inserted DNA corresponding to most, if

-55-

not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 4. This line was further evaluated by amplification using the primer pair E4L/E4R described above, and a product corresponding to the full-length E4 insert was detected.

- 5 Genomic Southern blotting was performed on DNA restricted with EcoRI and BamHI. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRI/BamHI E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell
- 10 line, the labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event.

- Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211
- 15 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG (KPL) as secondary. No immunoreactivity was detected. Therefore, to generate 211 clones containing recombinant fiber genes, the 211 clone was expanded by growing in RPMI medium and subjected to additional
- 20 electroporation with the fiber-encoding pCLF plasmid as described above.

- Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 µg/ml G418 (Gibco, Gaithersburg, MD). Positive cell lines remained hygromycin resistant. These candidate
- sublines of 211 were then screened for fiber protein expression by indirect
- 25 immunofluorescence as described above. The three sublines screened, 211A, 211B and 211R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSVβgal (1 pfu/cell) and stained 24 hours post-infection.

- Lines positive for nuclear staining in this assay were then subjected to
- 30 Western blot analysis under denaturing conditions using the same antibody. Several lines in which the antibody detected a protein of the predicted molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including

-56-

211A, 211B and 211R. The 211A cell line has been deposited with ATCC as described in Example 4.

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a semipreparative electrophoresis system demonstrated that the
5 fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein. The predicted molecular weight of a trimerized fiber is 186 kd. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in
10 complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.

D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses

In order to prepare adenoviral packaging cell lines other than those based
15 on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.

The region of the adenovirus genome containing the E1a and E1b gene is amplified from viral genomic DNA by PCR as previously described. The primers
20 used are E1L, the 5' or forward primer, and E1R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11). The E1L and E1R primers include the respective restriction sites NheI and XhoI as indicated by the underlines. The sites are used
25 to clone the amplified E1 gene fragment into the NheI/XhoI sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp.

The complete nucleotide sequence of pDEX/E1 is listed in SEQ ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides
30 from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the

-57-

pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the *E. coli gpt* gene that allows stable transfectants to be isolated using hypoxanthine/aminopterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide

5 positions 1-1454 and 5005-11152 of SEQ ID NO: 12.

E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins

To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211A, 211B and 211R, as described in Example 1C,

10 alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/E1 and pCLF, respectively for expressing E1, and fiber complementary proteins. Following

15 transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA using the primer set E1L/E1R, as described above. Functional insertion of the fiber gene is assayed by staining with the anti-fiber

20 antibody as previously described.

The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.

F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for Complementing Gene-Deleted Adenoviruses

The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in

30 various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and content of the complementing plasmids for

-58-

use in generating recombinant adenovirus viral vectors thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.

1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes

A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1B using the forward primer 5'GACGGATCGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAAGCCATAGAGCC3' (SEQ ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is amplified as previously described and then cloned into the pDEX/E1 plasmid, prepared in Example 1D. For cloning in the DNA fragment, the pDEX/E1 vector is first digested with NdeI, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.

The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides dexamethasone-inducible E1 function as described for DEX/E1 and expression of Ad5 fiber protein as described above.

The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3' ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended NdeI site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.

The resultant pE1/Fiber plasmid is then used to complement one or more delivery plasmids expressing E1 and fiber.

The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1E to generate stable chromosomal insertions performed as

-59-

previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes

5 Plasmid pCLF prepared as described in Example 1B is partially digested with BglII to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHI to produce a fragment containing E4. The E4 fragment is then inserted into the BamHI site of pCLF to form plasmid pE4/Fiber. The resultant plasmid provides expression of the fiber
10 gene as described for pCLF and E4 function as described for pE4/Hygro.

A schematic plasmid map of pE4/Fiber, having 10610 bp. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 bp from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3' ends of the Ad5 E4
15 gene are located at respective nucleotide positions 21 and 3149 followed by fused BglII/BamHI sites and pCDNA3 backbone including the CMV promoter again followed by BglII/BamHI sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHI/BglII sites and the 5' and 3' ends of the fiber gene located at respective nucleotide
20 positions 4372 and 6124.

Stable chromosomal insertions of pE4/Fiber in host cells are obtained as described above.

EXAMPLE 2

25 Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines

Adenoviral delivery vectors are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes. A preferred adenoviral delivery vector is replication competent but only via a
30 non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, these adenovirus delivery vectors have a higher capacity for insertion of foreign DNA.

-60-

A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use

To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid pΔ E1Bβgal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and *E. coli* β-galactosidase gene was isolated from pSVβgal (Promega) by digesting with *VspI*, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with *Bam* HI. The resulting fragment was cloned into the *EcoRV* and *Bam* HI sites in the polylinker of pΔ E1sp1B (Microbix Biosystems, Hamilton, Ontario) to form pΔ E1B βgal that therefore contained the left end of the adenovirus genome with the *Ela* region replaced by the LacZ cassette (nucleotides 6690 to 4151) of pSVβ gal. Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, *Nuc. Acids Res.*, 7:1513-1523 (1978) or by the Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid DNA was then purified by CsCl-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from *E. coli* by standard methods known in the art (e.g. see Sambrook *et al.*)

The second plasmid (pDV44), prepared as described herein, is derived from pBHG10, a vector prepared as described by Bett-*et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994) (see, also International PCT application No. WO 95/00655) using methods well known to one of skill in the art. This vector is also commercially available from Microbix and and contains an Ad5 genome with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme *PacI*. An 11.9 kb *Bam* HI fragment, which contains the right end of the adenovirus genome, is isolated from pBHG10 and cloned into the *Bam* HI site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. The p11.3 plasmid was then digested with *PacI* and *Sall* to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.

-61-

This fragment was replaced with a 3,4 kb fragment containing the ITR segments and the E4 gene which was generated by PCR amplification from pBHG10 using the following oligonucleotide sequences:

5' TGTACACCG GATCCGGCGCACACC3' SEQ ID NO: 17; and

5 5' CACAACGAGCTC AATTAATTAATTGCCACATCCTC3' SEQ ID NO: 18.

These primers incorporated sites for *PacI* and *BamHI*. Cloning this fragment into the *PacI* and blunt ended *Sall* sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHG10, by the ITRs and E4 region alone. The resulting p11.3 plasmid containing the ITR and E4 regions, designated plasmid pDV43a, was then digested with *BamHI*. This *BamHI* fragment was then used to replace a *BamHI* fragment in pBHG10 thereby creating pDV44 in a pBHG10 backbone.

In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Microbix Biosystems). As above, to simplify manipulations, the 11.9 kb *BamHI* fragment including the rightmost part of the Ad5 genome was removed from pBHG10 and inserted into pBS/SK. The resulting plasmid was termed p11.3.

The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHG10 using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a *Sall* restriction site. pDV42 was then digested with *PacI*, which cuts at a unique site (bold type) in one of the PCR primers, and with *Sall*, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding *PacI*/*XhoI* fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique *XhoI* site), creating pDV43.

30 A plasmid designated pDV44 was constructed by replacing the 11.9 kb *BamHI* fragment of pBHG10 by the analogous *BamHI* fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHG10 by the

-62-

deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).

Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was
5 constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10. pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Plasmids pBHG10 and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection
10 and subsequent homologous recombination with DNA carrying functional packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHG10 was cotransfected with p Δ E1B β gal, which contains the left end of the Ad5 genome with an SV40-driven β -galactosidase reporter gene inserted in place of the E1 region.
15 In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211A, 211B, 211R, A549, Vero cells, and the like, with plasmids carrying sequences
20 corresponding to viral gene delivery vectors.

A selected cell line is plated in dishes and cotransfected with pDV44 and p Δ E1B β gal using the calcium phosphate method as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a
25 full-length viral chromosome where pDV44 and p Δ E1B β gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of
30 the recombinant virus are produced by standard methods.

Because of the fiber deletion, a pDV44-derived virus is replication-defective, cells in which it is grown must complement this defect.

-63-

The 211B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 4) was used for rescue and propagation of the virus described here. pDV44 and p Δ E1 β gal were cotransfected into 211B cells, and the monolayers were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.

One of a total of 58 transfected dishes showed evidence of spreading cell death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5. β gal. Δ F) was plaque purified twice and then expanded. To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211B cells were plated in DMEM plus 10% fetal calf serum at approximately 1×10^7 cells/150 cm² flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5. β gal. Δ F, at approximately 100 particles/cell. At day two, an equal volume of medium was added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis via four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C. Purified Ad5. β gal. Δ F virus particles containing human adenovirus Ad5. β gal. Δ F genome (described further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 4.

For viral titering, as necessary in the below Examples, Ad preparations were titrated by plaque assay on 211B cells. Cells were plated on polylysine-coated 6 well plates at 1.5×10^6 cells/well. Duplicate dilutions of virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C, virus was removed and the wells overlaid with 2

-64-

ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.

As a control, the first-generation virus Ad5. β gal.wt, which is identical to Ad5. β gal. Δ F except for the fiber deletion, was constructed by cotransfection of
5 pBHG10 and p Δ E1B β gal. In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p Δ E1B β gal and pBHG10 produced virus.

In another embodiment, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector
10 having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to
15 prepare a viral vector lacking fiber. For genetic therapy, the fiber gene can be replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector. Methods for producing a fiberless vector with a complete TPL are described in Example 3.

Vectors for the delivery of any desired gene and preferably a therapeutic
20 gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p Δ E1sp1B (Microbix Biosystems), in an analogous manner as performed for preparing pE1B β gal as described above. The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later
25 Examples.

1. Characterization of the Ad5. β gal. Δ F Genome

To confirm that the vector genomes had the proper structures and that the fiber gene was absent from the Ad5. β gal. Δ F chromosome, the DNA isolated from viral particles was analyzed. Briefly, purified viral DNA was obtained by
30 adding 10 μ l of 10 mg/ml proteinase K, 40 μ l of 0.5 M EDTA and 50 μ l of 10% SDS to 800 μ l of adenovirus-containing culture supernatant. The suspension

-65-

was then incubated at 55°C for 60 minutes. The solution was then extracted once with 400 μ l of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 μ l of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Genomic DNA from Ad5. β gal.wt and Ad5. β gal. Δ F produced the expected restriction patterns following digestion with either EcoRI or with NdeI. Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the presence of fiber sequence in Ad5. β gal.wt but not in Ad5. β gal. Δ F DNA. As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. E4 signal was readily detectable in both genomes at equal intensities. The complete nucleotide sequence of Ad5. β gal. Δ F is presented in SEQ ID NO: 23 and is contained in the virus particle on deposit with ATCC.

2. Characterization of the Fiberless Adenovirus Ad5. β gal. Δ F

To verify that Ad5. β gal. Δ F was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5. β gal. Δ F or with Ad5. β gal.wt. Twenty-four hours post infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the Ad5. β gal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.

3. Growth of the Fiber-Deleted Ad5. β gal. Δ F Vector in Complementing Cells

Ad5. β gal. Δ F was found to readily be propagated in 211B cells. As assayed by protein concentration, CsCl-purified stocks of either Ad5. β gal. Δ F or Ad5. β gal.wt contained similar numbers of viral particles. The particles appeared to band normally on CsCl gradients. Infectivity of the Ad5. β gal. Δ F particles was lower than the Ad5. β gal.wt control, as indicated by an increased particle/PFU ratio. Ad5. β gal. Δ F was also found to plaque more slowly than the control

-66-

virus. When plated on 211B cells, Ad5.βgal.wt plaques appeared within 5-7 days, while plaques of Ad5.βgal.ΔF continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of Ad5.βgal.ΔF plaques was essentially normal.

5 4. Production of Fiberless Ad5.βgal.ΔF Particles

As Ad5. β gal. Δ F represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the determination of whether such particles would be stable and/or infectious. Either Ad5. β gal.wt or Ad5. β gal. Δ F was grown in 293 or 211B cells, and the resulting particles purified on CsCl gradients as previously described. Ad5. β gal. Δ F particles were readily produced in 293 cells at approximately the same level as the control virus and behaved similarly on the gradients, indicating that there was not a gross defect in morphogenesis of fiberless capsids.

Particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. The Ad5. β gal. Δ F particles produced in 293 cells did not contain fiber protein.

20 211B-grown Ad5. β gal. Δ F also contained less fiber than the Ad5. β gal.wt control virus. The infectivities of the different viral preparations on epithelial cells correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211B-grown Ad5. β gal. Δ F was only

25 50-100 fold less than that of Ad5. β gal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.

5. Composition and Structure of the Fiberless Ad5.βgal.ΔF Particles

The proteins contained in particles of 293-grown Ad5.βgal.ΔF were compared to those in Ad5.βgal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant. The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a

-67-

first-generation vector, with the exception of reduced intensity of the composite band resulting from proteins IIIa and IV (fiber). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors to proteins VI, VII, and VIII were not seen, it is possible that the

5 low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.

Cryo-electron microscopy was used to more closely examine the structure of the 293 grown Ad5.βgal.ΔF and of Ad5βgal.wt. The fiber, having an extended stalk with a knob at the end, was faintly visible in favorable

10 orientations of wild-type Ad5 particles, but not in images of the fiberless particles. Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.

Three-dimensional image reconstructions of fiberless and wild-type

15 particles at ~20 Å resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins IIIa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components

20 into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure. Another difference between the two penton base proteins was that there is a ~30 Å diameter depression in the fiberless penton base

25 around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.

6. Integrin-Dependent Infectivity of Fiberless Ad5.βgal.ΔF Particles

30 While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates

-68-

binding to the cells (via $\beta 2$ integrins) and internalization (through interaction with αv integrins). Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial cells.

To investigate this, THP-1 monocytic cells were infected with Ad5. β gal.wt or with Ad5. β gal. Δ F grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting 2×10^5 cells at the indicated m.o.i. in 0.5 ml of complete RPMI. Forty-eight hours post-infection, the cells were fixed with glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy. The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells. Large differences were seen in plaquing efficiency on epithelial (211B) cells. Infection of THP-1 cells by either Ad5. β gal. Δ F or Ad5. β gal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base). These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent Ad5. β gal. Δ F from internalizing into the cells and delivering its genome to the nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.

The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools in cultured cells and *in vivo* as described more fully in the Examples. For example, for studies of the effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCl gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ reporter gene allows the number and type of cells which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the

standard technologies which have been used in clinical trials to date. The immune response to the improved vectors described here is determined by assessing parameters such as inflammation, production of cytotoxic T lymphocytes directed against the vector, and the nature and magnitude of the antibody response directed against viral proteins.

Versions of the vectors which contain therapeutic genes such as CFTR for treatment of cystic fibrosis or tumor suppressor genes for cancer treatment are evaluated in the animal system for safety and efficiency of gene transfer and expression. Following this evaluation, they are used as experimental therapeutic agents in human clinical trials.

B. Retargeting of Adenoviral Gene Delivery Vectors by Producing Viral Particles Containing Different or Altered Fiber Proteins

As the specificity of adenovirus binding to target cells is largely determined by the fiber protein, viral particles that incorporate modified fiber proteins or fiber proteins from different adenoviral serotypes (pseudotyped vectors) have different specificities. Thus, the methods of expression of the native Ad5 fiber protein in adenovirus packaging cells as described above is also applicable to production of different fiber proteins.

Chimeric fiber proteins can be produced according to known methods (see, *e.g.*, Stevenson *et al.* (1995) *J. Virol.*, 69:2850-2857). Determinants for fiber receptor binding activity are located in the head domain of the fiber and an isolated head domain is capable of trimerization and binding to cellular receptors. The head domains of adenovirus type 3 (Ad3) and Ad5 were exchanged in order to produce chimeric fiber proteins. Similar constructs for encoding chimeric fiber proteins for use in the methods herein are contemplated. Thus, instead of the using the intact Ad5 fiber-encoding construct prepared in above and in U.S. application Serial No. 09/482,682) as a complementing viral vector in adenoviral packaging cells, the constructs described herein are used to transfect cells along with E4 and/or E1-encoding constructs.

Briefly, full-length Ad5 and Ad3 fiber genes were amplified from purified adenovirus genomic DNA as a template. The Ad5 and Ad3 nucleotide sequences are available with the respective GenBank Accession Numbers

-70-

M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHI and NotI for cloning into pcDNA plasmid as described in Example 1A. PCR is performed as described above.

The resulting products are then used to construct chimeric fiber constructs by PCR gene overlap extension (Horton *et al.* (1990) *BioTechniques*, 8:525-535). The Ad5 fiber tail and shaft regions (5TS; the nucleotide region encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are connected to the Ad5 fiber head region (5H; the nucleotide region encoding the amino acid residue positions 404 to 581) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.

The resultant chimeric fiber PCR products are then digested with BamHI and NotI for separate directional ligation into a similarly digested pcDNA 3.1. The TPL sequence is then subcloned into the BamHI as described in Example 1A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as previously described. Other fiber chimeric constructs are obtained with the various adenovirus serotypes using a similar approach.

In an alternative embodiment, the use of modified proteins including with modified epitopes (see, *e.g.*, Michael *et al.* (1995) *Gene Therapy*, 2:660-668 and International PCT application Publication No. WO 95/26412, which describe the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity). In particular, the authors described the

-71-

production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following

5 synthesis.

Similar constructs are contemplated for use in the complementing adenoviral packaging cell systems for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic.

Heterologous ligands contemplated for use herein to redirect fiber specificity
10 range from as few as 10 amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or
15 those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end using routine procedures known to those of skill in the art. The skilled
20 artisan will be with the preparation of linkers to accomplish sufficient protein presentation and to alter the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization. Moreover, within the context of this disclosure, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.

25

The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example

30 1.

The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGlySer (SEQ ID NO: 20)

-72-

followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucleotide contains sequences that overlap with the vector
5 sequence and allow its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site. The
10 resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral vector packaging systems.

In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously
15 described. A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber protein relevant for the purpose at hand. As the only fiber gene present is the
20 one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein. Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

EXAMPLE 3

25 Tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector are provided. The complete Ad5 TPL was constructed by assembling PCR fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5
30 genomic DNA using the synthetic oligonucleotide primers
5'CTCAACAATTGTGGATCCGTACTCC3' (SEQ ID No. 24) and
5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID No. 25). The resulting

-73-

product was cloned to the BamHI and BglII sites of pΔE1Sp1a (Microbix Biosystems) using sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1), the natural first intron (intron 1), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then
5 amplified using primers 5'GGCGCGTTCGGATCCACTCTCTTCC3' (SEQ ID No. 26) and 5'CTACATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID No. 27), and cloned into the BamHI site of pDV52 (again using sites in the primers) to create pDV55.

This plasmid contains a 1.2 kb BamHI/BglII fragment containing the first
10 TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID No 28 with the following nucleotide regions identified: 1-6 nt BamHI site; 7-47 nt first leader segment (exon 1); 48-1068 nt natural first intron (intron 1); 1069-1140 nt second leader segment (exon 2);
15 1141-1146 nt fused BamHI and BglII sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt BglII site.

EXAMPLE 4

Deposit of Materials

The following cell lines and plasmids were deposited on September 25,
20 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty): Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737),
25 211 Cell Line (accession number CRL-12193) and 211A Cell Line (accession number CRL-12194)

The following virus, Ad5.βgal.ΔF, was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.

Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were
30 deposited at the ATCC on January 5, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.

-74-

EXAMPLE 5**Preparation and Use of Adenoviral Packaging Cell Lines
Containing Plasmids Containing Alternative TPLs**

Plasmids containing tripartite leaders (TPLs) have been constructed. The
5 resulting plasmids that contain different selectable markers, such as neomycin
and zeocin, were then used to prepare fiber-complementing stable cell lines for
use as for preparing adenoviral vectors.

A. pDV60

Plasmid pDV60 was constructed by inserting this TPL cassette of SEQ ID
10 No. 28 into the BamHI site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a
neomycin selectable plasmid (see, e.g., U.S. application Serial No. 09/482,682
(also filed as International PCT application No. PCT/US00/00265 on January 14,
2000); see also Von Seggern *et al.*
(1998) *J. Gen Virol.*, 79: 1461-1468). The nucleotide sequence of pDV60 is
15 listed in SEQ ID NO: 29. Plasmid pDV60 has been deposited in the ATCC under
accession number PTA-1144.

B. pDV61

To construct pDV61, an Asp718/NotI fragment containing the CMV
promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone
20 terminator was transferred from pCLF (ATCC accession number 97737; and
described in copending U.S. application Serial No. 09/482,682 (also filed as
International PCT application No. PCT/US00/00265 on January 14, 2000);), to a
zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially
available from Invitrogen and for which the sequence is known).

25 C. pDV67

In an analogous process, pDV67 containing complete TPL was
constructed by transferring an Asp 718/XbaI fragment from pDV60 into
pCDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is set forth in

-75-

SEQ ID No. 30. Plasmid pDV67 is available from the ATCC under accession number PTA-1145.

D. pDV69

To prepare pDV69 containing a modified fiber protein, the chimeric
5 Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson *et al.* (1995) *J. Virol.*, 69: 2850-2857) using the primers 5'ATGGGAT
CAAGATGAAGCGCGCAAGACCG3' (SEQ ID No. 31) and
5'CACTATAGCGGCCGCGCATTCTCAGTCATCTT3' (SEQ ID No. 32), and cloned to
the BamHI and NotI sites of pcDNA3.1/Zeo(+) via new BamHI and NotI sites
10 engineered into the primers to create pDV68. Finally, the complete TPL
fragment described above was then added to the unique BamHI site of pDV68
to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID No. 33
and has been deposited in the ATCC under accession number PTA-1146.

E. Preparation of Stable Adenovirus Packaging Cell Lines

15 E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC #
CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also
referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID No. 34) and
pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in
SEQ ID No. 35), which provide complementation of the adenoviral E1 and E2a
20 functions, respectively. This line and its derivatives were grown in Richter's
modified medium (BioWhitaker) + 10% FCS. E1-2a S8 cells were
electroporated as previously described (Von Seggern *et al.* (1998) *J. Gen Virol.*,
79: 1461-1468) with pDV61, pDV67, or with pDV69, and stable lines were
selected with zeocin (600 µg/ml).

25 The cell line generated with pDV61 is designated 601. The cell line
generated with pDV67 is designated 633 while that generated with pDV69 is
designated 644. Candidate clones were evaluated by immunofluorescent
staining with a polyclonal antibody raised against the Ad2 fiber. Lines
expressing the highest level of fiber protein were further characterized.

30 For the S8 cell complementing cell lines, to induce E1 expression, 0.3 µM
of dexamethasone was added to cell cultures 16-24 hours prior to challenge
with virus for optimal growth kinetics. For preparing viral plaques, 5×10^5

-76-

cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone the day prior to infection with 0.5 μ M included at a final concentration in the agar overlay after infection.

F. Development of Cell Lines for Complementation of E1/E2a Vectors

- 5 The Adenovirus 5 genome was digested with *ScaI* enzyme, separated on an agarose gel, and the 6,095 bp fragment containing the left end of the virus genome was isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A.,
- 10 under accession number VR-5. The *ScaI* 6,095 bp fragment was digested further with *Clal* at bp 917 and *BglII* at bp 3,328. The resulting 2,411 bp *Clal* to *BglII* fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with *Clal* and *BglII*, to form pSE280-E.
- 15 Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an *XhoI* and *Sall* restriction site contiguous with Adenovirus 5 DNA bp 552 through 924. The primers which were employed were as follows:
- 5' end, Ad5 bp 552-585:
5'-GTCACTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATCTGCCACGGA
- 20 CC-3' (SEQ ID No 36)
- 3' end, Ad5 bp 922-891:
5'-CGAGATCGATCACCTCCGGTACAAGGTTTGGCATAG-3' (SEQ ID No. 37)
- 25 This amplified DNA fragment (sometimes hereinafter referred to as Fragment A) then was digested with *XhoI* and *Clal*, which cleaves at the native *Clal* site (bp 917), and ligated to the *XhoI* and *Clal* sites of pSE280-E, thus reconstituting the 5' end of the E1 region beginning 8 bp upstream of the ATG codon.
- 30 PCR then was performed to amplify Adenovirus 5 DNA from bp 3,323 through 4,090 contiguous with an *EcoRI* restriction site. The primers which were employed were as follows:
- 5' end, Ad5 bp 3323-3360:

-77-

5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID No. 38);
and

3' end, Ad5 bp 4090-4060:

5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAAATCC
5 -3' (SEQ ID No. 39).

This amplified DNA fragment (sometimes hereinafter referred to as
Fragment B) was digested with BglII, thereby cutting at the Adenovirus 5 BglII
site (bp 3,382) and EcoRI, and ligated to the BglII and EcoRI sites of pSE280-AE
to reconstruct the complete E1a and E1b region from Adenovirus 5 bp 552
10 through 4,090. The resulting plasmid is designated pSE280-E1.

A construct containing the intact E1a/b region under the control of the
synthetic promoter GRE5 was prepared as follows. The intact E1a/b region was
excised from pSE280-E1, which was modified previously to contain a BamHI site
3' to the E1 gene, by digesting with XhoI and BamHI. The XhoI to BamHI
15 fragment containing the E1a/b fragment was cloned into the unique XhoI and
BamHI sites of pGRE5-2/EBV (U.S. Biochemicals, Cleveland, Ohio) to form
pGRE5-E1).

Bacterial transformants containing the final construct were identified.
Plasmid DNA was prepared and purified by banding in CsTFA prior to use for
20 transfection of cells.

Construction of plasmid including Adenovirus 5 E2A sequence.

The Adenovirus 5 genome was digested with BamHI and SpeI, which cut
at bp 21,562 and 27,080, respectively. Fragments were separated on an
agarose gel and the 5,518 bp BamHI to SpeI fragment was isolated. The 5,518
25 bp BamHI to SpeI fragment was digested further with SmaI, which cuts at bp
23,912. The resulting 2,350 bp BamHI to SmaI fragment was purified from an
agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and
digested with BamHI and SmaI to form pSE280-E2 BamHI-SmaI.

PCR then was performed to amplify Adenovirus 5 DNA from the SmaI site
30 at bp 23,912 through 24,730 contiguous with NheI and EcoRI restriction sites.
The primers which were employed were as follows:

5' end, Ad5 bp 24,732-24,708:

-78-

5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID No. 40);
3' end, Ad5 bp 23,912-23,934:

5'-CACCCCGGGGAGGCGGCGGCGACGGGGACGGG-3' (SEQ ID No. 41)

This amplified DNA fragment was digested with SmaI and EcoRI, and
5 ligated to the SmaI and EcoRI sites of pSE280-E2 Bam-Sma to reconstruct the
complete E2a region from Ad5 bp 24,730 through 21,562. The resulting
construct is pSE280-E2a.

In order to convert the BamHI site at the 3' end of E2a to a Sall site, the
E2a region was excised from pSE280-E2a by cutting with BamHI and NheI, and
10 recloned into the unique BamHI and NheI sites of pSE280. Subsequently, the
E2a region was excised from this construction with NheI and Sall in order to
clone into the NheI and Sall sites of the pMAMneo (Clonetech, Palo Alto, CA)
multiple cloning site in a 5' to 3' orientation, respectively. The resulting
construct is pMAMneo E2a.

15 Bacterial transformants containing the final pMAMneo-E2a were
identified. Plasmid DNA was prepared and purified by banding in CsTFA.
Circular plasmid DNA was linearized at the XmnI site within the ampicillin
resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform
extraction and ethanol precipitation prior to use for transfection of cells.

20 **Transfection and selection of cells.**

In general, this process involved the sequential introduction, by calcium
phosphate precipitation, or other means of DNA delivery, of two plasmid
constructions each with a different viral gene, into a single tissue culture cell.
The cells were transfected with a first construct and selected for expression of
25 the associated drug resistance gene to establish stable integrants. Individual cell
clones were established and assayed for function of the introduced viral gene.
Appropriate candidate clones then were transfected with a second construct
including a second viral gene and a second selectable marker. Transfected cells
then were selected to establish stable integrants of the second construct, and
30 cell clones were established. Cell clones were assayed for functional expression
of both viral genes.

-79-

A549 (ATCC Accession No. CCL-185) were used for transfection.

Appropriate selection conditions were established for G418 and hygromycin B by standard kill curve determination.

Transfection of A549 cells with plasmids including E1 and E2a regions.

- 5 pMAMNeo-E2a was linearized with XmnI with the Amp^R gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by G418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum, and visualizing by immunofluorescence. E2a function was
- 10 screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J. Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to XmnI fragment from pGRE5-E1, which contains the GRE5 promoted
- 15 E1a/b region plus the hygromycin^R gene. Cells were selected for hygromycin resistance and assayed for E1a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale, N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus
- 20 establishing the expression of E1a/b and E2a in the positive cell clones.

A transfected A549 (A549 (ATCC Accession No. CCL-185);) cell lines showed good E1a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.

25 **G. Preparation of Adenoviral Vectors Containing Ad5.βgal.ΔF Genome in S8 Improved Fiber-Complementing Cell Lines**

- To prepare adenoviral vectors containing Ad5.βgal.ΔF (Ad5.βgal.ΔF has been deposited the ATCC under accession number VR2636) in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing Ad5.βgal.ΔF in
- 30 211B cells was followed with the exception of pretreatment with 0.3 μM dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless

-80-

Ad5. β gal. Δ F genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless Ad5. β gal. Δ F genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.

Thus, these viral preparations, prepared as described herein are useful for targeting delivery of the Ad5. β gal. Δ F, Ad5.GFP. Δ F, or other similarly constructed fiberless genome with either wild-type or modified fibers. Preferably for purposes herein the fibers are from an Ad serotype D virus, more preferably from Ad37.

EXAMPLE 6

10 Pseudotyping and Infectivity of Recombinant Adenoviral Vectors Produced with Improved Fiber-Complementing Cell Lines

A. Pseudotyping of Ad5. β gal. Δ F

To verify that adenoviral vectors were produced had altered tropisms, viral particles were purified from either 633 or 644 cells and were then Western
15 blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber (which detects the Ad5 and chimeric 5T3H fiber proteins).

B. Infectivity of Cells with 633 or 644 Generated Virus Particles The cell lines, 633 or 644, prepared as described above, were infected with the indicated number of particles/cell of Ad5. β gal. Δ F and virus particles produced.
20 Virus was then used to infect selected cell lines, including 211B, MRC-5 human fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells. Unbound virus was removed by washing the cells and the cells were further incubated at 37°C for 48 hours. Cells were then fixed with glutaraldehyde and stained with X-gal. The percentage of stained cells was then determined by light
25 microscopy where all experiments were done in triplicate.

The results indicated that adenoviral vectors could be retargeted by pseudotyping using packaging cell lines expressing different fiber proteins. Particles containing either fiber were equally infectious on 211B cells, while MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing
30 the chimeric fiber. The A-10 rat endothelial cells were more readily infected by particles containing the wildtype Ad5 fiber protein.

-81-

EXAMPLE 7

Transient Transcomplementation

The ability of adenovirus type 5 (Ad5) to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the coxsackievirus-adenoviral receptor (CAR). Because a wide-range of cells express CAR, it was thought that it would be difficult to use adenoviruses to deliver genes to specific cell types. A system for testing modified fiber genes to identify tropisms of interest is described in copending U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000). An *in vitro* system has been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate modified fibers expressed on a viral particle. This system can be used to produce therapeutic quantities of adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (*i.e.* binding to CAR) ablated.

Plasmids used were pDV60 and pDV55 were prepared as described herein and in U.S. application Serial No. 09/482,682 (also filed as International PCT application No. PCT/US00/00265 on January 14, 2000). pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5. β gal. Δ F and 211B are described above. 293T cells are identical to 293 cells except they express an integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts. 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. Transfections with fiber expression plasmids were performed with Lipofectamine (GIBCO-BRL) using 20mg DNA and 50ml Lipofectamine per 15cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine serum.

The fiber deletion mutation of Ad5. β gal. Δ F is complemented in *trans* by passaging virions through 211B, a cell line that stably expresses functional Ad5

-82-

fiber. The present system was designed to complement Ad5. β gal. Δ F by modified fibers expressed from transfected episomal plasmids in 293T-cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5. β gal. Δ F genome that does not require propagation of the virus.

5 The feasibility of transcomplementation of Ad5. β gal. Δ F with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists
10 for at least six days. Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with Ad5. β gal. Δ F passaged through 211B cells. Seventy-two hours later, a crude viral lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles. Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber
15 expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.

Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility
20 for quickly evaluating a bank of modified fibers for other binding properties, including new tropisms and the ablation of the native tropism. In addition to the rapid generation and testing of large numbers of modified fibers, there are other advantages to the Ad5. β gal. Δ F transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent
25 advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber for complementation with Ad5. β gal. Δ F. Because the Ad5. β gal. Δ F is deleted in E1, E3 and fiber, there is an additional gene deletion, which should render it very suitable for gene therapy. In addition, the presence of the fiber gene deletion decreases the opportunity to generate
30 replication-competent virus via recombination in the packaging cells. A single Ad vector preparation can be retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.

-83-

EXAMPLE 8**Preparation of Adenoviral Gene Delivery Vectors Containing the Ad37 fiber protein**

This example describes construction of packaging cell lines expressing the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad vector (such as Ad5. β gal. Δ F) containing this fiber protein. The fiber protein is attached to the viral capsid by binding to the penton base protein through its N-terminus, and the Ad37 fiber was modified in order to make its N-terminal sequence more closely match that of the Ad5 protein to ensure that it would efficiently bind the Ad5 penton base in these vectors.

A. Materials and methods

Cell lines and wild-type adenovirus. Human A549 lung carcinoma epithelial cells and human Chang C conjunctival cells (American Type Culture Collection) were maintained in complete Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum. Wild-type Ad19p and Ad37 (ATCC) were propagated in A549 cells and purified by banding on CsCl₂ density gradients as previously described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Viral protein concentration was determined by the Bio-Rad Protein Assay, and was used to calculate the number of viral particles based on the known molecular weight of Ad2 virions ($1 \mu\text{g} = 4 \times 10^9$ particles).

B. Construction of the Ad37 fiber expressing cell lines and the recombinant Ad37 knob protein.**1. Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80)**

The plasmid designated pDV80 (see, SEQ ID No. 42) prepared for expression of the Ad37 fiber protein in mammalian cells, uses the same regulatory elements as the elements in pDV60, pDV67, and pDV69 to express the Ad37 fiber in packaging lines. It was constructed in two steps.

First, the Ad37 fiber open reading frame was amplified from Ad37 genomic DNA using synthetic oligonucleotide primers, L37: 5' TGT-CCT GGA TCC AAG ATG AAG CGC GCC CGC CCC AGC GAA GAT GAC TTC 3' (SEQ ID NO. 43) and 37FR: 5' AAA CAC GGC GGC CGC TCT TTC ATT CTT G 3' (SEQ ID NO. 44). L37 contains nucleotides (underlined) that differ from the Ad37

-84-

genomic sequence in order to add a unique *Bam*H1 site (bold) before the start codon (italicized) and to create point mutations that make the N-terminal sequence of the fiber more closely match the N-terminal sequence of the Ad5 fiber protein as follows:

5 Ad37 MSKRLRVEDDFNPVYPY (SEQ ID No. 45)
 ↓ ↓ ↓ ↓ ↓
 KRARPS (SEQ ID No. 46)
 Ad5 MKRARPSEDTFNPVYPY (SEQ ID No. 47).

37FR also incorporates a unique *Not*I site (bold). The PCR product was inserted
 10 into the *Bam*H1 and *Not*I sites of pCDNA3.1zeo(+) (Invitrogen) to create pDV78. The correct sequence of the Ad37 fiber protein, including inserted changes, was confirmed by sequencing.

Two point mutations in the fiber gene in the 705 line, S356 to P356 and I362 to T362, were discovered by the sequencing. The mutations are not in the
 15 receptor binding domain in Ad37 fiber gene in the 705 cell line. They are buried in the knob trimer interface. To confirm that these mutations do not affect receptor binding, the Ad37 fiber protein with the correct sequence was recloned, and 293T cells transfected with the virus and subsequently infected with Ad5.GFPΔF to produce Ad37 pseudotyped virus. The results were the same as
 20 the results of the experiments with Ad37 pseudotyped virus produced from line 705 (see, Wu *et al.* (2001) *Virology* 279:78-89).

Second, a 1.2 kb *Bam* H1/*Bgl* II fragment containing an adenovirus type 5 tripartite leader was excised from pDV55 (see EXAMPLE 3) and inserted into the *Bam* H1 site of pDV78 to create pDV80 (SEQ ID No 42). Plasmid pDV80 has
 25 been deposited in the ATCC under accession number PTA-1147.

2. Construction of the recombinant Ad37 knob protein

Recombinant Ad37 knob protein containing an N-terminal T7•Tag was produced in *E. coli* using the PET expression system (Novagen). Ad37 fiber DNA (GenBank accession number U69132) was PCR amplified from wild-type Ad37
 30 genomic DNA using the following primers (SEQ ID Nos. 48 and 49):
 5' GGATCCATGGGATACTTGGTAGCA 3' (*Bam*HI site underlined and
 5' GCAACTCGAGTCATTCTTGGGCAATATAGG 3' (*Xho*I site underlined).

-85-

The PCR reactions were performed at 94°C (denaturation), 55°C (annealing), 72°C (extension, 30 cycles) using *Taq* DNA polymerase (Qiagen). The amplified DNA fragments, which contained residues 172 to 365 of the Ad37 fiber protein with the addition of an N-terminal start codon (italicized), were

5 purified and subcloned into the pCR-TOPO vector using the TA-Cloning Kit (Invitrogen). No replication errors were found by DNA sequencing. Plasmids from cultured transformed colonies were purified and digested with *Bam*HI and *Xho*I. The fragment was inserted into the *Bam*HI and *Xho*I sites of the bacterial expression vector, pET21a (Novagen), and transformed into (DE3)pLYS S

10 expression cells (Invitrogen). Colonies were selected for knob expression by induction with 1 mM IPTG for four hours at 37°C and knob expression was determined by SDS-PAGE. The colony displaying highest knob expression was used for large-scale knob expression and induced with 0.5 mM IPTG at 30°C for four hours.

15 The recombinant T7•Tagged Ad37 knob protein was purified from sonicated bacteria using the T7•Tag Affinity Purification Kit as recommended by the manufacturer (Novagen). Recovered protein was analyzed for purity by SDS-PAGE followed by Coomassie staining or Western blotting with an HRP-conjugated α -T7•Tag monoclonal antibody as described by the manufacturer

20 (Novagen) or an α -Ad37 fiber rabbit antibody.

3. Preparation of Cell Lines that Express the Ad37 fiber protein

Plasmid pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (see Examples herein; see also, Gorziglia *et al.* (1996) *J. Virology* 70:4173-4178;

25 and Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468). Stable clones were selected with 600 μ g/ml zeocin (Invitrogen).

Clones were expanded and were screened for fiber expression by indirect immunofluorescence (Von Seggern *et al.* (1998) *J. Gen. Virol.* 79:1461-1468) using a rabbit polyclonal antibody directed against the Ad37 fiber (α -Ad37 fiber

30 rabbit antibody) raised by immunizing rabbits with recombinant Ad37 fiber protein. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected.

-86-

EXAMPLE 9

Production of Pseudotyped Ad Vector Particles

To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately 5 1000 particles/cell) with Ad5. β gal. Δ F or with Ad5.GFP. Δ F.

Materials and methods

Ad5. β gal. Δ F

The construction of Ad5. β gal. Δ F is described in Example 2 (it has been deposited on January 15, 1999, with the ATCC as listed above under accession 10 number VR2636; see also, Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; copending U.S. application Serial No. 09/482,682 filed January 14, 2000, and also International PCT application No. PCT/US00/00265, filed January 14, 2000).

Ad5.GFP. Δ F

15 Ad5.GFP. Δ F was constructed by recombination in bacteria using a modification of the AdEasy System (see, U.S. Patent No. 5,922,576; see, also He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the system is publicly available from the authors and other sources).

First, a fiber-deleted genomic plasmid was constructed by removing the 20 fiber gene from pAdEasy-1 (see, U.S. Patent No. 5,922,576; and He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514; the AdEasy system and vectors are publicly available from He *et al.* at Johns Hopkins University). Plasmid pAdEasy-1 contains the entire Ad5 genome, except for nucleotides 1-3,533, which encompass the E1 genes, and nucleotides 28,,130-30,820, which 25 encompass the E3 gene.

Plasmid pDV43 (see Example 2; see, also Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608) was digested with *Pac*1, the ends blunted by treatment with the large fragment of *E. coli* DNA polymerase and dNTPs, and the product re-ligated to produce plasmid pDV76. The resulting plasmid pDV76 is identical to 30 pDV43 except for loss of the *Pac*1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.23 kb fragment from pDV76 was amplified using the oligonucleotide primers (SEQ ID Nos. 50 and 51:

-87-

5' CGC GCT GAC TCT TAA GGA CTA GTT TC 3', including the unique *Spe*1 site in the Ad5 genome (bold); and 5' GCG CTT AAT TAA CAT CAT CAA TAA TAT ACC TTA TTT T 3', including a new *Pac*1 site (bold) adjacent to the right Ad5 ITR. Hence the resulting PCR amplified fragment contains nucleotides

5 27,082 to 35,935 of the Ad5 genome with deletions of nucleotides 28,133 to 32,743 (the E3 and fiber genes), and was used to replace the corresponding *Spe*1/*Pac*1 fragment of pAdEasy 1 (see, U.S. Patent No. 5,922,576) to create pDV77.

Second, *E. coli* strain BJ5183 was electroporated with a mixture of
10 pDV77 and *Pme*1-linearized pAdTrack as described (U.S. Patent No. 5,922,576; He *et al.* (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:2509-2514), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete Ad5 genome with E1-, E3-, and fiber-deletions with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full length
15 Ad chromosome was isolated by *Pac*1 digestion, and transfected into the E1- and fiber-complementing 633 cells (Von Seggern *et al.* (2000) *J. Virol.* 74:354-362). The 633 cells were produced by electroporating pDV67 (SEQ ID No. 30, deposited under ATCC accession number PTA-1145) into the E1-2a S8 cells, described above. The recovered virus Ad5.GFP.ΔF was then plaque purified by
20 plating on 633 cells and virus stocks were prepared by freeze-thawing-cell pellets.

Ad5-pseudotype particle production

Particles with Ad5 fiber

Ad5-pseudotyped particles were generated by virus growth in 633 cells,
25 which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCl gradients (Von Seggern *et al.* (1999) *J. Virol.* 73:1601-1608; purified by centrifugation on preformed 15-40% CsCl gradients (111,000 x g for three hours at 4°C)). For analysis of viral proteins, ten μg of the purified particles were electrophoresed on 8-16% gradient gels and the protein
30 transferred to nylon membranes. The resulting blot was probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells.

-88-

Particles with Ad37 fiber

Cells from the Ad37 fiber producing cell line 705 were infected at approximately 1000 particles/cell with Ad5. β gal. Δ F or with Ad5.GFP. Δ F. Viral particles were isolated and purified over CsCl gradients. The bands were
5 harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C.

Viral protein analyses

For analysis of viral proteins, 10 μ g of purified Ad5. β gal. Δ F particles with no fiber (grown in 293 cells), the Ad5 fiber (grown in 633 cells), or the Ad37
10 fiber (grown in 705 cells) were electrophoresed by 8-16% polyacrylamide gradient SDS-PAGE and the proteins were transferred to nylon membranes. The blot was then probed with α -Ad37 fiber rabbit antibody. Ad5 fiber and penton base were detected by reprobing the blot with polyclonal antibodies raised against recombinant proteins expressed in baculovirus-infected cells (Wickman *et*
15 *al.* (1993) *Cell* 2:309-319).

Adenovirus infection and cell binding assays

Adherent Chang C and A549 cells were infected with GFP expressing Ad5 vectors containing the Ad5 fiber (Ad5.GFP. Δ F/5F) or the Ad37 fiber (Ad5.GFP. Δ F/37F) at 10,000 particles per cell for 3 hours at 37°C, 5% CO₂ in
20 DMEM, 10% FCS. Cells were washed twice with saline and then cultured overnight at 37°C, 5% CO₂. The next day, the cells were detached with buffer containing 0.05% (w/v) trypsin and 0.5 mM EDTA (Boehringer Mannheim) for 5 minutes at 37°C. Suspended cells were washed once with PBS and then resuspended in phosphate-buffered saline (PBS), pH 7.4. GFP fluorescence was
25 measured with a FACScan flow cytometer. A threshold established by the fluorescence of uninfected cells was used to distinguish cells expressing GFP. To assess the role of CAR in Ad infection, 10,000 attached cells were pre-incubated with 180 μ g/ml RmcB, a function-blocking anti-CAR monoclonal antibody (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), in complete DMEM for 1
30 hour at 4°C. A small volume containing Ad5.GFP. Δ F/5F or Ad5.GFP. Δ F/37F was then added at 10,000 particles per cell. The cells were infected for 3 hours, cultured overnight, harvested, and analyzed for GFP expression. Percent

-89-

cells expressing GFP was determined by the percent of cells detected above a threshold set by the fluorescence of uninfected Chang C cells.

To measure adenovirus binding to cells, wild type Ad37 was labeled with ^{125}I using Iodogen (Pierce) according to manufacturer instructions and separated
5 from free ^{125}I by gel filtration as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Binding of radiolabeled wild type Ad37 on Chang C cells was then quantitated as described (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). Non-specific binding was determined by incubating cells and labeled Ad37 particles in the presence of 100-fold concentration of unlabeled Ad37. Specific
10 binding was calculated by subtracting the non-specific binding from the total cpm bound. To examine if divalent cations are required for binding, 10 mM ethylenediaminetetraacetic acid (EDTA) or various concentrations of CaCl_2 , or MgCl_2 were added to cells before incubation with labeled virus. To examine if the receptor for Ad37 is a protein, cells were pretreated with 10 $\mu\text{g/ml}$ trypsin
15 (GIBCO), subtilisin (Sigma), proteinase K (Boehringer-Mannheim), and bromelain (Sigman) at 37°C for 1 hour, then washed twice with complete DMEM before adding labeled virus. Cells were >95% viable after protease treatment.

Ad37 binding to conjunctival cells is calcium-dependent. Specific ^{125}I -labeled Ad37 binding to Chang C cells was measured in the presence of 10 mM
20 EDTA and in the presence of varying concentrations of calcium chloride or magnesium chloride. Specific binding was determined by subtracting the nonspecific counts in the presence of 100-fold excess unlabeled virus from the total counts.

Pretreatment of conjunctival cells with proteases inhibits Ad37 binding.
25 Change C cells were pretreated with various proteases for 1 hour before binding ^{125}I -labeled Ad37 to the cells. Nonspecific binding was measured by adding 100-fold unlabeled Ad37 to cells with ^{125}I -labeled Ad37 and subtracting from total counts for specific binding. Percent inhibition represents the difference in specific binding of untreated cells and pretreated cells as a percentage of the
30 specific binding of untreated cells.

-90-

Virus overlay protein blot assay (VOPBA)

For VOPBA of human conjunctival membrane proteins probed with Ad37 in the presence of EDTA or calcium chloride, Chang C membrane fractions were separated by 8% SDS-PAGE and transferred to a PDVF membrane. The

5 membrane was subsequently probed with or without whole Ad37 particles, a polyclonal antibody against Ad37 fiber, and finally a horseradish peroxidase conjugated anti-rabbit antibody, in the presence of EDTA or calcium chloride. Transferred Chang C membrane proteins were probed with recombinant Ad37 knob protein, instead of Ad37 knob, in the presence of calcium chloride.

10 Confluent monolayers of Chang C and A549 cells were detached by scraping, pelleted by centrifugation, and then resuspended in 250 mM sucrose, 20 mM HEPES, pH 7.0, 1 mM EDTA, and 2 μ g/ml aprotinin and leupeptin. Cells were transferred into a dounce homogenizer and disrupted with 30 strokes. Organelles and nuclei were pelleted at 500g for 15 min. Plasma membrane
15 fragments were then pelleted from the supernatant of cell lysates at 200,000g for 1 hour and then resuspended in 10 mM Tris•Cl, pH 8.1, 10 μ g/ml aprotinin and leupeptin.

Cell membranes of Chang C or A549 cells were incubated (1:1) with a 2% SDS, non-reducing buffer and separated on an 8% polyacrylamide gel
20 without boiling. Membrane proteins were then electroblotted onto a PVDF membrane (Immobilon-P) and blocked in 5% (w/v) milk in PBS, pH 7.4, 0.02% Tween-20 (PBS-T). After blocking, the membrane was incubated with 1 μ g/ml wild-type Ad19p or Ad37 in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 , for 1 hour at room temperature. The membrane was then washed once with phosphate-
25 buffered saline, pH 7.4 (PBS), 1 mM CaCl_2 , and incubated with 1:500 dilution of α -Ad37 fiber rabbit antibody in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 , for 30 minutes at room temperature. The membrane was washed again with PBS, 1 mM CaCl_2 , and incubated with 1:5000 dilution of horseradish peroxidase (HRP) conjugated α -rabbit antibody (Sigma) in 0.5% (w/v) milk in PBS-T, 1 mM CaCl_2 ,
30 for 30 minutes at room temperature. The membrane was washed four times in PBS, 1 mM CaCl_2 , once with PBS-T, 1 mM CaCl_2 , and once in 1 mM CaCl_2 . The blot was developed with enhanced chemiluminescence reagents (Pierce) for 5

-91-

minutes and placed onto a piece of Biomax film (Kodak) for 5 seconds to 1 minute. For divalent metal cation experiments, membranes were incubated in the presence of 2 mM EDTA instead of 1 mM CaCl_2 in all solutions. To assay fiber knob binding to cell membrane proteins, membrane filters were incubated
5 with 1 $\mu\text{g/ml}$ purified T7-tagged Ad37 knob protein in Tris-buffered saline, 0.1% Tween-20, 1 mM CaCl_2 , for 1 hour at room temperature. α -Ad37 fiber rabbit antibody and HRP-conjugated anti-rabbit antibody were applied and the membrane was developed with substrate solution as described above.

10 **Results: Comparison of adenovirus infection of human conjunctival and lung epithelial cells with virus particles retargeted with Ad5 or Ad37 fiber proteins**

Packaging cell lines producing the Ad37 fiber protein were generated. Since the N-terminal amino acid sequences of the Ad5 and Ad37 fiber proteins differ significantly, and to ensure that the Ad37 fiber would be efficiently incorporated into Ad5 vector particles, several residues in the wild-type Ad37
15 fiber were mutated to more closely match the Ad5 sequence. Stable cell lines producing this fiber under control of the CMV promoter and the adenovirus type 5 tripartite leader were then generated and screened for fiber expression by indirect immunofluorescence. One clone (line 705), which expressed the Ad37 fiber at a high level, was selected for further study.

20 Cells from one cell line 633, which expresses the wild-type Ad5 fiber protein, and line 705 were infected with a fiber-deleted Ad5 vector carrying a β galactosidase reporter gene. The resulting vector particles contained the Ad5 fiber protein (Ad5. β gal. Δ F/5F) and the Ad37 fiber protein (Ad5. β gal. Δ F/37F), respectively. Incorporation of the correct fiber protein into viral particles was
25 verified by Western blotting. Adenoviral vectors containing the GFP reporter gene, Ad5.GFP. Δ F/5F and Ad5.GFP. Δ F/37F, were created in the same fashion.

Infection of a variety of cell types using the retargeted adenovirus particles was examined. As assayed by GFP fluorescence, Ad5.GFP. Δ F/5F exhibited good gene delivery to lung epithelial (A549) and conjunctival cells
30 (Chang C). In contrast, Ad5.GFP. Δ F/37F efficiently delivered GFP to Chang C cells, but exhibited very poor gene delivery to A549 cells. Although CAR is expressed on the surface of A549 cells, as indicated by Ad5.GFP. Δ F/5F

-92-

infection, Ad5.GFP. Δ F/37F was unable to infect these cells efficiently. This experiment shows that the Ad37 fiber protein can confer preferential infection of human conjunctival cells, but not CAR-expressing human lung epithelial cells.

Hence CAR is not the primary receptor for Ad37. Recent studies reported
5 that expression of CAR on the surface of chinese hamster ovary (CHO) cells did not improve Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 does not use CAR as a primary receptor. In order to verify this on human conjunctival cells, A549 and Chang C cells were pretreated with RmcB (Hsu *et al.* (1988) *J. Virol.* 62:1647-1652), a function-blocking monoclonal
10 antibody against CAR. The RmcB antibody inhibited infection of A549 cells by Ad5.GFP. Δ F/5F, but it had little effect on infection of Chang C cells by Ad5.GFP. Δ F/37F. This indicates that CAR is not the primary receptor for Ad37 on Chang C conjunctival cells.

Ad37 binding to conjunctival cells requires divalent metal cations. It has
15 been proposed (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) that a combination of fiber binding to CAR and penton base binding to α_v -integrins allows some adenovirus serotypes to attach to cells. Although α_v -integrin binding to the RGD motif of the adenovirus penton base is of relatively low affinity (Wickman *et al.* (1993) *Cell* 2:309-319), it may nonetheless contribute to viral attachment to the
20 cell surface. Ad37 shows a particularly strong affinity for binding to integrin $\alpha_v\beta_5$ (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675), suggesting that integrin $\alpha_v\beta_5$ might be a primary receptor for Ad37. Binding of the RGD motif by α_v -integrins requires the presence of divalent cations, such as calcium or magnesium (Stuiyer *et al.* (1996) *J. Cell Physiol.* 168:521-531). In contrast, no divalent cations were
25 required for binding in the CAR-Ad12 knob complex (Bewley *et al.* (1999) *Science* 286:1579-1583).

To investigate the potential role of α_v -integrins and divalent metal cations in Ad37 receptor binding, 125 I-labeled Ad37 binding to Chang C cells was examined in the absence or presence of EDTA. EDTA inhibited Ad37 binding to
30 conjunctival cells but did not alter Ad5 binding. These findings suggest a requirement for divalent metals for Ad37 binding.

-93-

The presence of either calcium or magnesium ions helps $\alpha_v\beta_5$ organize in focal contacts (Stuiver *et al.* (1996) *J. Cell Physiol.* 168:521-531), suggesting that calcium and magnesium aid in integrin $\alpha_v\beta_5$ function. To further test the potential role of integrin $\alpha_v\beta_5$ in Ad37 cell attachment, ^{125}I -labeled Ad37 binding

5 to Chang C cells was measured in the presence of varying concentrations of calcium or magnesium chloride. Magnesium ions had little effect on Ad37 binding to Chang C cells. In contrast, calcium ions dramatically enhanced Ad37 binding to Chang C cells. The optimal concentration of calcium chloride for Ad37 binding was 1 mM, while higher concentrations of calcium actually

10 decreased virus binding to cells. The fact that calcium, but not magnesium, promoted Ad37 attachment is not consistent with integrin $\alpha_v\beta_5$ as the primary receptor for viral attachment to the cells since either metal will support ligand binding to integrin $\alpha_v\beta_5$. Moreover, A549 cells express abundant α_v -integrins (Mathias *et al.* (1998) *J. Virol.* 72:8669-8675) but were unable to support

15 efficient binding of Ad37.

Wild-type Ad37 particles bind to three conjunctival membrane proteins. Recent studies reported that protease treatment of CHO cells abolished Ad37 binding (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), implying that Ad37 bound to a protein receptor on CHO cells. Scatchard analysis of Ad37 binding to Chang C

20 cells showed that each cell expresses approximately 24,000 fiber binding sites (Huang *et al.* (1999) *J. Virol.* 73:2798-2802). To determine if the Ad37 binding site on human conjunctival cells is also a protein, Chang C cells were treated with different proteases prior to measuring binding of ^{125}I -labeled Ad37. Digestion of surface proteins by all four proteases inhibited Ad37 binding to

25 Chang C cells by greater than 50%. This finding showed that Ad37 also binds to a protein receptor on Chang C cells.

Virus overlay protein blot assays (VOPBAs) were used to identify candidate viral protein receptors. This Western blot technique uses intact viral particles in place of antibodies to probe viral-receptors interactions. VOPBA was

30 used herein to identify Chang C membrane proteins that bind to Ad37. In the absence of Ad37 particles, no protein bands were observed, while addition of virus in the absence of calcium revealed binding to a single 45 kDa protein. In

-94-

the presence of 1 mM calcium chloride, Ad37 reacted with three proteins with approximate molecular weights of 45, 50 and 60 kDa. The same three proteins were detected using a recombinant Ad37 fiber knob alone, indicating that Ad37-receptor interactions are fiber mediated and do not involve interactions of other capsid proteins such as the penton base. The size of the calcium-independent protein (45 kDa) is very similar to the known molecular weight of CAR. A direct comparison of the Ad37 VOPBA and a CAR Western blot showed that the 45 kDa receptor co-migrates with CAR on SDS-PAGE. Moreover, two other members of subgroup D adenoviruses, Ad9 and Ad15, have been shown to bind to CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915).

Since CAR does not appear to mediate Ad37 binding on intact Chang C cells, the possibility that the 50 or 60 kDa protein serves this function was tested by examining an adenovirus serotype that does not bind to Chang C cells. Ad19p, a closely related subgroup D adenovirus, binds poorly to Chang C cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802) and Ad19p recognition of the Ad37 receptor is therefore unlikely. Ad19p particles bound to the 45 and 60 kDa receptors in the VOPBA, but did not bind to the 50 kDa receptor. Moreover, the 50 kDa receptor is expressed on Chang C cells, but not A549 cells, which only support low levels of Ad37 binding and infection. Taken together, these data indicate that the 50 kDa protein is a primary-candidate receptor for Ad37 on human conjunctival cells.

Discussion

The identification of the CAR protein as a major adenovirus receptor does not explain why certain subgroup D members, such as Ad37, preferentially infect ocular cells. A 50 kDa human conjunctival cell membrane protein is identified herein as a primary candidate for the receptor for Ad37. This 50 kDa protein is not present on A549 lung epithelial cells. Ad37 binding to this receptor is calcium-dependent, which is consistent with Ad37 binding and infection experiments. Ad37 also bound to a 60 kDa protein that is present on human conjunctival and lung epithelial cells. It does not, however, appear to be serotype specific. The molecular weights of MHC class I heavy chain, which has been proposed as a receptor for Ad5, and $\alpha\beta_3$ and $\alpha\beta_5$ integrins, receptors for

-95-

the penton base, are distinct from the 50 or to kDa receptor characterized in this study.

- The studies of Ad37-receptor interaction using VOPBAs are consistent with previous studies showing that subgroup D adenoviruses can bind to the extracellular domain of CAR (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915). Biochemical and structural studies on knob-CAR interactions indicate that the CAR binding site is located on the AB-loop of the fiber knob. Alignment of the fiber sequences of Ad37 and other adenoviruses reveals that the AB-loop of Ad37 is similar to those of Ad12 and Ad5. Moreover, a phylogenetic tree of adenovirus knobs (Roelvink *et al.* (1998) *J. Virol.* 72:7909-7915) shows that fiber proteins of subgroup D are similar to those of subgroup C and E, which use CAR as their primary receptor. Ad37 does not, however, appear to effectively use CAR as a primary receptor, as demonstrated by virus binding and infection studies on Chang C conjunctival cells and A549 lung epithelial cells.
- It has been reported that Ad37 uses sialic acid as a receptor on chinese hamster ovary (CHO) cells and human lung carcinoma (A549) cells (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). Human conjunctival cells were not studied. Human corneal epithelial (HCE) cells were the only ocular cell line studied and Ad37 binds relatively poorly to these cells, compared to binding on A549 cells (Arnberg *et al.* ((2000) *J. Virol.* 74:42-48). In addition, $8,4 \times 10^7$ wheat germ agglutinin molecules per cell were required to significantly inhibit Ad37 binding to sialic acid on sialic acid positive CHO cells (Arnberg *et al.* (2000) *J. Virol.* 74:42-48), three orders of magnitude higher than the number of Ad37 receptors on Chang C conjunctival cells (Huang *et al.* (1999) *J. Virol.* 73:2798-2802).
- Clearly, sialic acid is not the only factor responsible for Ad37 binding to the cell surface and its influence on Ad37 tropism is unclear.

The results herein show that Ad37 selects a 50 kDa cellular receptor for binding to conjunctival cells, but it is possible that sialic acid also plays a role in this interaction. The characterization and identification of the Ad37 receptor have therapeutic implications and also explain the different tropism of Ad37. The 50 kDa receptor for Ad37 may also be the receptor for other subgroup D adenoviruses that cause severe cases of EKC, Ad19a and Ad8. Ad19p is a

-96-

nonpathogenic variant of Ad19 (Arnberg *et al.* (1998) *Virology* 227:239-244) while Ad19A, along with Ad8 and Ad37, are major causes of EKC. Ad19a and Ad37 have identical fiber proteins (Arnberg *et al.* (1998) *Virology* 227:239-244) and have similar tropism in vivo. Ad8, Ad19a, and Ad37 agglutinate dog and guinea pig erythrocytes more effectively than four other serotypes that are associated with less severe forms of conjunctivitis (Arnberg *et al.* (1998) *Virology* 227:239-244), implying that the receptors of Ad18, Ad19A, and Ad37 have similar characteristics. Hence, this 50 kDa receptor is an attractive drug target against EKC caused by adenoviruses to provide therapeutic intervention of ocular diseases associated with these viruses.

EXAMPLE 10

Targeting of the Ad5 vector to photoreceptor cells

The fiber-deleted adenovirus vector Ad5.GFP. Δ F was propagated in 705 cells, which express a modified Ad37 fiber protein. Viral particles (Ad5.GFP. Δ f/37F) were harvested, CsCl-purified and dialized into 0.9% NaCl, 10 mM Tris, pH 8.1, and 10% glycerol. Two to three μ l of the resulting solution, containing approximately 1×10^9 particles/ μ l was injected into the vitreous chamber of a mouse eye. Seven days post-injection, eyes were harvested, fixed with paraformaldehyde and cryo-sectioned. Sections were stained with an anti-rhodopsin antibody to identify photoreceptor cells and with DAPI to show all-cell nuclei. The resulting sections showed red anti-rhodopsin staining in the photoreceptors, blue DAPI-stained nuclei, and green GFP staining in any transduced cells. The results revealed substantially exclusive transduction of photoreceptors. Co-localization of rhodopsin staining and GFP expression indicated selective transduction of photoreceptor cells.

As a control, contralateral eyes were injected with a stock of the fiber-deleted vector AD5. β gal. Δ F grown in the same Ad37 fiber-expressing cells. Since this virus (Ad5. β gal. Δ F/37F) produces β gal rather than GFP, the green staining is absent from the photoreceptors.

Additional experiments using the AD37 fiber for targeting to the photoreceptor cells have been performed. Subretinal and intravitreal injection have been used in mouse models and the results demonstrate targeting to the

-97-

photoreceptors. As with intravitreally injected eyes, the major cell type infected via subretinal administration was the photoreceptor.

As noted, Ad5.GFP. Δ F /37F infected Chang C cells efficiently, but A549 cells poorly. Ad37 fiber protein confers preferential infection on human.

- 5 conjunctival cells, but not CAR-expressing human lung epithelial cells. Binding to conjunctival cells requires divalent cations.

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

-98-

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule, comprising:
adenovirus inverted terminal repeat sequences; an adenovirus packaging
signal operatively linked thereto; and a photoreceptor-specific promoter.
- 5 2. The isolated nucleic acid molecule of claim 1, further comprising a
nucleic acid encoding a therapeutic product operatively linked to the promoter.
3. The isolated nucleic acid molecule of claim 1, wherein the
promoter is a rhodopsin promoter.
4. The nucleic acid molecule of claim 1, wherein the adenovirus
10 genome does not encode a functional fiber protein such that packaging the
nucleic acid requires complementation in a packaging cell.
5. A recombinant adenovirus vector, comprising the nucleic acid
molecule of any of claims 1-4 packaged therein.
6. A recombinant adenovirus vector of claim 5, wherein inverted
15 terminal repeat sequences (ITR) and a packaging signal are derived from
adenovirus type 2 or adenovirus type 5.
7. A recombinant adenovirus vector of claim 5, wherein the virus
comprises a fiber protein.
8. A recombinant adenovirus vector of claim 7, wherein the fiber
20 protein selectively binds to photoreceptors in the eye of a mammal.
9. A recombinant adenovirus vector of claim 7, wherein the fiber is a
chimera composed of N-terminal sequences from adenovirus type 2 or type 5,
and a sufficient portion of an adenovirus serotype D fiber for selective binding to
photoreceptors in the eye of a mammal.
- 25 10. A method for targeted delivery of a gene product to the eye of a
mammal, comprising:
administering a recombinant adenovirus virus that comprises heterologous
DNA encoding the gene product or resulting in expression of the gene product,
wherein the recombinant virus comprises a fiber protein that specifically or
30 selectively binds to receptors that are expressed on cells in the eye.

-99-

11. The method of claim 10, wherein the cells are photoreceptors.
12. The method of claim 10, wherein administration is effected by intraocular delivery.
13. The method of claim 10, wherein administration is effected by a
5 method selected from subretinal injection, intravenous administration, periorbital administration, and intravitreal administration.
14. The method of claim 10, wherein the recombinant virus comprises a fiber protein from an adenovirus type D serotype.
15. The method of any of claims 10-14, wherein the fiber protein is an
10 adenovirus type 37.
16. The method of any of claims 10-14, wherein the fiber is a chimeric protein containing a sufficient portion of the N-terminus of an adenovirus type 2 or type 5 fiber protein for interaction with an adenovirus type 2 or type 5 penton, and a sufficient portion of an adenovirus serotype D knob portion of the
15 fiber for selective binding to photoreceptors in the eye of a mammal.
17. The method of any of claims 10-16, wherein the recombinant virus is an adenovirus type D serotype.
18. The method of any of claims 10-17, wherein the encapsulated nucleic acid comprises a photoreceptor-specific promoter operatively linked to a
20 nucleic acid comprising the therapeutic product.
19. The method of claim 18, wherein the therapeutic product is selected from the group consisting of a trophic factor, an anti-apoptotic factor, a gene encoding a rhodopsin protein, a wild-type Stargardt disease gene (STDG1), an anti-cancer agent and a protein that regulates expression of a photoreceptor-
25 specific gene product.
20. The method of any of claims 10-19, wherein delivery is effected for treatment of an ocular disease.
21. The method of claim 20, wherein the disorder is a retinal degenerative disease.
- 30 22. The method of claim 20, wherein the disease is retinitis pigmentosa, Stargardt's disease, diabetic retinopathies, retinal vascularization, or retinoblastoma.

-100-

23. The method of any of claims 10-22, wherein the mammal is a human.

24. The method of any of claims 10-22, wherein the viral nucleic acid comprises:

5 an adenovirus inverted terminal repeat (ITR) sequences; and
an adenovirus packaging signal operatively linked thereto.

25. The method of claim 24, wherein the ITRs and packaging signal are derived from an adenovirus serotype B or C.

26. The method of claim 24, wherein the ITRs and packaging signal
10 are derived from an adenovirus type 2 or 5.

27. The method of claim 24, wherein the viral nucleic acid further comprises a photoreceptor-specific promoter.

28. A method of targeted gene therapy, comprising:
administering a recombinant viral vector that comprises an adenovirus
15 type 37 fiber protein or portion thereof, whereby the vector selectively transduces photoreceptors and delivers a gene product encoded by the recombinant viral vector; wherein the portion is sufficient for selective binding to photoreceptors.

29. The method of claim 28, wherein the vector is administered into
20 the eye.

30. The method of claim 28, wherein the vector is administered to the vitreous cavity of the eye.

31. The method of claim 28, wherein administration is effected by subretinal injection, intravenous administration, periorbital administration or
25 intravitreal administration.

32. The method of any of claims 10-31, wherein at least about 10^7 plaque forming units of virus are administered.

33. The method of any of claims 10-31, wherein about 1 plaque forming unit to about 10^{14} plaque forming units of virus are administered.

SEQUENCE LISTING

<110> VON SEGGERN, DANIEL
NEMEROW, GLEN R.
FRIEDLANDER, MARTIN

<120> VECTORS FOR OCULAR TRANSDUCTION AND USE THEREFOR FOR GENETIC THERAPY

<130> 756.1PCT/NOV0205P

<140>

<141> 2001-05-01

<150> 09/562,934

<151> 2000-05-01

<160> 51

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

cggtacacag aattcaggag acacaactcc

30

<210> 2

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

gcctggatcc ggggaagttac gtaacgtggg aaaac

35

<210> 3

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 3

cgcggtatccg cg

12

<210> 4

<211> 8710

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

```

<400> 4
cacctaaatt gtaagcggtta atattttgtt aaaattcgcg ttaaattttt gttaaatcag 60
ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac 120
cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga 180
ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggccactac gtgaaccatc 240
accctaataca agtttttttg ggtcaggttg ccgtaaagca ctaaatcgga accctaaagg 300
gagccccga tttagagctt gacggggaaa gccggcgaaac gtggcgagaa aggaaggga 360
gaaagcgaaa ggagcgggag ctagggcgct ggcaagtgtg gcggtcacgc tgcgcgtaac 420
caccacaccc gccgcgctta atgcgcgct acagggcgcg tccattcgc cattcaggct 480
gcgcaactgt tgggaaggcg gatcggtgcg ggctcttcg ctattacgcc agctggcgaa 540
agggggatgt gctgcaaggc gattaagtgt ggtaacgcca gggttttccc agtcacgacg 600
ttgtaaaacg acggccagtg aattgtaata cgactcacta tagggcgaaat tgggtaccgg 660
gccccccctc gaggtcgacg gtatcgataa gcttgataac gaattcagga gacacaactc 720
caagtgcata ctctatgtca ttttcattgg actggtcttg ccacaactac attaatgaaa 780
tatttgccac atcttttcat actttttcat acattgcccc agaataaaga atcgtttgtg 840
ttatgtttca acgtgtttat ttttcaattg cagaaaattt caagtcattt ttcattcagt 900
agtatagccc caccaccaca tagcttatac agatcacccg accttaatac aactcacaga 960
accctagtat tcaacctgcc acctccctcc caacacacag agtacacagt cctttctccc 1020
cggctggcct taaaagcat catatcatgg gtaacagaca tattcttagg tgttatattc 1080
cacacgggtt cctgtcgagc caaacgctca tcagtgatat taataaactc ccggggcagc 1140
tcacttaagt tcatgtcgct gtccagctgc tgagccacag gctgctgtcc aacttgcggt 1200
tgcttaacgg gccggcgaagg agaagtccac gcctacatgg gggtagagtc ataactcggt 1260
atcaggatag ggcggtggtg ctgcagcagc gcgcgaataa actgctgcgc ccgcgcgtcc 1320
gtcctgcagg aatacaacat ggcagtggtc tctcagcga tgattcgcac gcgcgcgacg 1380
ataaggcgcc ttgtcctccg ggcacagcag cgcacctga tctcaettaa atcagcacag 1440
taactgcagc acagcaccac aatattgttc aaaatcccac agtgcaaggc gctgtatcca 1500
aagctcatgg cggggaccac agaaccacg tggccatcat accacaagcg caggtagatt 1560
aagtggcgac cctcataaaa cagctggag ataaacatta cctcttttgg catggtgtaa 1620
ttcaccacct ccgggtacca tataaacctc tgattaaaca tggcgccatc caccaccatc 1680
ctaaaccagc tggccaaaac ctgcccgcg gctatacact gcagggaacc gggactggaa 1740
caatgacagt ggagagccca ggactcgtaa ccatggatca tcatgctcgt catgatata 1800
atgttgacac aacacaggca cactgtcata cactctctca ggattacaag cctctccgcg 1860
gttagaacca tatccaggg aacaacccat tcttgatca gcgtaaatcc cacactgcag 1920
ggaagacctc gcacgtaact cacgttgtgc attgtcaaag tgttacattc gggcagcagc 1980
ggatgatcct ccagtatggt agcgcgggtt tctgtctcaa aaggaggtag acgatcccta 2040
ctgtacggag tgcgccgaga caaccgagat cgtgttggtc gtagtgtcat gccaaatgga 2100
acgcggcagc tagtcatatt tcctgaagca aaaccagggt cgggcgtgac aaacagatct 2160
gcgtctccgg tctcgcgct tagatcgctc tgtgtagtag ttgtagtata tccactctct 2220
caaagcatcc aggcgcccc caggctcggg ttctatgtaa actccttcat gcgcgcgtgc 2280
cctgataaca tccaccaccg cagaataagc cacaccacg caacctacac attcgttctg 2340
cgagtacac acgggaggag cgggaagagc tggaagaacc atgtttttt tttattcca 2400
aaagattatc caaaacctca aaatgaagat ctattaagt aacgcgctcc cctccggtgg 2460
cgtggtcaaa ctctacagcc aaagaacaga taatggcatt tgtaagatgt tgcacaatgg 2520
cttccaaaag gcaaacggcc ctcatgtcca agtggacgta aaggctaaac ccttcagggt 2580
gaatctctc tataaacatt ccagcacctt caacctatgc caaataattc tcatctcgcc 2640
accttctcaa tatatctcta agcaaatccc gaattatta tccggocatt gtaaaaatct 2700
gctccagagc gccctccacc ttcagcctca agcagcgaat catgattgca aaaattcagg 2760
ttcctcacag acctgtataa gattcaaaag cggaacatta acaaaaatac cgcgatcccg 2820
taggtccctt cgcagggcca gctgaacata atcgtgcagg tctgcacgga ccagcgcggc 2880
cacttccccg ccaggaacct tgacaaaaga acccaactg attatgacac gataactcgg 2940
agctatgcta accagcgtag ccccgatgta agctttgtg catgggcggc gatataaaat 3000
gcaaggtgct gctcaaaaaa tcaggcaaag cctcgcgcaa aaaagaaagc acatcgtagt 3060
catgctcatg cagataaagg caggtaagct ccggaaccac cacagaaaaa gacaccattt 3120
ttctctcaa catgtctgcg ggtttctgca taaacacaaa ataaaataac aaaaaaacat 3180
ttaaacatta gaagctgtc ttacaacagg aaaaacaacc cttataagca taagacggac 3240
tacggcatg ccggcgtgac cgtaaaaaaa ctgggtcaccg tgattaaaaa gcaccaccga 3300
cagctcctcg gtcattgtcc gagtcataat gtaagactcg gtaaacacat caggttgatt 3360
catcggtcag tgctaaaaag cgaccgaaat agccggggg aatacatacc cgcaggcgta 3420
gagacaacat tacagcccc ataggaggta taacaaaatt aataggagag aaaaacacat 3480
aaacacctga aaaacctcc tgctaggcca aaatagcacc ctcccgcctc agaacaacat 3540

```

acagcgcttc	acagcggcag	cctaacagtc	agccttacca	gtaaaaaaga	aaacctatta	3600
aaaaaacacc	actcgacacg	gcaccagctc	aatcagtcac	agtgtaaaaa	agggccaagt	3660
gcagagcgag	tatatatagg	actaaaaaat	gacgtaacgg	ttaaagtcca	caaaaaacac	3720
ccagaaaacc	gcacgcgaac	ctacgcccag	aaacgaaagc	caaaaaaccc	acaacttcct	3780
caaatcgta	cttcggtttt	cccacgttac	gttaactccc	ggatccgcgg	cattcacagt	3840
tctccgcaag	aattgattgg	ctccaattct	tggagtgggtg	aatccggttag	cgaggtgccc	3900
ccggcttcca	ttcaggtcga	ggtggcccgg	ctccatgcac	cgcgacgcaa	cgccggggagg	3960
cagacaaggt	atagggcggc	gcctacaatc	catgccaaac	cgttccatgt	gctcgccgag	4020
gcggcataaa	tcgccgtgac	gatcagcggg	ccagtgatcg	aagttaggct	ggttaagagcc	4080
gcgagcgatc	cttgaagctg	tcctgatgg	tcgtcatcta	cctgcctgga	cagcatggcc	4140
tgcaacgcgg	gcatcccgat	gccgccggaa	gcgagaagaa	tcataatggg	gaaggccatc	4200
cagcctcgcg	tcgcgaacgc	cagcaagacg	tagcccagcg	cgtcgccgcg	catgccttgc	4260
ttcatccccg	tggcgcgttg	ctcgcggttg	ctggcgggtg	ccccggaaga	aatatatttg	4320
catgtcttta	gttctatgat	gacacaaaac	ccgcccagcg	tcttgtcatt	ggcgaattcg	4380
aaacgcgaga	tgcaagtcgg	gcggcgcggt	cccaggtcca	cttcgcatat	taagggtgac	4440
cgtgtggcct	cgaacaccga	gcgaccctgc	agcgaccgcg	ttaacagcgt	caacagcgtg	4500
ccgcagatcc	cgggcaatga	gatatgaaaa	agcctgaact	caccgcgacg	tctgtcgaga	4560
agtttctgat	cgaaaagttc	gacagcgtct	ccgacctgat	gcagctctcg	gagggcggaag	4620
aatctcgtag	tttcagcttc	gatgtaggag	ggcgtggata	tgctctgcgg	gtaaaatagt	4680
gcgcgatgg	tttctacaaa	gatcggtatg	tttatcgcca	ctttgcacgc	gccgcgctcc	4740
cgattccgga	agtgcctgac	attggggaat	tcagcgagag	ccctgacctat	tgcatctccc	4800
gccgtgcaca	gggtgtcacg	ttgcaagacc	tgccgtgaaac	cgaactgccc	gctgttctgc	4860
agccggtcgc	ggaggccatg	gatgcgatcg	ctgcggccga	tcttagccag	acgagcgggt	4920
tcggcccat	cggaccgcaa	ggaatcggtc	aatacactac	atggcgatg	ttcatatgag	4980
cgattgctga	tccccatgtg	tatcactggc	aaactgtgat	ggacgacacc	gtcagtgcgt	5040
ccgtcgcgca	ggctctcgat	gagctgatgc	tttgggcccga	ggactgcccc	gaagtccggc	5100
acctcgtag	cgcgatttcc	ggctccaaca	atgtcctgac	ggacaatggc	cgcataacag	5160
cggtcattga	ctggagcgag	gcgatgttcg	gggatcccc	atacaggtc	gccaacatct	5220
ttctctggag	gccgtggttg	gcttgatgg	agcagcagac	gcgctacttc	gagcggaggc	5280
atccggagct	tgacggatcg	ccgcggctcc	ggcggtatat	gctccgcatt	ggtcttgacc	5340
aactctatca	gagcttggtt	gacggcaatt	tcgatgatgc	agcttgggcg	caggggtcgat	5400
gcgacgcaat	cgtccgatcc	ggagccggga	ctgtcgggcg	tacacaaatc	gccccgagaa	5460
gcgcggccgt	ctggaccgat	ggctgtgtag	aagtactcgc	cgatagtggg	aaccgacgcc	5520
ccagcactcg	tccgagggca	aaggaatagg	ggagatgggg	gaggctaact	gaaacacgga	5580
aggagacaat	accggaagga	acccgcgcta	tgacggcaat	aaaaagacag	aataaaacgc	5640
acgggtgttg	ggtcgtttgt	tcataaacgc	gggggttcggt	cccagggctg	gcaactctgc	5700
gataccccc	cgagacccca	ttggggccaa	tacgcocgcg	tttcttcctt	ttccccacc	5760
caccccccaa	gttcgggtga	aggcccaggg	ctcgagocca	acgtcggggc	ggcagccctc	5820
gccatagcca	ctggcccccgt	gggttaggga	cggggtcccc	catggggaat	ggtttatggg	5880
tcgtgggggt	tattattttg	ggcgttgctg	gggggtctggt	ccacgactgg	actgagcaga	5940
cagaccatg	gttttttgat	ggcctgggca	tggaccgcac	gtactggcgc	gacacgaaca	6000
ccgggcgtct	gtggctgcca	aacaccccgc	accocccaaa	accaccgcgc	ggatttctgg	6060
cgcccagtcg	cgtcgaccgg	tcattggctgc	gccccgacac	ccgccaacac	ccgctgacgc	6120
gccctgacgg	gcttgtctgc	tcccggcatc	cgcttacaga	caagctgtga	ccgtctccgg	6180
gagctgcatg	tgtcagaggt	tttcaccgtc	atcacccaaa	cgcgcgaggg	agccggatca	6240
taatcagcca	taccacattt	gtagaggttt	tacttgcttt	aaaaaacctc	cccacctccc	6300
cctgaacctg	aaacataaaa	tgaatgcaat	tggtgtgtgt	aacttgttta	ttgcagctta	6360
taatggttac	aaataaagca	atagcatcac	aaatttcaca	aataaagcat	tttttttact	6420
gcattctagt	tgtggtttgt	ccaaactcat	caatgtatct	tatcatgtct	ggatccacta	6480
gttctagagc	ggccgccacc	gcggtggagc	tccagctttt	gttcccttta	gtgagggtta	6540
attctagact	tggcgtaatc	atggtcatag	ctgtttcctg	tgtgaaattg	ttatccgctc	6600
acaattccac	acaacatacg	agccggaagc	ataaagtgtg	aagcctgggg	tgccaatga	6660
gtgagctaac	tcacattaat	tgctgtgcgc	tactgcccgc	ctttccagtc	gggaaacctg	6720
tcgtgccagc	tgcattaatg	aatcggccaa	cgcgccggga	gagggcggtt	gcgtattggg	6780
cgctctccg	cttcctcgct	cactgactcg	ctgcgctcgg	tcgttcgggt	gcggcgagcg	6840
gtatcagctc	actcaaaggc	ggtaatacag	ttatccacag	aatcagggga	taacgcagga	6900
aagaacatgt	gagcaaaagg	ccagcaaaag	gccaggaacc	gtaaaaaggc	cgcggttgcg	6960
gcgtttttcc	ataggctccg	ccccctgac	gagcatcaca	aaaatcgacg	ctcaagtcag	7020
agtgggcgaa	acccgacagg	actataaaga	taccaggcgt	ttccccctgg	aagctccctc	7080
gtgcgctctc	ctgttccgac	cctgcgcgtt	accggatacc	tgctccgctt	ttcccttcg	7140
ggaagcgtgg	cgctttctca	tagctcacgc	tgtaggtatc	tcagttcggt	gtaggtcggt	7200
cgctccaagc	tgggctgtgt	gcacgaaccc	ccggttcagc	ccgaccgctg	cgccttatcc	7260

```

ggtaactatc gtcttgagtc caaccggtg agacacgact tatcgccact ggcagcagcc 7320
actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg 7380
tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct gctgaagcca 7440
gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 7500
ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 7560
cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg ttaagggatt 7620
ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt 7680
tttaaatacaa tctaaagtat atatgagtaa acttgggtctg acagttacca atgcttaatc 7740
agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc 7800
gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtg cgcattgata 7860
ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg 7920
gccgagcgca gaagtgggtc tgcaacttta tccgcctcca tccagtctat taattgttgc 7980
cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct 8040
acaggcatcg tgggtgacag ctcgctggtt ggtatggctt cattcagctc cggttcccaa 8100
cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcgggttag ctccctcggg 8160
cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca 8220
ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tgggtgagtag 8280
tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcggtc 8340
atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt 8400
tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc 8460
actcgtgcac ccaactgac ttcagcatct tttactttca ccagcgtttc tgggtgagca 8520
aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata 8580
ctcatactct tcctttttca atattattga agcatttatc aggggttattg tctcatgagc 8640
ggatacatat ttgaatgtat ttgaaaaaat aaacaaatag ggggtccgcg cacatttccc 8700
cgaaaagtgc                                     8710

```

<210> 5
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 5
 atgggatcca agatgaagcg cgcaagaccg 30

<210> 6
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 6
 cataacgcgg ccgcttcttt attcttgggc 30

<210> 7
 <211> 7148
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

<400> 7
 gacggatcgg gagatctccc gatccccat ggtcgactct cagtacaatc tgctctgatg 60
 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttaggggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacgggggc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccataa gggactttcc 420
attgacgtca atgggtggac tatttacggg aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg gcttggcatt 540
atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacctcaa tggcggtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgt acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acgggtgggag gtctatataa gcagagctct ctggctaact agagaacca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gcttggtagc 900
gagctcggat ccaagatgaa gcgcgcaaga ccgtctgaag ataccttcaa ccccggtgat 960
ccatatgaca cggaaaccgg tcttccaact gtgccttttc ttactcctcc ctttgtatcc 1020
cccaatgggt ttcaagagag gtactctctt tgcgcctatc cgaacctota 1080
gttacctcca atggcatgct tgcgctcaaa atgggcaacg gcctctctct ggacgaggcc 1140
ggcaacctta cctcccaaaa tgtaaccact gtgagccac ctctcaaaaa aaccaagtca 1200
aacataaacc tggaaatatc tgcacccctc acagttacct cagaagccct aactgtgggt 1260
gccgcgcac ctctaattgg cgcgggcaac acactacca tgcaatcaca ggcccgcgt 1320
accgtgcacg actccaaact tagcattgpc acccaaggac ccctcacagt gtcagaagga 1380
aagctagccc tgcaaacatc aggcctctc accaccacg atagcagtac ccttactatc 1440
actgcctcac ccctctaac tactgccact ggtagcttgg gcattgactt gaaagagccc 1500
atttatacac aaaatggaaa actaggacta aagtacgggg ctectttgca tgtaacagac 1560
gacctaaaca ctttgaccgt agcaactggt ccagggtgta ctattaataa tacttctttg 1620
caaactaaag ttactggagc cttgggtttt gattcacaag gcaatatgca acttaatgta 1680
gcaggaggac taaggattga ttctcaaaac agacgcctta tacttgatgt tagttatccg 1740
tttgatgctc aaaaccaact aaatctaaga ctaggacagg gccctctttt tataaactca 1800
gccacaact tggatattaa ctacaacaaa ggcctttact tgtttacagc ttcaaacat 1860
tccaaaaagc ttgaggttaa cctaagcact gccaaagggt tgatgtttga cgctacagcc 1920
atagccatta atgcaggaga tgggcttgaa tttggttcac ctaatgcacc aaacacaaat 1980
cccctcaaaa caaaaattgg ccatggccta gaatttgatt caaacaaggc tatgggtcct 2040
aaactaggaa ctggccttag ttttgacagc acagggtgcca ttacagttag aaacaaaaat 2100
aatgataagc taactttgtg gaccacacca gctccatctc ctaactgtag actaaatgca 2160
gagaaagatg ctaaactcac tttggtctta acaaaatgtg gcagtcaaat acttgctaca 2220
gtttcagttt tggctgttaa aggcagtttg gctccaatat ctggaacagt tcaaagtgt 2280
catcttatta taagatttga cgaaaatgga gtgctactaa acaattcctt cctggaccac 2340
gaatattgga actttagaaa tggagatctt actgaaggca cagcctatac aaacgtgtt 2400
ggatttatgc ctaacctatc agcttatcca aaatctcac gtaaaactgc caaaagtaac 2460
attgtcagtc aagtttactt aaacggagac aaaactaaac ctgtaacact aaccattaca 2520
ctaaacggta cacaggaaac aggagacaca actccaagt catactctat gtcattttca 2580
tgggactggg ctggccacaa ctacattatg gaaatatttg ccacatctc ttacatttt 2640
tcatacttg cccaagaata aagaacgggc cgctcgagca tgcatctaga gggccctatt 2700
ctatagtgtc acctaaatgc tagagctcgc tgatcagcct cgactgtgcc ttctagttgc 2760
cagccatctg ttgtttgccc ctcccccggt gcattcgatt ccctggaagg tggcactccc 2820
actgtccttt cctaataaaa tgaggaaatt gcatcgcat gtctgagtag gtgtcattct 2880
attctggggg gtgggggtgg gcaggacagc aagggggagg attgggaag caatagcagg 2940
catgctgggg atgcggtggg ctctatggct tctgaggcgg aaagaaccag ctggggctct 3000
agggggtatc ccacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg 3060
cgacgctga ccgtacact tgcagcgcc ctagecccg cgtcaagctc taaatcggg catcctttt 3120
tcctttctcg ccacgttcgc cggtttccc acggaacctc gacccccaaa aacttgatta ggggtgattg 3240
tcacgtagtg ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg 3300
ttctttaata gtggactctt gttccaaact ggaacaacac tcaacctat ctcggtctat 3360
tcttttgatt tataagggat tttggggatt tgggctatt ggttaaaaaa tgagctgatt 3420
taacaaaaat ttaacgcgaa ttaattctgt ggaattgtgt tcagttagg tgtggaaagt 3480
ccccaggctc ccaggcgagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc 3540
aggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 3600
tagtcagcaa ccatagtccc gccctaact ccgcccattc cgccttaac tccgcccagt 3660
tccgcccatt ctccgcccc ttgctgacta atttttttta tttatgcaga gcccgaggcc 3720
gctctgccc ctgagctatt ccagaagtag tgaggaggct tttttggagg cctaggcttt 3780
tgcaaaaagc tccggggagc ttgtatatcc attttcggat ctgatcaaga gacaggatga 3840
ggatcggttc gcatgattga acaagatgga ttgcacgcag gttctccggc cgcttgggtg 3900

gagaggctat tcggctatga ctgggcacaa cagacaatcg gctgctctga tgccgcctg 3960
ttccggctgt cagcgcaggg gcgcccgggt ctttttgtca agaccgacct gtccggtgcc 4020
ctgaatgaac tgcaggacga ggcagcgcgg ctatcgtggc tggccacgac gggcgttcct 4080
tgcgcagctg tgctcgacgt tgtcactgaa gcgggaaggg actggctgct attgggcgaa 4140
gtgccggggc aggatctcct gtcattctac cttgctcctg ccgagaaagt atccatcatg 4200
gctgatgcaa tgcggcggct gcatacgctt gatccggcta cctgcccatt cgaccaccaa 4260
gcgaacatc gcatcgagcg agcacgtact cggatggaag ccggtcttgt cgatcaggat 4320
gatctggacg aagagcatca ggggctcgcg ccagccgaac tgttcgccag gctcaaggcg 4380
cgcatgcccg acggcgagga tctcgtcgtg acccatggcg atgectgctt gccgaatatc 4440
atgggtgaaa atggccgctt ttctggattc atcgactgtg gccggctggg tgtggcggac 4500
cgctatcagg acatagcgtt ggctaccctg gatattgctg aagagcttgg cggcgaatgg 4560
gctgaccgct tcctcgtgct ttacgggtatc gccgctcccg attcgcagcg catcgccctc 4620
tatcgccctt ttgacgagtt cttctgagcg ggactctggg gttcgaaatg accgaccaag 4680
cgacgcgcaa cctgccatca cgagatttct gattccacgc cgccttctat gaaagggttg 4740
gcttcggaat cgttttccgg gacgcggctt ggatgacct ccagcgcggg gatctcatgc 4800
tggagttctt cgcccacccc aacttggtta ttgcagctta taatgggtac aaataaagca 4860
atagcatcac aaatttcaca aataaagcat ttttttctact gcattctagt tgtgggttgt 4920
ccaaactcat caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg 4980
cgtaatcatg gtcatagtct ttctctgtgt gaaattgtta tccgctcaca attccacaca 5040
acatacgagc cggaagcata aagtgtaaag cctgggggtgc ctaatgagtg agctaactca 5100
cattaattgc gttgcgctca ctgcccgtt tccagtcggg aaacctgtcg tgccagctgc 5160
attaatgaat cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt 5220
cctcgctcac tgactcgctg cgctcggtcg ttcggtgctg gcgagcggta tcagctcact 5280
caaaaggcgt aatacggtta tccacagaat caggggataa aacatgtgag aacatgtgag 5340
caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata 5400
ggctccgccc ccctgacgag catcacaaaa atcgacgctc aagtccagag tggcgaaacc 5460
cgacaggact ataaagatac caggcgcttc cccctggaag ctccctcgtg cgctctcctg 5520
ttccgacctt gccgcttacc ccgctttctt ccgctttctt agcgtggcgc agcgtggcgc 5580
tttctcaatg ctacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg 5640
gctgtgtgca cgaaccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc 5700
ttgagtccaa ccggttaaga cagcacttat cgccactggc agcagccact ggtaacagga 5760
ttagcagagc gaggtatgta ggcggtgcta cagagttctt gaagtggagg cctaactaag 5820
gctacactag aaggacagta ttgtgtatct gcgctctgct gaagccagtt accttcgga 5880
aaagagttgg tagctcttga tccggcaaac aaaccaccgc tggtagcggg ggtttttttg 5940
tttgcaagca gcagattacg cgcagaaaaa aaggatctca agggattttg gtcattgagat 6000
ctacggggtc tgacgctcag tggaaacgaaa actcacgtta agggattttg gtcattgagat 6060
tatcaaaaag gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct 6120
aaagtatata tgagtaaaact tgggtctgaca gttaccaatg cttaatcagt gaggcaccta 6180
tctcagcgat ctgtctatct cgttcatcca tagttgectg actccccgtc gtgtagataa 6240
ctacgatagc ggagggttta ccatctggcc ccagtgtgc aatgataccg cgagaccac 6300
gctcacggc tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa 6360
gtggctctgc aactttatcc gectccatcc agtctattaa ttgttgccgg gaagctagag 6420
taagtagttc gccagttaat agtttgcgca acgttggtgc cattgctaca ggcacgtgg 6480
tgtcacgctc gtcggtttgg atggcttcat tcagctecgg ttcccaacga tcaaggcgag 6540
ttacatgac ccccatgttg tgcaaaaaag cggttagctc cttcggctct ccgacgttg 6600
tcagaagtaa gttggccgca gtgttatcac gcatggttat ggcagcactg cataattctc 6660
ttactgtcat gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcac 6720
tctgagaata gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata 6780
ccgcgccaca tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa 6840
aactctcaag gatcttaccg ctgttgagat ccagttcgat gtaaccact cgtgcaacca 6900
actgatcttc agcatctttt actttcacca cggtttctgg gtgagcaaaa acaggaaggc 6960
aaaatgccgc aaaaaaggga ataaggcgca cagggaatg ttgaatactc atactcttcc 7020
tttttcaata ttattgaagc atttatcagg gttattgtct catgagcggg tacatatttg 7080
aatgtattta gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac 7140
ctgacgtc 7148

<210> 8

<211> 7469

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 8

gacggatcgg	gagatctccc	gatccccat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggctcgt	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggtttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cggtgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggccccgc	tggctgaccg	cccaacgacc	360
cccgcccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggg	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgccacgta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcaggggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccatgacg	caaattggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctgggtaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttggtacc	900
gagctcggat	ctgaattcga	gctcgctgtt	gggctcgccg	ttgaggacaa	actcttcgcg	960
gtctttccag	tactcttggg	tccgaaaccc	gtcggcctcc	gaacggtact	ccgccaccga	1020
gggacctgag	cgagtcgcga	tgcaccggat	cggaaaacct	ctcgagaaag	gcgtctaacc	1080
agtcacagtc	gcaaggtagg	ctgagcaccg	tggcggggcg	cagcgggtgg	cggtcggggg	1140
tgtttctggc	ggaggtgctg	ctgatgatgt	aattaaagta	ggcgggtctg	agacggcgga	1200
tggtcgagg	gaggtgtggc	aggcttgaga	tccaagatga	agcgcgcaag	accgtctgaa	1260
gataccttca	accccggtga	tccatagac	acggaaaacc	gtcctccaac	tgtgcctttt	1320
cttactcctc	cctttgtatc	ccccaatggg	tttcaagaga	gtccccctgg	ggtactctct	1380
ttgcgcctat	ccgaacctct	agttacctcc	aatggcatgc	ttgcgctcaa	aatgggcaac	1440
ggcctctctc	tggacgaggc	cggcaacctt	acctcccaaa	atgtaaccac	tgtgagccca	1500
ccctcaaaaa	aaaccaagtc	aaacataaac	ctggaaaatat	ctgcacccct	cacagttacc	1560
tcagaagccc	taactgtggc	tgcgcgcgca	cctctaattg	tcgcggggcaa	cacactcacc	1620
atgcaatcac	aggccccgct	aaccgtgcac	gactccaaac	ttagcattgc	caoccaaagga	1680
cccctcacag	tgtcagaagg	aaagctagcc	ctgcaaacat	caggccccct	caccaccacc	1740
gatagcagta	cccttactat	cactgcctca	ccccctctaa	ctactgccac	tggtagcttg	1800
ggcattgact	tgaagagacc	catttatata	caaaatggaa	aactaggact	aaagtacggg	1860
gctcctttgc	atgtaacaga	cgacctaaac	actttgaccg	tagcaactgg	tccaggtgtg	1920
actattaata	atacttcctt	gcaaaactaa	gttactggag	ccttgggttt	tgattcacia	1980
ggcaatatgc	aacttaattg	agcaggagga	ctaaggattg	attctcaaaa	cagacgcctt	2040
atacttgatg	ttagttatcc	gtttgatgct	caaaaaccaac	taaatctaag	actaggacag	2100
ggcctctctt	ttataaaactc	agcccacaac	ttggatatta	actacaacaa	aggcctttac	2160
ttgtttacag	cttcaaaaca	ttccaaaaag	cttgagggtta	acctaagcac	tgccaaaggg	2220
ttgatgtttg	acgctacagc	catagccatt	aatgcaggag	atgggcttga	atttggttca	2280
cctaattgcac	caaacacaaa	tcccccaaaa	acaaaaaattg	gccatggcct	agaatttgat	2340
tcaaacaagg	ctatggttcc	taaactagga	actggcctta	gttttgacag	cacaggtgcc	2400
attacagtag	gaaacaaaaa	taatgataag	ctaactttgt	ggaccacacc	agctccatct	2460
cctaactgta	gactaaatgc	agagaaagat	gctaaactca	ctttggtctt	aacaaaaatgt	2520
ggcagtcaaa	tacttgctac	agtttcagtt	ttggctgtta	aaggcagttt	ggctocaata	2580
tctggaacag	ttcaaagtgc	tcatcttatt	ataagatttg	acgaaaatgg	agtgtacta	2640
aacaattcct	tcctggaccc	agaatattgg	aactttagaa	atggagatct	tactgaaggc	2700
acagcctata	caaacgctgt	tggatttatg	cctaacctat	cagcttatcc	aaaaatctcac	2760
ggtaaaaactg	ccaaaagtaa	cattgtcagt	caagtttact	taaacggaga	caaaaactaaa	2820
cctgtaaacac	taaccattac	actaaacggt	acacaggaaa	caggagacac	aactccaagt	2880
gcatactcta	tgtcattttc	atgggactgg	tctggccaca	actacattaa	tgaatatatt	2940
gccacatcct	cttacacttt	ttcatacatt	gcccagaagt	aaagaagcgg	ccgctcgagc	3000
atgcatctag	agggccctat	tctatagtgt	cacctaaatg	ctagagctcg	ctgatcagcc	3060
tcgactgtgc	cttctagtgt	ccagccatct	gttgtttgcc	cctccccctg	gccttccttg	3120
accctggaag	gtgccactcc	cactgtcctt	tcctaataaa	atgaggaaat	tgcatcgcat	3180
tgtctgagta	ggtgtcattc	tattctgggg	ggtgggggtg	ggcaggacag	caagggggag	3240
gattgggaag	acaatagcag	gcattgctgg	gatgccgttg	gctctatggc	ttctgaggcg	3300
gaaagaacca	gctggggctc	taggggggat	ccccacgcgc	cctgtagcgc	cgcattaacg	3360
gcggcgggtg	tgggtggttac	gcgcagcgtg	accgctacac	ttgccagcgc	cctagcgcgc	3420
gctcctttcg	ctttcttccc	ttcctttctc	gccacgttcg	ccggctttcc	ccgtcaagct	3480

ctaaatcggg	gcatcccttt	agggttcgga	tttagtgctt	tacggcacct	cgaccccaaa	3540
aaacttgatt	agggtgatgg	ttcacgtagt	gggccatcgc	cctgatagac	ggtttttcgc	3600
cctttgacgt	tggagtccac	gttctttaat	agtggactct	tggtccaaac	tggaaacaaca	3660
ctcaacccta	tctcgggtcta	ttcttttgat	ttataaggga	ttttggggat	ttcggcctat	3720
tggttaaaaa	atgagctgat	ttaacaaaaa	tttaacgcga	attaattctg	tggaaatgtgt	3780
gtcagttagg	gtgtggaaag	tccccaggct	ccccaggcag	gcagaagtat	gcaaagcatg	3840
catctcaatt	agtcagcaac	caggtgtgga	aagtcgccag	gctcccccag	aggcagaagt	3900
atgcaaagca	tgcatctcaa	ttagtcagca	accatagtc	cgccccctaa	tccgccctac	3960
ccgcccctaa	ctccgcccag	ttccgccc	tctccgcccc	atggctgact	aatttttttt	4020
atztatgcag	aggccgaggc	cgctctgccc	tctgagctat	tccagaagta	gtgaggaggc	4080
ttttttggag	gcctaggctt	ttgcaaaaag	ctcccgggag	cttgatatc	catttttcgga	4140
tctgatcaag	agacaggatg	aggatcggtt	cgcatgattg	aacaagatgg	attgcacgca	4200
ggttctccgg	ccgcttgggt	ggagaggcta	ttcggctatg	actgggcaca	acagacaatc	4260
ggctgctctg	atgccgccgt	gttccggctg	tcagcgcagg	ggcgcccggt	tctttttgtc	4320
aagaccgacc	tgtccgggtg	cctgaatgaa	ctgcaggacg	aggcagcgcg	gctatcgtgg	4380
ctggccacga	cgggcgcttc	ttgcgagct	gtgctcgacg	ttgtcactga	agcgggaagg	4440
gactggctgc	tattgggcca	agtgccgggg	caggatctcc	tgctcatctc	cctttgctcc	4500
gccgagaaa	tatccatcat	ggctgatgca	atgcggcggc	tgcatacgct	tgatccgget	4560
acctgccc	tcgaccacca	agcgaaacat	cgcatcgagc	gagcacgtac	tcggatggaa	4620
gccggctctg	tcgatcagga	tgatctggac	gaagagcatc	aggggctcgc	gccagccgaa	4680
ctgttcgcca	ggctcaaggc	gcgcatgccc	gacggcgagg	atctcgtcgt	gacccatgge	4740
gatgcctgct	tgccgaatat	catggtggaa	aatggcgct	tttctggatt	catcgactgt	4800
ggccggctgg	gtgtggcgga	ccgctatcag	gacatagcgt	tggctacccg	tgatattgct	4860
gaagagcttg	gcggcgaaatg	ggctgaccgc	ttcctcgtgc	tttacggtat	cgccgctccc	4920
gattcgcagc	gcatcgccct	ctatcgccct	cttgacgagt	tcttctgagc	gggactctgg	4980
ggttcgaaat	gaccgaccaa	gcgacgcca	acctgccatc	acgagatttc	gattccaaccg	5040
ccgccttcta	tgaaagggtg	ggcttcggaa	tcgttttccg	ggacgcccgc	tggatgatcc	5100
tccagcgcg	ggatctcatg	ctggagtct	tcgcccaccc	caacttgttt	attgcagctt	5160
ataatggtta	caaataaagc	aatagcatca	caaatttcac	aaataaagca	tttttttcac	5220
tgcatcttag	ttgtggtttg	tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	5280
cgacctctag	ctagagcttg	gcgtaatcat	ggctcatagct	gtttcctgtg	tgaaattgtt	5340
atccgctcac	aattccacac	aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	5400
cctaattgagt	gagctaactc	acattaattg	cgttgcgctc	actgcccgt	ttccagtcgg	5460
gaaactgtgc	gtgccagctg	cattaatgaa	tcggccaacg	cgcggggaga	ggcggtttgc	5520
gtattggcg	ctcttcgct	tcctcgtcca	tcgactcgct	gcgctcggtc	gttcgggtgc	5580
ggcgagcggt	atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	5640
acgcaggaaa	gaacatgtga	gcaaaaaggc	agcaaaaaggc	caggaaaccgt	aaaaaggccg	5700
cgttgctggc	gtttttccat	aggctccgac	ccccctgacga	gcatcacaaa	aatcgacgt	5760
caagttagag	gtggcgaaac	ccgacaggaa	tataaagata	ccaggcggtt	ccccctggaa	5820
gctccctcgt	gcgctctcct	gttccgaccc	tgccgcttac	cggataacctg	tcgcgctttc	5880
tcccttcggg	aagcgtggcg	ctttctcaat	gctcacgctg	taggtatctc	agttcgggtg	5940
aggctcgttcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctcgg	6000
ccttatccgg	taactatcgt	cttgagtcca	acccggtaag	acacgactta	tcgcgactgg	6060
cagcagccac	tggtaacagg	attagcagag	cgaggatgt	aggcgggtgt	acagagttct	6120
tgaagtgggtg	gcctaactac	ggctacacta	gaaggacagt	atttgggtatc	tgcgctctgc	6180
tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaaa	caaaccaccg	6240
ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	6300
aagaagatcc	tttgatcttt	tctacggggg	ctgacgctca	gtggaacgaa	aactcacgtt	6360
aagggtat	ggatcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	6420
aatgaagttt	taaatcaatc	taaagtatat	atgagtaaac	ttggctctgac	agttaccaat	6480
gcttaatcag	tgaggcacct	atctcagcga	tctgtctatt	tcgttcaccc	atagttgect	6540
gactccccgt	cgtgtagata	actacgatac	gggagggtct	accatctggc	ccagtgctg	6600
caatgatacc	gcgagaccca	cgctcacccg	ctccagattt	atcagcaata	aaccagccag	6660
ccggaagggc	cgagcgcaga	agtggctctg	caactttatc	cgctccatc	cagctctatta	6720
attgttgccg	ggaagctaga	gtagtagtt	cgccagttaa	tagtttgccg	aacgttggtg	6780
ccattgctac	aggcatcgtg	gtgtcacgct	cgctggttgg	tatggcttca	ttcagctccg	6840
gttcccaacg	atcaaggcga	gttacctgat	cccccatgtt	gtgcaaaaaa	gcgggttagct	6900
ccttcgggtc	tccgatcgtt	gtcagaagta	agttggccgc	agtgttatca	ctcatgggtta	6960
tggcagcact	gcataattct	cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	7020
gtgagtactc	aaccaagtca	ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgcc	7080
cggcgtcaat	acgggataat	accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	7140
gaaaacgttc	ttcggggcgga	aaactctcaa	ggatcttacc	gctggttgaga	tccagttcga	7200

tgtaaccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg 7260
 ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat 7320
 gttgaatact catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 7380
 tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca 7440
 catttccccg aaaagtgcc cctgacgtc 7469

<210> 9
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 9
 tgcttaagcg gccgcgaagg agaagtcc 28

<210> 10
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 10
 ccgagctagc gactgaaaat gag 23

<210> 11
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 11
 cctctcgaga gacagcaaga cac 23

<210> 12
 <211> 11152
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

<400> 12
 aagcttgggc agaaatgggt gaactccga gagtgtccta cacctagggg agaagcagcc 60
 aaggggttgt tccccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120
 aaagacatat tcattctctg ctgcaaaactt ggcatagtct tgctttgcct ggggctattg 180
 ggggaagttg cggttcgtgc tcgcagggct ctcacccttg actcttttaa tagctcttct 240
 gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
 cagccaactt cctcttaca ggcgcacgca ttttgtcctt cagaaataga aataagaatg 360
 cttgctaaaa attatatttt taccaataag accaatccaa taggtagatt attagttact 420
 atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480
 atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540
 ttgaccacag gcctagaagt aaaaaagggg aaaaagagtg tttttgtcaa aataggagac 600
 aggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgcccc 660
 ttaccatata caggaagata tgacttaaat tgggtaggt ggggtacagt caatggetat 720

aaagtgttat	atagatccct	cccttttcgt	gaaagactcg	ccagagctag	acctccttgg	780
tgtatgttgt	ctcaagaaga	aaaagacgac	atgaaacaac	aggtacatga	ttatatattat	840
ctaggaacag	gaatgcactt	ttggggaaag	attttccata	ccaaggaggg	gacagtggct	900
ggactaatag	aacattatct	tgcaaaaact	catggcatga	gttattatga	atagccttta	960
ttggcccaac	cttgcggttc	ccagggctta	agtaagtttt	tggttacaaa	ctgttcttaa	1020
aacgaggatg	tgagacaagt	ggtttcctga	cttggttttg	tatcaaagg	tctgatctga	1080
gctctgagt	ttctattttc	ctatgttctt	ttggaattta	tccaaatctt	atgtaaagtc	1140
ttatgtaaac	caagatatata	aagagtgcgt	attttttgag	taaaactgca	acagtcctaa	1200
cattcacctc	ttgtgtgttt	gtgtctgttc	gccatcccgt	ctccgctcgt	cacttatcct	1260
tcactttcca	gaggggtccc	ccgcagaccc	cggcgaccct	caggtcggcc	gactcggcca	1320
gctggcgccc	gaacagggac	cctcggataa	gtgacccttg	tctctatttc	tactatttgg	1380
tgtttgtctt	gtattgtctc	ttctttgtct	aacgatcatc	acaagagcgg	aacggactca	1440
ccatagggac	caagctagcg	actgaaaatg	agacatatta	tctgccacgg	aggtgttatt	1500
accgaagaaa	tggccgcccag	tcttttgac	cagctgatcg	aagaggtaact	ggctgataat	1560
cttccacctc	ctagccattt	tgaaccacct	acccttcacg	aactgtatga	tttagacgtg	1620
acggccccc	aagatcccaa	cgaggaggcg	gtttcgcaga	ttttcccgga	ctctgtaag	1680
ttggcggtgc	aggaagggat	tgacttactc	acttttcgcg	cggcgcccg	ttctccggag	1740
ccgctcacc	tttcccgga	gcccagacag	ccggagcaga	gagccttggg	tccggtttct	1800
atgccaaacc	ttgtaccgga	ggatgatcgat	cttacctgcc	acgaggtcgg	ctttccaccc	1860
agtgacgacg	aggatgaaga	gggtgaggag	tttgtgttag	attatgtgga	gcaccccggg	1920
cacggttgca	ggcttgttca	ttatcaccgg	aggaatacgg	gggaccaga	tattatgtgt	1980
tcgctttgct	atatgaggac	ctgtggcatg	tttgtctaca	gtaagtga	attatgggca	2040
gtgggtgata	gagtggtggg	tttggtgtgg	taattttttt	tttaattttt	acagttttgt	2100
ggtttaaaaga	attttgtatt	gtgatttttt	taaaagggtcc	tgtgtctgaa	cctgagcctg	2160
agcccagacc	agaaccggag	cctgcaagac	ctacccgcgg	tcctaaaatg	gcgcctgcta	2220
tcctgagacg	cccagacatca	cctgtgtcta	gagaatgcaa	tagtagtacg	gatagctgtg	2280
actccggtcc	ttctaacaca	cctcctgaga	tacaccgggt	ggtcccgtcg	tgccccatta	2340
aaccagttgc	cgtgagagtt	gggtggcgctc	gccaggctgt	ggaatgtatc	gaggacttgc	2400
ttaacgagcc	tgggcaacct	ttggacttga	gctgtaaacg	ccccaggcca	taagggtgaa	2460
acctgtgatt	gcgtgtgtgg	taaacgcctt	tgtttgctga	atgagtttaa	gtaagtttaa	2520
ttaaagggtga	gataatgttt	aaacttgcag	gcgtgttaaa	tggggcgggg	cttaaagggt	2580
atataatgcg	ccgtgggcta	atcttggtta	catctgacct	catggaggct	tgggagtggt	2640
tggaaagattt	ttctgtgtgt	cgtaacttgc	tggaaacagag	ctctaacagt	acctcttgg	2700
tttgagggtt	tctgtggggc	tcaccccagg	caaagttagt	ctgcagaatt	aaggagatt	2760
acaagtggga	atgttgagag	cctttgaaat	cctgtgggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcacaaagac	tttggttttt	tcacaccgg	2880
ggcgcgctgc	ggctgtgtgt	gcttttttga	gttttataaa	ggataaatgg	agcgaagaaa	2940
cccatctgag	cgggggggtac	ctgctggatt	ttctggccat	gcactctgtg	agagcggttg	3000
tgagacacaa	gaatgcctcg	ctactgttgt	cttccgctcg	cccggcgata	ataccgacg	3060
aggagcagca	gcagcagcag	gaggaaagcca	ggcgccggcg	gcaggagcag	agcccatgga	3120
acccgagagc	cggcctggac	cctcggaat	gaatgttgta	caggtggctg	aactgtatcc	3180
agaactgaga	cgcattttga	caattacaga	ggatgggag	gggctaaagg	gggtaaaag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctaggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgta	ttacttttca	acagatcaag	gataattgag	ctaagagct	3360
tgatctgctg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tgagccagg	3420
ggatgatatt	gaggaggcta	ttagggtata	tgcaaagggt	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaaactg	taaataatcag	gaattgttgc	tacatttctg	ggaacggggc	3540
cgaggtggag	atagatacgg	aggataggg	ggcctttaga	tgtagcatga	taaatatgtg	3600
gccgggggtg	cttggcatgg	acgggggtgg	tattatgaat	gtaagggtta	ctggcccaaa	3660
ttttagcgg	acgggttttc	tggccaatac	caaccttatc	ctacacgggtg	taagcttcta	3720
tgggtttaac	aatacctgtg	tggaaagcct	gaccgatgta	agggttcggg	gctgtgcctt	3780
ttactgtctg	tggaaagggg	tggtgtgtcg	ccccaaaagc	agggttcaa	taagaaatg	3840
cctctttgaa	agggtgtacct	tgggtatcct	ctctgagggt	aactccaggg	tgccgcaaa	3900
tgtggcctcc	gactgtggtt	gcttcatgct	agtgaagagc	gtggctgtga	ttaagcataa	3960
catggtatgt	ggcaactgcg	aggacagggc	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgttag	cagccactct	cgcaaggcct	ggccagtgtt	4080
tgagcataac	atactgacct	gctgttctct	gcatttgggt	aacaggaggg	gggtgttctt	4140
accttaccac	tgcaatttga	gtcacactaa	gatattgctt	gagcccgaga	gcatgtocaa	4200
ggtgaacctg	aacgggggtg	ttgacatgac	catgaagatc	tggaaaggtg	tgaggtacga	4260
tgagaccgcg	accaggtgca	gacctgtcga	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccgatcac	ttgggtgctg	cctgcacccg	4380
cgctgagttt	ggctctagcg	atgaagatac	agattgaggt	actgaaatgt	gtggcgctgg	4440

cttaagggtg	ggaaagaata	tataagggtg	gggtctttatg	tagtttttga	tctgttttgc	4500
agcagccgcc	gccgccatga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggccggggt	gcgtcagaat	gtgatgggct	ccagcattga	4620
tggtcgcccc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gccgttgagg	actgcagcct	ccgcccgccg	ttcagccgct	gcagccaccg	cccgcgggat	4740
tgtgactgac	tttgctttcc	tgagcccgct	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttggc	acaattggat	tctttgaccc	gggaacttaa	4860
tgtcggttct	cagcagctgt	tggatctcg	ccagcaggtt	tctgccctga	aggcttccct	4920
ccctcccaat	gcggtttaaa	acataaataa	aaaaccagac	tctgtttgga	tttggtatcaa	4980
gcaagtgtct	tgctgtctct	cgagggatct	ttgtgaagga	accttacttc	tgtgggtgta	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgttaaacta	ctgattctaa	ttgtttgtgt	attttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tgggtggaatg	cctttaatga	ggaaaacctg	ttttgctcag	5220
aagaaatgcc	atctagtgtat	gatgaggcta	ctgctgactc	tcaacattct	actcctecaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccttc	agaattgcta	agttttttga	5340
gtcatgtgt	gttttagtaat	agaactcttg	cttgctttgc	tatttcacac	acaaaggaaa	5400
aagctgcact	gctatacaag	aaaattatgg	aaaaatatte	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgtctg	5520
ctattaataa	ctatgctcaa	aaattgtgta	ccttttagctt	tttaatttgt	aaaggggtta	5580
ataaggataa	tttgatgtat	agtgccctga	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	5700
atgaatgcaa	ttgttggtgt	taacttggtt	attgcagctt	ataatgggtta	caaataaagc	5760
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcattctag	ttgtgggttg	5820
tccaaactca	tcaatgtatc	ttatcatgtc	tggatccggc	tgtggaatgt	gtgtcagtta	5880
gggtgtggaa	agtcctcagg	ctccccagca	ggcagaagta	tgcaaaagcat	gcatctcaat	5940
tagtcagcaa	ccagggtgtg	aaagtcacca	ggctccccag	caggcagaag	tatgcaaagc	6000
atgcatctca	attagtcagc	aaccatagtc	ccgcccctaa	ctccgcccct	cccgcacctc	6060
actccgcccc	gttccgcccc	ttctccgccc	catggetgac	taattttttt	tatttatgca	6120
gaggccgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttgga	6180
ggcctaggct	tttgcaaaaa	gcttgacac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	cccgcgtcag	ggagaggcag	tgcgtaaaaa	gacgcggact	catgtgaaat	6300
actggttttt	agtgcgccag	atctctataa	tctcgcgcaa	cctatttttc	cctcgaacac	6360
tttttaagcc	gtagataaac	aggctgggag	acttcacatg	agcgaaaaat	acatcgtcac	6420
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaggc	attattgccc	taagccgtgg	cggtctggta	ccgggtgcgt	tactggcgcg	6540
tgaactgggt	attcgctcat	tcgataccgt	ttgtatttcc	agctacgatc	acgacaacca	6600
gcgcgagctt	aaagtgcgtga	aacgcgcaga	aggcgatggc	gaaggcttca	tcggtattga	6660
tgacctgggt	gataccgggtg	gtactgcgggt	tgcgattcgt	gaaatgtatc	caaaaagcga	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	tgcgtccgctg	gttgatgact	atgttggtga	6780
tatcccgcga	gatacctgga	ttgaacagcc	gtgggatatg	ggcgctcgat	tgcgtcccgc	6840
aatctccggt	gcctaattctt	ttcaacgcct	ggcactgccg	ggcgttgctc	tttttaactt	6900
caggcggggt	acaatagttt	ccagtaagta	ttctggaggc	tgcacatcatg	acacaggcaa	6960
acctgagcga	aacctgttc	aaaccccgct	ttaaacatcc	tgaacacctg	acgctagtcc	7020
gccgctttaa	tcacggcgca	caaccgcctg	tgcagtcggc	ccttgatggt	aaaaccatcc	7080
ctcactggta	tgcgatgatt	aaccgtctga	tgtggatctg	gcgcggcatt	gacccacgcg	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaaacgtacc	gacgatgatt	7200
tatacgatac	ggtgattggc	taccgtggcg	gcaactggat	ttatgagtg	gccccggatc	7260
tttgatgaagg	aaccttactt	ctgtgggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaatat	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgtttgtg	tatttttagat	tccaacctat	ggaactgatg	aatgggagca	gtgggtggaat	7440
gccttttaatg	aggaaaacct	gttttgctca	gaagaaatgc	catctagatga	tgtagaggct	7500
actgctgact	ctcaacattc	tactcctoca	aaaaagaaga	gaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcatgctg	tggttagtaa	tagaactctt	7620
gcttgctttg	ctattttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctgtaacctt	tataagtagg	cataacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaatttgtg	7800
accttttagct	tttttaattg	taaaggggtt	aataaggaat	atttgatgta	tagtgccttg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagagggt	ttacttgctt	taaaaaacct	7920
cccacacctc	cccctgaacc	tgaaacataa	aatgaatgca	attggtgttg	ttaacttggt	7980
ttttgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	8040
atttttttca	ctgcattcta	gttggtgggt	gtccaaactc	atcaatgtat	cttatcatgt	8100
ctggatcccc	aggaagctcc	tctgtgtcct	cataaacctc	aacctcctct	acttgagagg	8160

```

acattccaat cataggtgc ccatccaccc tctgtgtcct cctgttaatt aggtcactta 8220
acaaaaagga aattgggtag ggggtttttca cagaccgctt tctaagggtta attttaaaat 8280
atctgggaag tcccttccac tgctgtgttc cagaagtgtt ggtaaacagc ccacaaatgt 8340
caacagcaga aacatacaag ctgtcagctt tgcacaaggg cccaacaccc tgctcatcaa 8400
gaagcactgt gggtgtgtgt ttagtaatgt gcaaaacagg aggcacattt tccccacctg 8460
tgtaggttcc aaaatatcta gtgttttcat ttttacttgg atcaggaacc cagcactcca 8520
ctggataagc attatcctta tccaaaacag ccttgtggtc agtggttcac tgctgactgt 8580
caactgtagc attttttggg gttacagttt gagcaggata tttggctctg tagtttgcta 8640
acacaccctg cagctccaaa gggtcccccac caacagcaaa aaaatgaaaa tttgaccctt 8700
gaatgggttt tccagcacca ttttcatgag ttttttgtgt ccctgaatgc aagttaaca 8760
tagcagttac cccaataacc tcagttttaa cagtaacagc ttcccacatc aaaatatttc 8820
cacagggttaa gtcctcattt aaattaggca aaggaattct tgaagacgaa agggcctcgt 8880
gatacgcta tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcagggtg 8940
cacttttcgg ggaaatgtgc gcggaacccc tatttgttta tttttctaaa tacattcaaa 9000
tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa 9060
gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcct 9120
tctgttttt gctcaccag aaacgctggg gaaagtaaaa gatgctgaag atcagttggg 9180
tgcacgagtg gggtacatcg aactggatct caacagcggg aagatccttg agagttttcg 9240
ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt 9300
atcccgtgtt gacgccgggc aagagcaact cggtcgcccgc atacactatt ctgagaatga 9360
cttggttagt tactcaccag tcacagaaaa gcactcttac gatggcatga cagtaagaga 9420
attatgcagt gctgccataa ccatgagtga taactctgcg gccaaactac ttctgacaac 9480
gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc atgtaactcg 9540
ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac 9600
gatgcctgca gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct 9660
agcttcccgg caacaattaa tagactggat ggaggcggat aaagtgcag gaccacttct 9720
gcgctcggcc ctccggctg gctggtttat tgctgataaa tctggagccg gtgagcgtgg 9780
gtctcgggt atcattgcag cactggggcc agatggtaag cctcccgtta tcgtagtatt 9840
ctacacgacg gggagttagg caactatgga tgaacgaaat agacagatcg ctgagatagg 9900
tgctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata tactttagat 9960
tgatttaaaa cttcattttt aatttaaaag gatctagggt aagatccttt ttgataatct 10020
catgacaaa atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa 10080
gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgtctgt tgcaaaaaa 10140
aaaaaccacg ctaccagcgg tggtttgttt gccggatcaa gagctaacca ctctttttcc 10200
gaaggttaact ggcttcagca gagcgcagat accaaatact gtccttctag tgtagccgta 10260
gttaggccac cacttcaaga actctgtagc accgcctaca tactctgctc tgctaatect 10320
gttaccagt gctgctgcca gtggcgataa gtcgtgtcct accgggttgg actcaagacg 10380
atagttaccg gataaggcgc agcggtcggg ctgaacgggg gggttcgtgca cacagcccag 10440
cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc 10500
cacgcttccc gaaggagaa aggcggacag gtatccggta agcggcaggg tcggaacagg 10560
agagcgacag agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt 10620
tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 10680
gaaaaacgcc agcaacgcgg cttttttacg gttcctggcc ttttgctggc cttttgctca 10740
catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagt 10800
agctgatacc gctcgcgcga gccgaacgac cgagcgagc gagtcagtga gcgaggaagc 10860
ggaagagcgc ctgatgcggt attttctcct tacgcatctg tgccgtatg ttaagccagt atactactcg 10920
atggtgcact ctgagtacaa tctgctctga tgccgcatag ccccgacacc cgccaacacc cgctgacgag 10980
ctatcgctac gtgactgggt catggctgcg ccccgacacc gcttacagac aagctgtgac cgtctccggg 11040
ccctgacggg cttgtctgct cccggcatcc gcttacagac aagctgtgac cgtctccggg 11100
agctgcatgt gtcagaggtt ttcaccgtca tcaccgaaac gcgcgaggca gc 11152

```

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 13

gacggatcgg gagatctcc

19

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 14
ccgcctcaga agccatagag cc.

22

<210> 15
<211> 14455
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 15
aagcttgggc agaaatggtt gaactcccga gagtgtccta cacctagggg agaagcagcc 60
aaggggttgt ttcccaccaa ggacgaccg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcattctctg ctgcaaatctt ggcatactgc tgctttgcct ggggctattg 180
ggggaagttg cggttcgtgc tcgcagggct ctcacccttg actcttttaa tagctcttct 240
gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
cagccaactt cctcttacia gccgcacga ttttgcctt cagaaataga aataagaatg 360
cttgctaaaa attatatttt atcttttagt actattttta ctcaaattca gaagttagaa 480
atggttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480
atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaaaggga aaaaagagtg tttttgtcaa aataggagac 600
agggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgcccc 660
ttaccatata caggaagata tgacttaaat tgggataggt ggggtacagt caatggctat 720
aaagtgttat atagatccct cccttttcgt gaaagactcg ccagagctag acctccttgg 780
tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatttat 840
ctagaaacag gaatgcactt ttgggaaag attttccata ccaaggaggg gacagtggct 900
ggactaatag aacattatct tgcaaaaact catggcatga gttattatga atagccttta 960
ttggcccaac cttgcgggtc ccagggtcta agtaagtttt tgggtacaaa ctgttcttaa 1020
aacgaggatg tgagacaagt ggtttcctga cttgggttgg tatcaaaggt tctgatctga 1080
gctctgagtg ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaatgc 1140
ttatgtaaac caagatatga attttttgag taaacttgca caagtcctaa atagtcctaa 1200
cattcacctc ttgtgtgttt gtgtctgttc gccatcccg ctccgctcgt cacttatcct 1260
tcactttcca gaggggtccc ccgcagaccc cggcgaccct caggtcggcc gactgcccga 1320
gctggcgccc gaacagggac cctcggataa gtgacccttg tctctatttc tactatttgg 1380
tgtttgtctt gtattgtctc ttctttgtct ggctatcatc acaagagcgg aacggactca 1440
ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500
accgaagaaa tggccgcccag tcttttgagc cagctgatcg aagaggtact ggctgataat 1560
cttccacctc ctagccattt tgaaccacct accttcacg aactgtatga tttagacgtg 1620
acggcccccg aagatcccaa cgaggaggcg gtttcgcaga tttttcccga ctctgtaaatg 1680
ttggcgggtg aggaagggat tgacttactc acttttcgc cggcgccgg ttctccggag 1740
ccgcctcacc tttcccggca gcccagacag ccggagcaga gagccttggg tccggtttct 1800
atgccaaacc ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860
agtgcagacg aggatgaaga ggggtgaggag tttgtgttag attatgtgga gcaccccggg 1920
cacgggtgca ggtcttgtca ttatcaccgg aggaatacgg gggaccaga tattatgtgt 1980
tcgctttgct atatgaggac ctgtggcatg tttgtctaca gtaagtgaat attatgggca 2040
gtgggtgata gagtgggtgg tttgggtgtg taattttttt ttttaatttt acagttttgt 2100
ggtttaaaga attttgtatt gtgatttttt taaaagggtc tgtgtctgaa cctgagcctg 2160
agccccagac agaaccggag cctgcaagac ctaccgccc tcctaaaatg gcgcctgcta 2220
tctgagacg cccgacatca cctgtgtcta tagtagtagc gatagctgtg 2280
actccggtcc ttctaacaca cctcctgaga tacaccgggt ggtcccgtg tgccccatta 2340
aaccagttgc cgtgagagtt ggtgggcgtc gccaggctgt ggaatgtatc gaggacttgc 2400
ttaacgagcc tgggcaacct ttggacttga gctgtaaaacg ccccgaggcca taaggtgtaa 2460

acctgtgatt	gcgtgtgtgg	ttaacgcctt	tgtttgcgtga	atgagttgat	gtaagtttaa	2520
taaaggggtga	gataatgttt	aacttgcatg	gcgtgtttaa	tggggagggt	cttaaagggt	2580
atataatgcg	ccgtgggcta	atcttggtta	catctgacct	catggaggct	tgaggagtgt	2640
tggaagattt	ttctgctgtg	cgtaacttgc	tggaacagag	ctctaacagt	acctcttggg	2700
tttggagggt	tctgtggggc	tcatcccagg	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atgtgaagag	cttttgaaat	cctgtggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcatcaagac	tttggatttt	tccacaccgg	2880
ggcgcgctgc	ggctgctgtt	gcttttttga	gttttataaa	ggataaatgg	agcgaagaaa	2940
cccatctgag	cgggggggtac	ctgctggatt	ttctggccat	gcatctgtgg	agagcgggtg	3000
tgagacacaa	gaatcgctcg	ctactgttgt	cttccgctccg	cccggcgata	ataccgacgg	3060
aggagcagca	gcagcagcag	gagggaagcca	ggcggcgggcg	gcaggagcag	agcccatgga	3120
acccgagagc	cggcctggac	cctcgggaat	gaatgttgta	cagggtggctg	aactgtatcc	3180
agaactgaga	cgcattttga	caattacaga	ggatgggcag	gggctaaagg	gggtaaagag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctagggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgtg	ttacttttca	acagatcaag	gataattgcg	ctaattgagct	3360
tgatctgtcg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tgagcgcagg	3420
ggatgatttt	gaggaggcta	ttagggtata	tgcaaaagggtg	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaacttg	taaatatcag	gaattgttgc	tacatttctg	ggaacggggc	3540
cgaggtggag	atagatacgg	aggatagggt	ggcctttaga	tgtagcatga	taaatatgtg	3600
gccgggggtg	cttggcatgg	acgggggtgg	tattatgaat	gtaaggttta	ctggcccaa	3660
ttttagcggg	acgggttttc	tggccaatc	caaccttatc	ctacacgggtg	taagcttcta	3720
tgggtttaac	aatacctgtg	tggaagcctg	gaccgatgta	aggggttcggg	gctgtgcctt	3780
ttactgtctg	tggaaggggg	tggtgtgtcg	ccccaaaagc	agggcttcaa	ttaagaaatg	3840
cctctttgaa	aggtgtacct	tggttatcct	gtctgagggg	aactccaggg	tgcgccacaa	3900
tgtggcctcc	gactgtgggt	gcttcatgct	agtgaagagc	gtggctgtga	ttaagcataa	3960
catggtatgt	ggcaactgcg	aggacagggt	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgtagc	cagccactct	cgcaaggcct	ggccagtgtt	4080
tgagcataac	atactgaccc	gctgttcctt	gcatttgggt	aacaggaggg	gggtgttcct	4140
accttaccac	tgcaatttga	gtcacactaa	gatattgctt	gagcccagga	gcatgtccaa	4200
gggtgaacctg	aacgggggtg	tgacatgac	catgaagatc	tggaagggtg	tgagggtacga	4260
tgagaccgct	accagggtgca	gacctgcca	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccagatcac	ttggtgctgg	cctgcacccg	4380
cgctgagttt	ggctctagcg	atgaagatac	agattgaggt	actgaaatgt	gtgggcgtgg	4440
cttaagggtg	ggaaagaata	tataagggtg	gggtcttatg	tagtttttga	tctgttttgc	4500
agcagccgct	gcccgcctga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggcccgggt	gcgtcagaat	gtgatgggct	ccagcattga	4620
tggtcgcccc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gccgttgag	actgcagcct	ccgcgcgcgc	ttcagccgct	gcagccaccg	cccgcggggt	4740
tgtgactgac	tttgccttcc	tgagcccgtc	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttggc	acaattggat	tctttgaccc	gggaacttaa	4860
tgctggttct	cagcagctgt	tggtctgcg	ccagcagggt	tctgccctga	aggcttccct	4920
ccctcccaat	gcgggtttaa	acataaataa	aaaaccagac	tctgtttgga	tttggtatcaa	4980
gcaagtgtct	tgctgtctct	cgaggatctc	ttgtgaagga	accttacttc	tgtgggtgta	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgttaaacta	ctgattctaa	ttgtttgtgt	atttttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tggtggaatg	cctttaatga	ggaaaacctg	ttttgtctag	5220
aagaaatgcc	atctagtgtg	gatgaggcta	ctgtgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gacccaagg	actttccttc	agaattgcta	agttttttga	5340
gtcatgctgt	gtttagtaat	agaactcttg	cttgccttgc	tatttacacc	acaaaggaaa	5400
aagctgcact	gctatacaag	aaaattatgg	aaaaatatcc	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgtctg	5520
ctattaataa	ctatgctcaa	aaattgtgta	cctttagctt	tttaatttgt	aaaggggtta	5580
ataaggaata	tttgatgtat	agtgcttga	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	5700
atgaatgcaa	ttgttgttgt	taactgtttt	attgcagctt	ataatgggtta	caaataaagc	5760
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcatctctag	ttgtgggttg	5820
tccaaactca	tcaatgtatc	ttatcatgtc	tggtaccggc	tggtggaatg	gtgtcagtta	5880
gggtgtggaa	agtcccaggg	ctccccagca	ggcagaagta	tgcaaagcat	gcatctcaat	5940
tagtcagcaa	ccagggtgtg	aaagtcccca	ggctccccag	caggcagaag	tatgcaaagc	6000
atgcatctca	attagtcagc	aaccatagtc	ccgcccctaa	ctccgcccct	cccgcoccta	6060
actccgcccc	gttccgcccc	ttctccgccc	catggctgac	taattttttt	tattttatga	6120
gaggccgagg	ccgctcgggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttggg	6180

ggcctaggct tttgcaaaaa gcttggacac aagacaggct tgcgagatat gtttgagaat 6240
accactttat cccgcgtcag ggagaggcag tgcgtaaaaa gacgcggact catgtgaaat 6300
actgggtttt agtgccgagc atctctataa tctcgcgcaa cctattttcc cctcgaacac 6360
tttttaagcc gtagataaac aggtggggac acttcacatg agcgaaaaat acatcgtcac 6420
ctgggacatg ttgcagatcc atgcacgtaa actcgcaagc cgactgatgc cttctgaaca 6480
atggaaaggg attattgccc taagccgtgg cgggtcggta ccgggtgcgt tactggcgcg 6540
tgaactgggt attcgatcag tcgataccgt ttgtatttcc agctacgatc acgacaacca 6600
gcgcgagctt aaagtgcgtg aacgcgcaga aggcgatggc gaaggcttca tcggtattga 6660
tgacctgggt gataccgggt gtactgcggt tgcgattcgt gaaatgtatc caaaagcgca 6720
ctttgtcacc atcttcgcaa aaccggctgg tcgctccgctg gttgatgact atgttgttga 6780
tatcccgcga gatacctgga ttgaacagcc gtgggatatg ggcgtcgtat tcgctccgcc 6840
aatctccggt cgctaattct ttcaacgcct ggcactgccg ggcgttgttc tttttaactt 6900
caggcggggt acaatagttt ccagtaagta ttctggaggc tgcattcatg acacaggcaa 6960
acctgaagca aaccctgttc aaaccccgct ttaaaccatcc tgaacctcg acgctagtc 7020
gccgctttaa tcacggcgca caaccgctg ccttgatggg aaaacctacc 7080
ctcactggta tcgcatgatt aaccgtctga tgtggatctg gcgcggcatt gacccacgcg 7140
aaatcctcga cgtccaggca cgtattgtga tgagcgatgc cgaacgtacc gacgatgatt 7200
tatacgatac ggtgattggc tactcggtggc gcaactggat ttatgagtgg gcccgggac 7260
tttgtgaagg aaccttactt ctgtgggtgtg acataattgg agtcattggt acaaaactacc tacagagatt 7320
taaagctcta aggtaaatat aaaattttta agtgtataat gtgttaaact actgattcta 7380
attgtttgtg tatttttagat tccaacctat gttttgtcga gaagaaatgc aatgggagca gtggtggaat 7440
gcctttaatg agggaaacct tactcctcca aaaaagaaga gaaaggtaga agaccccaag 7500
actgctgact ctcaacattc tagaattgct aagtttttgg agtcattgct tgtttagtaa tagaactctt 7560
gactttcctt ctattttacac cacaaggaa aaagctgcac cataacagtt ataatacataa actatgctca 7620
gcttgctttg ctgtaacctt tataagtagg gctattaata aataagggaat atttgatgta tagtgcctg 7680
gaaaaatatt tttcttactc cacacaggca tagagtgtct tgaaggaat ttacttgctt taaaaacct 7740
acttttagct ataatacagc ataccacatt tgtagagggt aatgaatgca caaatattca caaataaagc 7800
ccacacacct cccctgaacc tgaacataa caatagcatc gtccaaactc atcaatgtat cttatcatgt 8100
tattgcagct tataatgggt gttgtgggtt tctgtgtcct cataaaccct aacctcctct acttgagagg 8160
atattccaat cataggctgc ccatccaccc tctgtgtcct cctgttaatt aggtcactta 8220
acaaaaagga aattgggtag ggggttttca cagaccgctt tctaagggta attttaaaat 8280
atctgggaag tcccttccac tgctgtgttc cagaagtgtt ggtaaacagc ccacaaatgt 8340
caacagcaga aacatacaag ctgtcagctt tgcacaaggg ccaacacccc tgcctcatca 8400
gaagcactgt ggttgctgtg ttagtaattg gcaaaacagg aggcacattt tccccacctg 8460
tgtaggttcc aaaatatcta gtgttttcat ttttacttgg atcaggaacc cagcactcca 8520
ctggataagc attatcctta tccaaaacag ccttgtgggtc agtggttcac tgctgactgt 8580
caactgtagc attttttggg gttacagttt gagcaggata tttgggtcctg tagtttgcta 8640
acacacctg cagctccaaa ggttccccac caacagcaaa aaaatgaaaa ttgacctt 8700
gaatgggttt tccagcacca ttttcatgag tttttgtgt ccctgaatgc aagtttaaca 8760
tagcagttac cccaataacc tcagttttaa cagtaacagc ttccccacatc aaaatatttc 8820
cacaggttaa gtccctcattt aaattaggca aaggaattct tgaagacgaa agggcctcgt 8880
gatacgctta tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcaggtgg 8940
cacttttcgg ggaaatgtgc gcggaacccc tatttgttta ttttctaaa tacattcaaa 9000
tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa 9060
gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcct 9120
tcctgttttt gctcaccag aaacgctggg gaaagtaaaa gatgctgaag atcagttggg 9180
tgacagagtg ggttacatcg aactggatct aagatccttg aagattttcg 9240
ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcgggtatt 9300
atcccgtgtt gacgcggggc aagagcaact cggtcgccgc atacactatt ctccagatga 9360
cttggttgag tactcaccag tcacagaaaa gcatcttacg gatggcatga cagtaagaga 9420
attatgcagt gctgccataa ccatgagtga taacctgtt ttgcaaac aacgacgagc gtgacaccac 9480
gatcgaggga ccgaaggagc taaccgcttt ttgcaaac atgggggatc atgtaacctg 9540
ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac 9600
gatgcctgca gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct 9660
agcttccggg caacaattaa tagactggat ggaggcggat aaagttgcag gaccacttct 9720
gcgctcggcc cttccggctg cctgggttat gctgataaaa tctggagccg gtgagcgtgg 9780
gtctcggggt atcattgcag cactggggcc agatggtaag cctcccgta tcgtagttat 9840
ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg 9900

tgccctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	tacttttagat	9960
tgatttaaaa	cttcattttt	aattttaaaag	gatctagggtg	aagatccttt	ttgataatct	10020
catgaccaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	10080
gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	10140
aaaaccaccg	ctaccagcgg	tggtttgttt	gccggatcaa	gagctaccaa	ctctttttcc	10200
gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gtccttctag	tgtagccgta	10260
gttaggccac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	tgctaatect	10320
gttaccagtg	gctgctgcca	gtggcgataa	gtcgtgtcct	accgggttgg	actcaagacg	10380
atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	cacagcccag	10440
cttgaggcga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	10500
cacgcttccc	gaaggagaa	aggcggacag	gtatccggta	agcggcaggg	tcggaacagg	10560
agagcgcacg	aggagcctc	cagggggaaa	cgcttgggtat	ctttatagtc	ctgtcgggtt	10620
tcgccacctc	tgaactgagc	gtcgattttt	gtgatgctcg	tcaggggggc	ggagccctatg	10680
gaaaaacgcc	agcaacgcgg	cctttttacg	gttctctggc	ttttgctggc	cttttgctca	10740
catgttcttt	cctgcgttat	cccctgattc	tgtggataac	cgtattaccg	cctttgagtg	10800
agctgatacc	gctcgcgcga	gccgaacgac	cgagcgcagc	gagtcagtga	cgaggaagc	10860
ggaagagcgc	ctgatgcggg	attttctcct	tacgcactctg	tgcggtattt	cacaccgcat	10920
accgcctcag	aagccataga	gcccaccgca	tccccagcat	gcctgctatt	gtcttcccaa	10980
tcctccccct	tgctgtcctg	ccccacccca	ccccccagaa	tagaatgaca	cctactcaga	11040
caatgcgatg	caatttcttc	attttattag	gaaaggacag	tgggagtggc	accttecagg	11100
gtcaagggaag	gcacggggga	ggggcaaaaca	acagatggct	ggcaactaga	aggcacagtc	11160
gaggtctatc	agcgagctct	agcatttagg	tgacactata	gaatagggcc	ctctagatgc	11220
atgctcgagc	ggccgcttct	ttattcttgg	gcaatgtatg	aaaaagtgtg	agaggatgtg	11280
gcaaataatt	cattaatgta	gttgtggcca	gaccagtcct	atgaaaatga	catagagtat	11340
gcacttggag	ttgtgtctcc	tgtttctcgt	gtaccgttta	gtgtaatggt	tagtggttac	11400
ggtttagttt	tgtctccggt	taagtaaaact	tgactgacaa	tgttactttt	ggcagtttta	11460
ccgtgagatt	ttggataagc	tgatagggtta	ggcataaaatc	caacagcggt	tgtataggct	11520
gtgccttcag	taagatctcc	atttctaaag	ttccaatatt	ctgggtccag	gaaggaattg	11580
tttagtagca	ctccattttc	gtcaaactct	ataataagat	gagcactttg	aactgttcca	11640
gatattggag	ccaaactgcc	tttaacagcc	aaaactgaaa	ctgtagcaag	tatttgactg	11700
ccacattttg	ttaagaccaa	agtgaagtta	gcacttttct	ctgcatttag	tctacagtta	11760
ggagatggag	ctggtgtggt	ccacaaagtt	agcttatcat	tatttttggt	tcctactgta	11820
atggcacctg	tgctgtcaaa	actaaggcca	gttcctagtt	taggaacct	agccttggtt	11880
gaatcaaatt	ctaggccatg	gccaatttt	gttttgagg	gatttggtt	tggtgcatta	11940
ggtgaaccaa	attcaagccc	atctcctgca	ttaatggcta	tggctgtagc	gtcaaacatc	12000
aaccccttgg	cagtgccttag	gttaacctca	agcttttttg	aattgtttga	agctgtaaac	12060
aagtaaaggc	ctttgtttgta	gttaatatcc	aagttgtggg	ctgagtttat	aaaaagaggg	12120
ccctgtccta	gtcttagatt	tagttggttt	tgagcatcaa	acggataact	aacatcaagt	12180
ataaggcgtc	tgttttgaga	atcaatcctt	agtcctcctg	ctacattaa	ttgcatattg	12240
ccttgatgaat	caaaaaccaa	ggctccagta	actttagttt	gcaaggaagt	attattaata	12300
gtcacacctg	gaccagttgc	tacggtcaaa	gtgttttaggt	cgtctgttac	atgcaaagga	12360
gccccgtact	ttagtcctag	ttttccattt	tgtgtataaa	tgggctcttt	caagtcaatg	12420
cccaagctac	cagtggcagt	agtttagagg	ggtgaggcag	tgatagtaag	ggtactgcta	12480
tcggtgggtg	tgaggggggc	tgatgtttgc	agggctagct	ttccttctga	cactgtgagg	12540
ggctccttgg	tggcaatgct	aagtttggag	tcgtgcacgg	ttagcggggc	ctgtgattgc	12600
atggtgagtg	tggtgccccg	gaccattaga	ggtgccccgg	cagccacagt	tagggcttct	12660
gaggttaactg	tgaggggtgc	agatatttcc	aggtttatgt	ttgacttggg	ttttttgaga	12720
ggtgggctca	cagtgggttac	attttgggag	gtaaggttgc	cggcctcgtc	cagagagagg	12780
ccgttgccca	ttttgagcgc	aagcatgcca	ttggaggtaa	ctagagggtc	ggataggcgc	12840
aaagagagta	ccccaggggg	actctcttga	aaccatttgg	gggatacaaa	gggaggagta	12900
agaaaaggca	cagttggagg	accggtttcc	gtgtcatatg	gatacacggg	gttgaaggta	12960
tcttcagacg	gtcctgcgcg	cttcactctg	gatctcaagc	ctgccacacc	tcacctcgac	13020
catccgcgtg	ctcaagaccg	cctactttaa	ttacatcatc	agcagcacct	ccgccagaaa	13080
caaccccgac	cgccacccgc	tgcgcgccgc	cacggtgctc	agcctacctt	gcgactgtga	13140
ctgggttagac	gcctttctcg	agaggttttc	cgatccgggc	gatcgggact	cgctcaggtc	13200
cctcggtggc	ggagtaccgt	tcggaggccg	acgggtttcc	gatccaagag	tactggaaaag	13260
accgcgaaga	gtttgtcctc	aaccgcgagc	ccaacgcga	gctcgaatc	agatccgagc	13320
tcggtacca	gcttgggtct	ccctatagtg	agtcgtatta	atttcgataa	gccagtaagc	13380
agtgggttct	ctagttagcc	agagagctct	gcttatatag	acctcccacc	gtacacgcct	13440
accgcccatt	tgcgtaaatg	gggcggagtt	gttacgacat	tttggaaggt	cccggttgatt	13500
ttggtgccaa	aacaaactcc	cattgacgtc	aatgggggtg	agacttgga	atccccgtga	13560
gtcaaacgcg	tatccacgcg	cattgatgta	ctgccaaaac	cgcatcacca	tggtaatagc	13620

```
gatgactaat acgtagatgt actgccaagt aggaaagtcc cataaggtca tgtactgggc 13680
ataatgccag gcgggccatt taccgtcatt gacgtcaata gggggcgtag ttggcatatg 13740
atacacttga tgtactgcca agtgggcagt ttaccgtaaa tagtccaccc attgacgtca 13800
atggaaagtc cctattggcg ttactatggg aacatacgtc attattgacg tcaatgggcg 13860
gggggtcggtg ggcggtcagc caggcgggcc atttaccgta agttatgtaa cgcggaactc 13920
catatatggg ctatgaacta atgaccccg tattgattac tattaataac tagtcaataa 13980
tcaatgtcaa cgcgtatata tggcccgtag atcgcgaagc agcgcaaaac gcctaaccct 14040
aagcagattc ttcatgcaat tgcggtcaa gccttgccct gttgtagctt aaattttgct 14100
cgcgactac tcagcgacct ccaacacaca agcagggagc agatactggc ttaactatgc 14160
ggcatcagag cagattgtac tgagagtcga ccatagggga tcgggagatc tcccgatccg 14220
tctatgggtc actctcagta caatctgtc tgatgcccga tagttaagcc agtatacact 14280
ccgctatcgc tacgtgactg ggtcatggct gcgccccgac acccgccaac acccgctgac 14340
gcgccttgac gggcttgctt gtcgccgca tccgcttaca gacaagctgt gaccgtctcc 14400
gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag gcagc 14455
```

<210> 16

<211> 10610

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 16

```
gacggatcgg gagatccgcg cggtagacag aattcaggag acacaactcc aagtgcatac 60
tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 120
tcctcttaca ctttttcata cattgcccaa gaataaagaa tcgtttgtgt tatgtttcaa 180
cgtgtttatt tttcaattgc agaaaatttc aagtcatttt tcattcagta gtatagcccc 240
accaccacat agcttatata gatcaccgta ccttaatcaa actcacagaa ccctagtatt 300
caacctgcca cctccctccc aacacacaga gtacacagtc ctttctcccc ggtggcctt 360
aaaaagcatc atatcatggg taacagacat attcttaggt gttatatcc acacggttcc 420
ctgtcgagcc aaacgctcat cagtgatatt aataaactcc ccgggcagct cacttaagtt 480
catgtcgctg tccagctgct gagccacagg ctgctgtcca acttgcggtt gcttaacggg 540
cggcgaagga gaagtccacg cctacatggg ggtagagtca taatcgtgca tcaggatagg 600
gcggtgggtg tgcagcagcg cgcaataaaa ctgctgccgc cgccgctccg tcctgcagga 660
atacaacatg gcagtggtct cctcagcgat gattcgacc gcccgagca taaggcgctt 720
tgtctccggg gcacagcagc gcacctgat ctacttaaaa tcagcacagt aactgcagca 780
cagcaccaca atattgttca aaatcccaca gtgcaaggcg ctgtatccaa agctcatggc 840
ggggaccaca gaacccacgt ggccatcata ccacaagcgc aggtagatta agtggcgacc 900
cctcataaac acgctggaca taaacattac ctcttttggc atgttgtaat tcaccacctc 960
ccggtaccat ataaacctct gattaaacat gcgcgccatcc accaccatcc taaaccagct 1020
ggccaaaacc tgcccgccgg ctatacactg cagggaaccg ggactggaac aatgacagtg 1080
gagagccag gactcgtaac catggatcat catgctcgtc atgatataa tgttggcaca 1140
acacaggcac acgtgcatac acttctcag gattacaagc tctctcccg ttagaaccat 1200
atcccaggga acaaccatt cctgaatcag cgtaaatccc acactgcagg gaagacctcg 1260
cacgtaactc acgttgtgca ttgtcaaagt gttacattcg ggcagcagcg gatgatctc 1320
cagtatggta gcgcgggttt ctgtctcaaa aggaggtaga cgatccctac tgtacggagt 1380
gcgcccagac aaccgagatc gtgttggtcg tagtgtcatg ccaaattggaa cgccggacgt 1440
agtcataatt cctgaagcaa aaccaggtgc gggcgtgaca aacagatctg cgtctccggt 1500
ctgcgcgtt agatcgctct gtgtagtagt ttgtatatat ccactctctc aaagcatcca 1560
ggcgccccct ggcttcgggt tctatgtaaa ctcttcatg cgccgctgoc ctgataacat 1620
ccaccaccgc agaataagcc acaccagcc aacctacaca ttcgttctgc gagtcacaca 1680
cgggaggagc ggggaagagc ggaagaacca tgttttttt tttattccaa aagattatcc 1740
aaaacctcaa aatgaagatc tattaagtga acgcgtccc ctccggtggc gtggtcaaac 1800
tctacagcca aagaacagat aatggcattt ctcaaatggt gcacaatggc ttccaaaagg 1860
caaacggccc tcacgtccaa gtggacgtaa aggctaaacc cttcagggtg aatctcctct 1920
ataaacattc cagcaccttc aacctgccc aaataattct catctcgcca ccttctcaat 1980
atatctctaa gcaaatcccg aatattaagt ccggccattg taaaaatctg ctccagagcg 2040
ccctccacct tcagcctcaa gcagcgaatc atgattgcaa aaattcaggt tctccacaga 2100
cctgtataag attcaaaagc ggaacattaa caaaaatacc gcgatcccgt aggtcccttc 2160
gcagggccag ctgaacataa tcgtgcaggt ctgcacggac cagcgcgcc acttccccgc 2220
```

caggaacctt	gacaaaagaa	cccacactga	ttatgacacg	catactcgga	gctatgctaa	2280
ccagcgtagc	cccgatgtaa	gctttgttgc	atgggcgggc	atataaaatg	caaggtgctg	2340
ctcaaaaaat	caggcaaagc	ctcgcgcaaa	aaagaaagca	catcgtagtc	atgctcatgc	2400
agataaaggc	aggtaagctc	cggaaaccacc	acagaaaaag	acaccatttt	tctctcaaac	2460
atgtctgctg	gtttctgcat	aaacacaaaa	taaaaataaca	aaaaaacatt	taaaccattag	2520
aagcctgtct	tacaacagga	aaaacaaccc	ttataagcat	aagacggact	acggccatgc	2580
cggcgtgacc	gtaaaaaaac	tggtcaccgt	gattaaaaag	caccaccgac	agctcctcgg	2640
tcatgtccgg	agtcataatg	taagactcgg	taaacacatc	agggtgatcc	atcggctcagt	2700
gctaaaaagc	gaccgaaata	gcccggggga	atacatacc	gcaggcgtag	agacaacatt	2760
acagccccca	taggaggtat	aacaaaatta	ataggagaga	aaaacacata	aacacctgaa	2820
aaacctcct	gcctaggcaa	aatagcacc	tcccgtcca	gaacaacata	cagcgcttca	2880
cagcgcgagc	ctaacagtca	gccttaccag	taaaaaagaa	aacctattaa	aaaaacacca	2940
ctcgacacgg	caccagctca	atcagtcaca	gtgtaaaaaa	gggccaagt	cagagcgagt	3000
atatatagga	ctaaaaaatg	acgtaacggt	taaagtccac	aaaaaacacc	cagaaaaaccg	3060
cacgcgaacc	tacgccaga	aacgaaagcc	aaaaaaccca	caacttcctc	aaatcgtcac	3120
ttcogtttcc	ccacgttagc	taacttcccg	gatcctctcc	cgatccccta	tggtcgactc	3180
tcagtacaat	ctgctctgat	gccgcatagt	taagccagta	tctgctccct	gcttggtgtg	3240
tggaggtcgc	tgagtagtgc	gcgagcaaaa	tttaagctac	aacaaggcaa	ggcttgaccg	3300
acaattgcat	gaagaatctg	cttaggggta	ggcgttttgc	gctgcttcgc	gatgtacggg	3360
ccagatatac	gcgttgacat	tgattattga	ctagtattta	atagtaatca	attacggggg	3420
cattagttca	tagcccatat	atggagttcc	cggttacata	acttacggta	aatggcccg	3480
ctggctgacc	gccaacgac	ccccgcccat	tgacgtcaat	aatgacgtat	gttcccatag	3540
taacgccaat	agggactttc	cattgacgtc	aatgggtgga	ctatttacgg	taaactgccc	3600
acttggcagt	acatcaagt	tatcatatgc	caagtacgcc	ccctattgac	gtcaatgacg	3660
gtaaatggcc	gccttgccat	tatgcccagt	atgggacttt	atgggacttt	cctacttgcc	3720
agtacatcta	cgtattagtc	atcgctatta	ccatgggtgat	gcggttttgg	cagtacatca	3780
atgggcgtgg	atagcggttt	gactcacggg	gatttccaag	tctccacccc	attgacgtca	3840
atgggagttt	gttttggcac	caaaatcaac	gggactttcc	aaaatgtcgt	aacaactccg	3900
ccccattgac	gcaaatgggc	ggtaggcgtg	tacggtggga	ggtctatata	agcagagctc	3960
tctggctaac	tagagaaccc	actgcttact	ggcttatcga	aattaatacg	actcactata	4020
gggagacca	agcttggtac	cgagctcgga	tctgaattcg	agctcgctgt	tgggctcgcg	4080
ggtgaggaca	aactcttcgc	ggtctttcca	gtactcttgg	atcggaiaacc	cgtcggccctc	4140
cgaacgggtac	tccgccaccg	agggaacctga	gcgagtcggc	atcgaccgga	tccgaaaacc	4200
tctcgagaaa	ggcgtctaac	cagtcacagt	cgcaaggtag	gctgagcacc	gtggcgggcg	4260
gcagcggtg	gcggtcgggg	ttgtttctgg	cggaggtgct	gctgatgatg	taattaaagt	4320
aggcggtctt	gagacggcgg	atggctcgagg	tgaggtgtgg	caggcttgag	atccaagatg	4380
aagcgcgcaa	gaccgtctga	agataccttc	aaccccggtg	atccatata	cacggaaacc	4440
ggctctccaa	ctgtgccttt	tcttactcct	ccctttgtat	cccccaatgg	gtttcaagag	4500
agtcctccctg	gggtactctc	tttgcccta	tccgaacctc	tagttacctc	caatgctatg	4560
cttgcgctca	aaatgggcaa	cggcctctct	ctggacgagg	ccggcaacct	tacctcccaa	4620
aatgtaacca	ctgtgagccc	acctctcaaa	aaaaccaagt	caaacataaa	cctgggaaata	4680
tctgcacccc	tcacagttac	ctcagaagcc	ctaactgtgg	ctgcccggcg	acctctaatt	4740
gtcgcgggca	acacactcac	catgcaatca	caggccccgc	taaccgtgca	cgactccaaa	4800
cttagcattg	ccacccaagg	acctctcaca	gtgtcagaag	gaaagctagc	cctgcaaaaa	4860
tcaggccccc	tcaccaccac	cgatagcagt	accttacta	tcactgcctc	acccctctta	4920
actactgcca	ctggtagctt	gggcattgac	ttgaaagagc	ccatttatat	acaaaatgga	4980
aaactaggac	taaagtacgg	ggctcctttg	cattgtaacg	acgacctaaa	cactttgacc	5040
gtagcaactg	gtccagggtg	gactattaat	aatacttctt	tgcaaaactaa	agttactgga	5100
gccttggtgt	ttgattcaca	aggcaatatg	caacttaatt	tagcaggagg	actaaggatt	5160
gattctcaaa	acagacgcct	tatacttgat	gttagttatc	cgtttgatgc	tcaaaaacca	5220
ctaaatctaa	gactaggaca	gggcccctct	tttataaaact	cagccacaaa	cttggaattt	5280
aactacaaca	aaggccttta	cttggttaca	gcttcaaaaa	attccaaaaa	gcttgagggt	5340
aacctaaagc	ctgccaaggg	gttgatgttt	gacgctacag	ccatagccat	taatgcagga	5400
gatgggcttg	aatttggttc	acctaatgca	ccaacacaaa	atccctcaa	aacaaaaatt	5460
ggccattggc	tagaatttga	ttcaaaaca	gctatgggtc	ctaaactagg	aactggccct	5520
agttttgaca	gcacaggtgc	cattacagta	ggaaacaaaa	ataatgataa	gctaactttg	5580
tggaccacac	cagctccatc	tcctaactgt	agactaaatg	cagagaaaaga	tgctaacttc	5640
actttgggtc	taacaaaatg	tggcagtcac	atacttgcta	cagtttcagt	tttggtgtgt	5700
aaaggcagtt	tggctccaat	atctggaaca	gttcaaaagt	ctcatcttat	tataagattt	5760
gacgaaaatg	gagtgctact	aaacaattcc	ttcctggacc	cagaatattg	gaactttaga	5820
aatggagatc	ttactgaagg	cacagccttg	acaaacgctg	ttggatttat	gctaacccta	5880
tcagcttacc	caaaatctca	cggtaaaact	gccaaaagta	acattgtcag	tcaagtttac	5940

ttaaaccggag acaaaactaa acctgtaaca ctaaccatta cactaaacgg tacacaggaa 6000
acaggagaca caactccaag tgcatactct atgtcatttt catgggactg gtctggccac 6060
aactacatta atgaaatatt tgccacatcc tcttacactt tttcatacat tgcccaagaa 6120
taaagaagcg gccgctcgag catgcatcta gagggcccta ttctatagtg tcacctaaat 6180
gctagagctc gctgatcagc ctcgactgtg ccttctagtt gccagccatc tgttgtttgc 6240
ccctcccccg tgcttccctt gaccctggaa ggtgccactc ccactgtcct ttcttaataa 6300
aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg ggggtggggtg 6360
gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcattgctgg ggatggcggtg 6420
ggctctatgg cttctgaggc ggaaagaacc agctgggggt ctagggggta tccccacgcg 6480
ccctgtagcg gcgcattaa ggcggcggtt atgcatctca cgcgagcgt gaccgctaca 6540
cttgccagcg ccctagcgcc cgctcctttc gctttcttcc ctctctttct cgccacgttc 6600
gccggctttc ccgtcaagc tctaaatcgg ggcatccctt tagggttccg atttagtgct 6660
ttacggcacc tcgaccocaa aaaacttgat tagggtagtg gttcacgtag tggggccatcg 6720
ccctgataga cggtttttcg ccttttgacg ttggagtcca cgttctttaa tagtggactc 6780
ttgttccaaa ctggaacaa actcaaccct atctcggtct attcttttga tttataaggg 6840
attttgggga tttcgcccta ttggttaaaa aatgagctga ttttaacaaa atttaacgcg 6900
aattaattct gtggaatgtg tgtcagttag ggtgtggaaa gtccccaggc tccccaggca 6960
ggcagaagta tgcaaaagcat gcatctcaat tagtcagcaa ccagggtgtg aaagtcccca 7020
ggctccccag caggcagaag tatgcaaagc atgcatctca attagttagc aaccatagtc 7080
ccgccccctaa ctccgccccat cccgccccct actccgcccc gttccgcccc ttctccgccc 7140
catggctgac taattttttt tatttatgca gagggccagg ccgctctgct ctctgagcta 7200
ttccagaagt agtgaggagg ctttttttga ggcctaggct tttgcaaaaa gctcccgga 7260
gcttgatat ccattttcgg atctgatcaa gagacaggat gaggatcggt tcgcatgatt 7320
gaacaagatg gattgcacgc aggttctccg gccgcttggg tggagaggct attcggtat 7380
gactgggcac aacagacaat cggctgctct gatgccgccc tgttccggct gtcagcgag 7440
gggcgccccg ttctttttgt caagaccgac ctgtccgggt ccctgaatga actgcaggac 7500
gaggcagcgc ggctatcgtg gctggccacg acgggcgctt cttgcgcage tgtgctcgac 7560
gttgtcactg aagcgggaag ggactggctg ctattgggag aagtgccggg agaggatetc 7620
ctgtcatctc accttgctcc tgccgagaaa gtatccatca tggctgatgc aatgcgggg 7680
ctgcatacgc ttgatccggc tacctgccca ttccgaccacc aagcgaaaca tcgcatcgag 7740
cgagcacgta ctccggatgga agccggtcct gtcgatcagg atgatctgga cgaagagcat 7800
caggggctcg cgccagccga actgttcgag aggtcacaag cgcgcatgcc cgacggcgag 7860
gatctcgctg tgacccatgg cgatgctgct ttgccgaata tcatgggtga aaatggccg 7920
ttttctggat tcatcgactg tggccggctg ggtgtggcgg accgctatca ggacatagcg 7980
ttggctaccc gtgatattgc tgaagagctt ggcggcgaaat gggctgaccg cttcctcgct 8040
ctttacggta tcgcgcctcc cgattcgag cgcctcgct tctatcgct tcttgacgag 8100
ttcttctgag cgggactctg gggttcgaaa tgaccgacca agcgacgccc aacctgccat 8160
cacgagattt cgattccacc gccgccttct atgaaagggt gggcttcgga atcgttttcc 8220
gggacgccgg ctggatgatc ctccagcgcg gggatctcat gctggagttc ttccgccacc 8280
caaacttggt tattgcagct tataatgggt acaaaataag caatagcatc acaaatttca 8340
caaataaagc atttttttca ctgcatctta gtttggttt gtccaaactc atcaatgat 8400
cttatcatgt ctgtataccg tcgacctcta gctagagctt ggcgtaatca tggcatagc 8460
tgtttcctgt gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca 8520
taaagtgtaa agcctggggt gcctaattgag tgagctaact cacattaatt gcgttgcgct 8580
cactgcccgc tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcgccaac 8640
gcgcggggag aggcgggttg cgtattgggc gctcttcgct ttoctcgctc actgactgc 8700
tgcgctcggt cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacgg 8760
tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 8820
ccaggaaccg taaaaaggcc gcgttgctgg cgtttttoca taggctccgc cccctgacg 8880
agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat 8940
accaggcggt tccccctgga agctccctcg tgctctccgacc tgttccgacc ctgccgctta 9000
ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcaa tgctcacgct 9060
gtaggtatct cagttcggtg taggtcgctt gctccaagct gggctgtgtg cactgacccc 9120
ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtc aaccgggtaa 9180
gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg 9240
taggcgggtg tacagagttc ttgaagtggg ggcctaacta cggctacact agaaggacag 9300
tatttggtat ctgcgctctg ctgaagccag ttacctcgg aaaaagagtt ggtagctctt 9360
ctccgggcaa acaaacacc gctggtagcg gtggtttttt tggttgcaag cagcagatta 9420
gcgcgcaaaa aaaaggatct caagaagatc ttgtgatctt ttctacgggg tctgacgctc 9480
agtggaacga aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca 9540
cctagatcct tttaaattaa aaatgaagtt ttaaataaat ctaaagtata tatgagtaaa 9600
cttgggtctga cagttaccaa tgcttaata ctaaggtata atctgtctat 9660

```

ttcgttcac  catagttgcc  tgactccccg  tcgtgtagat  aactacgata  cgggagggct  9720
taccatctgg  cccagtgct  gcaatgatac  cgcgagaccc  acgtccaccc  gctccagatt  9780
tatcagcaat  aaaccagcca  gccggaaggg  ccgagcgag  aagtgggtcct  gcaactttat  9840
ccgcctccat  ccagttctatt  aattgttgcc  gggaagctag  agtaagtagt  tcgccagtta  9900
atagtttgcg  caacgttggt  gccattgcta  caggcatcgt  ggtgtcacgc  tcgtcgtttg  9960
gtatggcttc  attcagctcc  gggtcccaac  gatcaaggcg  agttacatga  tcccccatgt  10020
tgtgcaaaaa  agcggttagc  tccttcggtc  ctccgatcgt  tgtcagaagt  aagttggccg  10080
cagtgttatc  actcatgggt  atggcagcac  tgcataattc  tcttactgtc  atgccatccg  10140
taagatgctt  ttctgtgact  ggtgagtact  caaccaagtc  attctgagaa  tagtgtatgc  10200
ggcgaccgag  ttgctcttgc  ccggcgtaaa  tacgggataa  taccgcgcca  catagcagaa  10260
ctttaaaagt  gctcatcatt  ggaaaacgtt  cttcggggcg  aaaactctca  aggatcttac  10320
cgctgttgag  atccagttcg  atgtaaccca  ctctgcacc  caactgatct  tcagcatctt  10380
ttactttcac  cagcgtttct  gggtagcaaa  aaacaggaag  gcaaaaatgcc  gcaaaaaagg  10440
gaataagggc  gacacggaaa  tgttgaatac  tcatactctt  cctttttcaa  tattattgaa  10500
gcatttatca  gggttattgt  ctcatgagcg  gatacatatt  tgaatgtatt  tagaaaaata  10560
aacaaatagg  ggttcgcgc  acatttcccc  gaaaagtgcc  acctgacgtc  10610

```

<210> 17
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 17
 tgtacaccgg atccggcgca cacc

24

<210> 18
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 18
 cacaacgagc tcaattaatt aattgccaca tcctc

35

<210> 19
 <211> 4
 <212> PRT
 <213> adenovirus

<400> 19
 Thr Leu Trp Thr
 1

<210> 20
 <211> 12
 <212> PRT
 <213> adenovirus

<400> 20
 Pro Ser Ala Ser Ala Ser Ala Ser Ala Pro Gly Ser
 1 5 10

<210> 22
 <211> 327
 <212> DNA

<213> adenovirus

<400> 22

agatctgaat	tcgagctcgc	tgttgggctc	gcggttgagg	acaaactctt	cgcggtcttt	60
ccagtactct	tggatcggaa	acccgtcggc	ctccgaacgg	tactccgcca	ccgagggacc	120
tgagcgagtc	cgcacgcacc	ggatcggaaa	acctctcgag	aaaggcgctc	aaccagtcac	180
agtcgcaagg	taggctgagc	accgtggcgg	gcggcagcgg	gtggcggtcg	gggttggttc	240
tggcgagggt	gctgctgatg	atgtaattaa	agtaggcggg	cttgagacgg	cggatggctg	300
aggtgagggt	tggcaggctt	gagatct				327

<210> 23

<211> 32480

<212> DNA

<213> adenovirus

<400> 23

catcatcaat	aatatacctt	atattggatt	gaagccaata	tgataatgag	ggggtggagt	60
ttgtgacgtg	gcgcggggcg	tgggaacggg	gcgggtgacg	tagtagtggt	gcggaagtgt	120
gatgttgcaa	gtgtggcgga	acacatgtaa	gcgacggatg	tggcaaaagt	gacgtttttg	180
gtgtgcgcgg	gtgtacacag	gaagtgacaa	ttttcgcgcg	gttttaggcg	gatgttgtag	240
taaatttggg	cgtaaccgag	taagatttgg	ccattttcgc	gggaaaactg	aataagagga	300
agtgaatct	gaataatttt	gtgttactca	tagcgcgtaa	tctctagcat	cgatgtcgac	360
aagcttgaat	tcgattaatg	tgagttagct	cactcattag	gcaccccagg	ctttacactt	420
tatgcttccg	gctcgtatgt	tgtgtggaat	tgtgagcgga	taacaatttc	acacaggaaa	480
cagctatgac	catgattacg	aattcggcgc	agcaccatgg	cctgaaataa	cctctgaaag	540
aggaacttgg	ttaggtacct	tctgaggcgg	aaagaaccag	ctgtggaatg	tgtgtcagtt	600
aggggtgtgga	aagtccccag	gctccccagc	aggcagaagt	atgcaaagca	tgcatctcaa	660
ttagtcagca	accaggtgtg	gaaagtcctc	aggctcccca	gcaggcagaa	gtatgcaaag	720
catgcatctc	aattagtcag	caaccatagt	cccgcctcta	actccgcccc	tcccgcctct	780
aactccgccc	agttccgccc	attctccgcc	ccatggctga	ctaatttttt	ttattttatgc	840
agagggccgag	gccgcctcgg	cctctgagct	attccagaag	tagtgaggag	gctttttttg	900
aggcctaggc	ttttgcaaaa	agcttgggat	ctctataatc	tcgcgcaacc	tattttcccc	960
tcgaacactt	tttaagccgt	agataaacag	gctgggacac	ttcacatgag	cgaaaaatac	1020
atcgctacct	gggacatggt	gcagatccat	gcacgtaaac	tcgcaagccg	actgatgect	1080
tctgaacaat	ggaaaggcat	tattgccgta	agccgtggcg	gtctgggtacc	gggtgggtgaa	1140
gaccagaaac	agcacctcga	actgagccgc	gatattgccc	agcgtttcaa	cgcgctgtat	1200
ggcgagatcg	atcccgctgt	tttacaacgt	cgtgactggg	aaaaccctgg	cgttacccaa	1260
cttaatcgcc	ttgcagcaca	tccccctttc	gttcccacgg	gtaatatcgga	agaggcccg	1320
accgatcgcc	cttcccaaca	gttgcgcagc	ctgaatggcg	aatggcgctt	tgccctggtt	1380
ccggcaccag	aagcgggtgcc	ggaaagctgg	ctggagtgcg	atcttccctga	ggccgatact	1440
tgctgcgtcc	cctcaaaactg	gcagatgcac	ggttacgatg	cgcccatcta	caccaacgta	1500
acctatccca	ttacgggtcaa	tccgcgcttg	gttcccacgg	agaatccgac	gggtgtgttac	1560
tcgctcacat	ttaatgttga	tgaagctggg	ctacaggaag	gccagacggg	aattattttt	1620
gatggcggtta	actcggcggt	tcatctgtgg	tgcaacgggc	gctgggtcgg	ttacggccag	1680
gacagtcggt	tgccgtctga	atttgacctg	agcgcatttt	tacgcgcggg	agaaaaccgc	1740
ctcgcgggtga	tgggtgctgcg	ttggagtgcg	ggcagttatc	tggaagatca	ggatagtgtg	1800
cggatgagcg	gcatttttccg	tgacgtctcg	ttgctgcata	aaccgactac	acaaatcagc	1860
gattttccatg	ttgccactcg	ctttaatgat	gatttcagcc	gcgctgtact	ggaggctgaa	1920
gttcagatgt	gcggcgagtt	gcgtgactac	ctacgggttaa	cagtttcttt	atggcagggt	1980
gaaacgcagg	tcgccagcgg	caccgcgctc	ttcggcggtg	aaattatcga	tgagcgtggt	2040
ggttatgcgg	atcgcgtcac	actacgtctg	aacgtcgaaa	acccgaaact	gtggagcgcc	2100
gaaatcccca	atctctatcg	tgccgtgggt	gaactgcaca	ccgccgacgg	cacgctgatt	2160
gaagcagaag	cctgcgatgt	cggtttccgc	gaggtgcgga	ttgaaaatgg	tctgctgctg	2220
ctgaacggca	agccgttgct	gattcgaggc	gttaaccgtc	acgagcatca	tcctctgcat	2280
ggtcaggtca	tggatgagca	gacgatgggt	caggatatcc	tgctgatgaa	gcagaacaac	2340
tttaacgcgg	tgcgctgttc	gcattatccg	aacctaccgc	tgtggtacac	gctgtgcgac	2400
cgctacggcc	tgtatgtggg	ggatgaagcc	aatattgaaa	cccacggcat	ggtgccaatg	2460
aatcgctctga	ccgatgatcc	gcgctggcta	ccggcgatga	gcgaacgcgt	aacgcgaatg	2520
gtgcagcgcg	atcgtaataca	cccagtggtg	atcatctggg	cgctggggaa	tgaatcaggc	2580
cacgcgcgcta	atcacgacgc	gctgtatcgc	tggatcaaat	ctgtcgatcg	ttcccgcctg	2640
gtgcagtatg	aaggcgccgg	agccgacacc	acggccaccg	atattatttg	cccgatgtac	2700
gcgcgcgtgg	atgaagacca	gcccttcccc	gctgtgccga	aatgggtccat	caaaaaatgg	2760

ctttcgctac	ctggagagac	gcgcccgcgtg	atccctttgcg	aatacgccca	cgcgatgggt	2820
aacagtctttg	gcggttttcgc	taaatactgg	caggcgctttc	gtcagtatcc	ccgttttacag	2880
ggcggcttcg	tctgggactg	ggtggatcag	tcgctgatta	aatatgatga	aaacggcaac	2940
ccgtggctgg	cttacggcgg	tgattttggc	gatacgccga	acgatcgcca	gttctgtatg	3000
aacggtctgg	tctttgccga	ccgcacgcgc	catccagcgc	tgacggaagc	aaaacaccag	3060
cagcagtttt	tccagttccg	tttatccggg	caaaccatcg	aagtgaccag	cgaataacctg	3120
ttccgctata	gcgataacga	gctcctgcac	tggatgggtg	cgctggatgg	taagccgctg	3180
gcaagcgggtg	aagtgcctct	ggatgtcgct	ccacaaggta	aacagttgat	tgaactgcct	3240
gaactaccgc	agccggagag	cgccgggcaa	ctctggctca	cagtacgcgt	agtgcacccg	3300
aacgcgaccg	catggtcaga	agccggggcac	atcagcgctt	ggcagcagtg	gcgtctggcg	3360
gaaaacctca	gtgtgacgct	ccccgcgcgc	tcccgcgcca	tcccgcacct	gaccaccagc	3420
gaaatggatt	tttgcatacg	gctgggtaat	aagcgtttgg	aatttaaccg	ccagtcaggc	3480
tttctttcac	agatgtggat	tggcgataaa	aaacaactgc	tgacgcgcgt	gcgcgatcag	3540
ttcaccgcgtg	caccgctgga	taacgacatt	ggcgtaagtg	aagcgacccg	cattgaccct	3600
aacgcctggg	tgaacgcgtg	gaaggcggcg	ggccattacc	aggccgaagc	agcgttgttg	3660
cagtgcacgg	cagatacact	tgctgatgag	gtgctgatta	cgaccgctca	cgcgtggcag	3720
catcagggga	aaaccttatt	tatcagccgg	aaaacctacc	ggattgatgg	tagtgggtcaa	3780
atggcgatta	ccgttgatgt	tgaagtggcg	agcgatacac	cgcatccggc	gcggattggc	3840
ctgaactgcc	agctggcgca	ggtagcagag	cgggtaaact	ggctcgggatt	agggccgcaa	3900
gaaaactatc	ccgaccgcct	tactgccgc	tgttttgacc	gctgggatct	gccattgtca	3960
gacatgtata	ccccgtacgt	cttcccgcgc	gaaaacgggtc	tgccgctgcg	gacgcgcgaa	4020
ttgaattatg	gcccacacca	gtggcgcggc	gacttccagt	tcaacatcag	ccgctacagt	4080
caacagcaac	tgatggaaac	cagccatcgc	catctgctgc	acgcggaaga	aggcacatgg	4140
ctgaatatcg	acggtttcca	tatggggatt	gggtggcgag	actcctggag	cccgtcagta	4200
tcggcggaat	tccagctgag	cgccggctgc	taccattacc	agttgggtctg	gtgtcaaaaa	4260
taataataac	cgggcaggcc	atgtctgccc	gtatttcgcg	taaggaaatc	cattatgtac	4320
tatttaaaaa	acacaaactt	ttggatgttc	ggtttattct	ttttctttta	cttttttatc	4380
atgggagcct	acttcccgtt	tttcccgcgt	tggtctacatg	acatcaacca	tatcagcaaa	4440
agtgtacgg	gtattatttt	tgccgcgtatt	tctctgttct	cgctattatt	ccaaccgctg	4500
tttggctctgc	tttctgacaa	actcggaaact	tgtttattgc	agcttataat	ggttacaaat	4560
aaagcaatag	catcacaaat	ttcacaaata	aagcattttt	ttcactgcat	tctagtgttg	4620
gtttgtccaa	actcatcaat	gtatcttatt	atgtctggat	ccagatctgg	gcgtggctta	4680
aggggtgggaa	agaatatata	aggtgggggt	cttatgtagt	tttgtatctg	ttttgcagca	4740
gccgcgcgcg	ccatgagcac	caactcgttt	gatggaagca	ttgtgagact	atatttgaca	4800
acgcgcgatgc	ccccatgggc	cgggggtgcgt	cagaatgtga	tgggctccag	cattgatggt	4860
cgccccgtcc	tgcccgcaaa	ctctactacc	ttgacctacg	agaccgtgtc	tggaaacgcg	4920
ttggagactg	cagcctccgc	cgccgcgttc	gcccgtgcag	ccaccgcgcc	cgggatttgtg	4980
actgactttg	ctttcctgag	cccgccttga	agcagtgcag	cttcccgttc	atccgcccgc	5040
gatgacaagt	tgacggctct	tttggcacaa	ttggattctt	tgaccgggga	acttaattgc	5100
gtttctcagc	agctgttgga	tctgcgccag	caggtttctg	ccctgaaggc	ttcctccctt	5160
cccaatgcgg	tttaaaacat	aaataaaaaa	ccagactctg	tttggatttg	gatcaagcaa	5220
gtgtcttgct	gtcttttatt	aggggttttg	cgcgcgcggg	agggccggga	ccagcggctt	5280
cggtcgctga	gggtcctgtg	tattttttcc	aggacgtggg	aaagggtgact	ctggatgttc	5340
agatacatgg	gcataagccc	gtctctgggg	tggaggttag	accactgcag	agcttcatgc	5400
tgccgggttg	tgtgtagat	gatccagctg	tagcaggagc	gctgggcgtg	gtgcctaaaa	5460
atgtctttca	gtagcaagct	gattgccagg	ggcaggccct	tgggtgaagt	gtttacaaag	5520
cggttaagct	gggatgggtg	catacgtggg	gatatgagat	gcactcttga	ctgtattttt	5580
aggttggcta	tgttcccagc	catatccctc	cggggattca	tgttgtgcag	aaccaccagc	5640
acagtgtatc	cgggtgcactt	gggaaatttg	tcatgtagct	tagaaggaaa	tgctgggaag	5700
aacttggaga	cgcccttggtg	acctccaaga	ttttccatgc	attcgtccat	aatgatggca	5760
atgggccccac	gggcggcggc	ctgggcgaag	atatttctgg	gatcactaac	gtcatagttg	5820
tgttccagg	tgagatcgtc	ataggccatt	tttacaagc	gcgggcggag	gggtccagac	5880
tgccgtataa	tggttccatc	cggcccaggg	gcgtagttac	cctcacagat	ttgcatttcc	5940
cacgctttga	gttcagatgg	ggggatcatg	tctacctgcg	gggcgatgaa	gaaaacgggt	6000
tccggggtag	gggagatcag	ctgggaagaa	agcaggttcc	tgagcagctg	cgacttaccg	6060
cagccgggtg	gcccgtaaat	cacacctatt	accgggtgca	actggtagtt	aagagagctg	6120
cagctgccgt	catccctgag	caggggggccc	acttcgttaa	gcatgtccct	gactgcctg	6180
ttttccctga	ccaaatccgc	cagaaggcgc	tcgcgcgcca	gcgatagcag	ttcttgcaag	6240
gaagcaaaagt	ttttcaacgg	tttgagaccg	tcgcgcgtag	gcattgcttt	gagcgtttga	6300
ccaagcagtt	ccaggcggtc	ccacagctcg	gtcacctgta	ctacggcatc	tcgatccagc	6360
atatctcttc	gtttcgcggg	ttggggcggc	tttcgctgta	cggcagtagt	cggtgctcgt	6420
ccagacgggc	cagggtcatg	tctttccacg	ggcgcagggt	cctcgtcagc	gtagtctggg	6480

tcacgggtgaa ggggtgcgct ccgggctgcg cgctggccag ggtgcgcttg aggetgggtcc 6540
tgctgggtgct gaagcgctgc cggctcttcgc cctgcgcgctc ggccaggtag catttgacca 6600
tggtgtcata gtccagcccc tccgcggcgt ggcccttggc gcgcagcttg cccttggagg 6660
aggcgccgca cgaggggagc tgcagacttt tgagggcgta gagcttgggc gcgagaaata 6720
ccgattccgg ggagtaggca tccgcgcgcg agggcccgca gacggctcgc cattccacga 6780
gccagggtgag ctctggccgt tccgggtcaa aaaccagggt tccccatgc ttttggatgc 6840
gtttcttacc tctggtttcc atgagccggt gtccacgctc ggtgacgaaa aggetgtccg 6900
tgtccccgta tacagacttg agaggcctgt cctcgagcgg tgttccgcgg tccctcctcgt 6960
atagaaactc ggaccactct gagacaaagg ctgcgctcca ggccagcacg aaggaggcta 7020
agtgggaggg gttagcggtcg ttgtccacta ggggggtccac tgcgtccagg gtgtgaagac 7080
acatgtcgcc ctcttcggca tcaagggaagg tgattggttt gtagggtgag gccacgtgac 7140
cgggtgttcc tgaagggggg ctataaaagg ggggtgggggc gcgttcgtcc tcaactctctt 7200
ccgcacgct gtctgcgagg gccagctggt ggggtgagta ctccctctga aaagcgggca 7260
tgactttcgc gctaagattg tcagtttcca aaaacgagga ggatttgata ttcacctggc 7320
ccgcgggtgat gcctttgagg gtggccgcat ccatctggtc agaaaagaca atctttttgt 7380
tgtcaagctt ggtggcaaac gacccgtaga gggcggttga cagcaacttg gcgatggagc 7440
gcagggtttg gtttttgcg cgatcggcgc gctccttggc cgcatgttt agctgcacgt 7500
attcgcgcgc aacgcaccgc cattcgggaa agacgggtgt gcgctcgtcg ggcaccagggt 7560
gcacgcgcca accgcggttg tgcagggtga caaggctaac gctggtggat acctctccg 7620
gtaggcgctc gttggtccag cagaggcggc cgcccttgcg cgagcagaat ggcggtaggg 7680
ggtctagctg cgtctcgtcc ggggggtctg cgtccacggt aaagaccccg ggcagcaggc 7740
gcgcgtcgaa gtagtctatc ttgcatcctt gcaagtctag cgctcgtgc catgcgcggg 7800
cggcaagcgc gcgctcgtat ggggtgagtg ggggacccca tggcatgggg tgggtgagcg 7860
cggagggcta catgccgcaa atgtcgtaaa cgtagagggg ctctctgagt attccaagat 7920
atgtagggtg gcatcttcca ccgcggatgc tggcgcgcac gtaatcgtat agttcgtgcg 7980
aggagcgag gaggtcggga ccgaggttgc tacgggcggg ctgctctgct cggaagacta 8040
tctgcctgaa gatggcatgt gagttggatg atatggttgg acgctggaag acgttgaagc 8100
tggtgctgt gagacctacc gcgtcacgca cgaaggaggc gtaggagtgc cgcagcttgt 8160
tgaccagctc ggcggtgacc tgcaactcta gggcgagta gtccagggtt tcttgatga 8220
tgtcatactt atcctgtccc tttttttcc acagctcgcg gttgaggaca aactcttgc 8280
ggtctttcca gtactcttg atcggaaacc cgctcgccctc cgaacggtaa gagcctagca 8340
tgtagaactg gttacggcc tggtaggcgc agcatccctt ttctacgggt agcgcgtatg 8400
cctgcgcggc cttccggagc gaggtgtggg tgagcgcaaa ggtgtccctg accatgactt 8460
tgaggtactg gtatttgaag tcagtgtcgt cgcacccgcc ctgctccag agcaaaaagt 8520
ccgtgcgctt tttggaacgc ggatttggca gggcgaaagt gacatcgttg aagagtatct 8580
ttccgcgcgc aggcataaag ttgcgtgtga tgcggaaggg tcccgccacc tcggaacggt 8640
tggttaattac ctgggcggcg agcacgatct cgtcaaagcc gttgatgttg tggccacaa 8700
tgtaaagttc caagaagcgc gggatgccct tgatggaagg caatttttta agttcctcgt 8760
aggtgagctc ttcaggggag ctgagcccgt gctctgaaag ggcccagctc gcaagatgag 8820
ggttggaaag gacgaatgag ctccacaggc cacgggccat tagcatttgc aggtgggtcgc 8880
gaaaggtcct aaactggcga cctatggcca tttttctgg ggtgatgcag taggtctcgc 9000
gcgggtcttg ttcacagcgg tccatcccaa ggttcgcggc taggtctcgc gggcagcagc 9060
ctagaggctc atctccgccc aacttcatga ccagcatgaa gggcacgagc tgggtgcgag 9120
aggcccccat ccaagtatag gtctctacat cgtaggtgac aaagagacgc attggaggag 9180
gatgcgagcc gatcgggaag aactggatct cccgccacca attgaggag tggctattga 9240
tgtggtgaaa gtagaagtcc ctgcgacggg ccgaacactc gtgctggctt ttgtaaaaac 9300
gtgcgagta ctggcagcgg tgcacgggct gtacatcctg cacgaggttg acctgacgac 9360
cgcgcacaaag gaagcagagt ggggaatttga gccctcgcg tggcggggtt ggctgggtgt 9420
cttctacttc ggctgcttgt ccttgaccgt ctggctgctc gaggggagtt acgggtggatc 9480
ggaccaccac gccgcgcgag cccaaagtcc agatgtccgc gcgcggcggc cggagcttga 9540
tgacaacatc gcgcagatgg gagctgtcca tggctggag ggtcgggct cccccggcag 9600
gcgggagctc ctgcaggttt acctcgcata gacgggtcag ggcgcgggct agatecagggt 9660
gataccta at tccagggggc tggttgggtg cggcgtcgat ggcttgcaag aggcgcgcatc 9720
cccgcggcgc gactacggta ccgcgcggcg ggcgggtggc cgcggggggtg tccctggatg 9780
atgcatctaa aagcggtgac cggggcgagc ccccgagggt aggggggggt cccgaccgcg 9840
cgggagaggg ggcaggggca cgtcggcgct gcgcgcgggc aggagctggt gctgcgcgcg 9900
taggttgctg gcgaacgcga cgacgcggcg gttgatctcc tgaatctggc gctctgcgt 9960
gaagacgagc ggcccgggtga gcttgagcct gaaagagagt cgcacagaat caatttcggt 10020
gtcgttgac gcggcctggc gcaaatctc ctgcacgtct cctgagttgt cttgatagge 10080
gatctcggc atgaactgct gcatctcttc ctctcgga gaaggggggt cctcgcgtc 10140
cacgggtggc gcgaggtcgt tggaaatgcg ggccatgagc tgcgagaagg cgttgaggcc 10200
tccctcgttc cagacgcggc tgtagaccac gcccccttcg gcatcgcggg cgcgcagac

caactgcgcg	agattgagct	ccacgtgccg	ggcgaagacg	gcgtagtctc	gcaggcgctg	10260
aaagaggtag	ttgaggggtg	tggcggtgtg	ttctgccacg	aagaagtaca	taaccacgag	10320
tcgcaacgtg	gattcggtga	tatcccccaa	ggcctcaagg	cgctccatgg	cctcgtagaa	10380
gtccacggcg	aagttgaaaa	actgggagtt	gcgcgcggac	acggttaact	cctcctccag	10440
aagacggatg	agctcggcga	cagtgctcgcg	caactcgccg	tcaaaggcta	cagggggcctc	10500
ttcttcttct	tcaatctcct	cttcataaag	ggcctcccct	tcttcttctt	ctggcgggcg	10560
tgggggaggg	gggacacggc	ggcgacgacg	gcgcacccgg	aggcggtcga	caaagcgctc	10620
gatcatctcc	ccgcggcgac	ggcgcatggt	ctcggtgacg	gcgcggccgt	tctcgcgggg	10680
gcgcagttgg	aagacgcggc	ccgtcatgtc	ccggttatgg	gttggcgggg	ggctgccatg	10740
cggcagggat	acggcgctaa	cgatgcatct	caacaattgt	tgtgtaggta	ctccgcggcc	10800
gagggacctg	agcgagtcg	catcgaccgg	atcggaatac	ctctcgagaa	aggcgcttaa	10860
ccagtcacag	tcgcaaggta	ggctgagcac	cgtggcgggc	ggcagcgggc	ggcggtcggg	10920
gttggttctg	gcggaggtgc	tgctgatgat	gtaattaaag	taggcggtct	tgagacggcg	10980
gatggtcgac	agaagcacca	tgtccttggg	tccggcctgc	tgaatgcgca	ggcggtcggc	11040
catgccccag	gcttcgtttt	gacatcgggc	caggtctttg	tagtagtctt	gcatagacct	11100
ttctaccggc	acttcttctt	ctccttcttc	ttgtcctgca	tctcttgcat	ctatcgctgc	11160
ggcgggcgcg	gagtttgggc	gtaggtggcg	ccctcttctt	cccatgcgtg	tgaccccgaa	11220
gccccctcat	ggctgaagca	gggctaggtc	ggcgacaacg	cgctcggtta	atatggcctg	11280
ctgcacctgc	gtgagggtag	actggaagtc	atccatgtcc	acaaagcggt	ggtatgcgcc	11340
cgtgttgatg	gtgtaagtgc	agtggccat	aacggaccag	ttaacggtct	ggtgacccgg	11400
ctgcgagagc	tcggtgtacc	tgagacgcga	gtaagccctc	gagtcacaata	cgtagctggt	11460
gcaagtccgc	accaggtact	ggtatcccac	caaaaagtgc	ggcgggcggt	ggcggttagag	11520
gggcccagcgt	aggggtggccg	gggctccggg	ggcgagatct	tccaacataa	ggcgatgata	11580
tccgtagatg	tacctggaca	tccaggtgat	gcccggcgcg	gtggtggagg	cgcgcgga	11640
gtcgcggacg	cggttccaga	tgttgccag	cggcaaaaag	tgctccatgg	tcgggacgct	11700
ctggccggtc	aggcgcgcg	aatcgttgac	gctctagacc	gtgcaaaagg	agagcctgta	11760
agcgggcact	cttccgtggt	ctggtggata	aattcgcaag	ggtatcatgg	cggacgaccc	11820
gggttcgagc	cccgtatccg	gcccgtccgc	gtgatccatg	cggttaccgc	ccgcgtgtcg	11880
aacccaggtg	tgcgacgtca	gacaacgggg	gagtgctcct	tttggcttcc	ttccaggcgc	11940
ggcggtgct	gcgctagctt	ttttggccac	tggcgcgcg	cagcgtaagc	ggttaggctg	12000
gaaagcgaaa	gcattaaagt	gctcgctccc	tgtagccgga	gggttatctt	ccaaggggtg	12060
agtgcgcggg	cccccggttc	gagtcctcga	ccggcccgac	tgccgcgaac	gggggtttgt	12120
ctccccgtca	tgcaagacct	cgcttgcaaa	ttcctccgga	aacagggagc	agccctttt	12180
ttgcttttcc	cagatgcac	cggtgctgcg	gcagatgcgc	ccccctcttc	agcagcgcca	12240
agagcaagag	cagcggcaga	catgcagggc	accctcccct	cctcctaccg	cgtcaggagg	12300
ggcgacatcc	gcggttgacg	cggcagcaga	tgggtgattac	gaacccccgc	ggcgccgggc	12360
ccggcactac	ctggacttgg	aggagggcga	gggcctggcg	cggctaggag	cgccctctcc	12420
tgagcggtag	ccaagggtag	agctgaagcg	tgatagcggt	gagcggtacg	tgcccgggca	12480
gaacctgttt	cgcgaccgcg	aggagagga	ccccgaggag	atgcgggata	gaaagtcca	12540
cgcagggcgc	gagctgcggc	atggcctgaa	tcgcgagcgg	ttgctgcgcg	aggaggactt	12600
tgagcccagc	gcgcgaaccg	ggattagctc	cgcgcgcgca	cacgtggcgg	ccgcgcacct	12660
ggtaaccgca	tacgagcaga	cggtgaacca	ggagattaac	tttcaaaaaa	gctttaacaa	12720
ccacgtgcgt	acgcttggtg	cgcgcgagga	ggtggctata	ggactgtgac	atctgtggga	12780
ctttgtaagc	gcgctggagc	aaaacccaaa	tagcaagccg	ctcatggcgc	agctgttctt	12840
tatagtgcag	cacagcaggg	acaacgaggc	attcagggat	gcgctgctaa	acatagtaga	12900
gcccaggggc	cgctggctgc	tcgatttgat	aaacatcctg	cagagcatag	tggtgcaggga	12960
gcgcagcttg	agcctggctg	acaaggtggc	cgccatcaac	tattccatgc	ttagcctggg	13020
caagttttac	gcccgaaga	tataccatac	cccttacgtt	cccatagaca	aggaggtaaa	13080
gatcgagggg	ttctacatgc	gcatggcgct	gaaggtgctt	accttgagcg	acgacctggg	13140
cgtttatcgc	aacgagcgca	tccacaaggc	cgtgagcgtg	agccggcggc	gcgagctcag	13200
cgaccgcgag	ctgatgcaca	gcctgcaaa	ggccttggtg	ggcacgggca	gcggcgatag	13260
agagggcgag	tcctactttg	acgcgggcgc	tgacctgcgc	tgggccccaa	ccgcagcgcg	13320
cctggaggca	gctggggccg	gacctgggct	ggcggtggca	cccgcgcgcg	ctggcaacgt	13380
cggcgcgctg	gaggaatatg	acgaggacga	tgagtacgag	ccagaggacg	gcgagtagta	13440
agcggtgatg	tttctgatca	gatgatgcaa	gacgcaacgg	acccggcggt	gcggcgcgcg	13500
ctgcagagcc	agccgtccgg	ccttaactcc	acggacgact	ggcgccaggt	catggaacgc	13560
atcatgtcgc	tgactgcgcg	caatcctgac	gcgttccggc	agcagccgca	ggccaacggg	13620
ctctccgcaa	ttctggaagc	ggtggctccg	gcgcgcgcaa	acccacgcga	cgagaaggtg	13680
ctggcgatcg	taaacgcgct	ggccgaaaac	agggccatcc	ggcccgacga	ggccggcctg	13740
gtctacgacg	cgctgcttca	gcgcgtggct	cgttacaaca	gcggcaacgt	gcagaccaac	13800
ctggagccgc	tggtggggga	tgtgcgcgag	gccgtggcgc	agcgtgagcg	cgcgagcag	13860
gagggcaacc	tgggctccat	ggttgccacta	aacgccttcc	tgagtacaca	gcccgcgaac	13920

gtgccgcggg	gacaggagga	ctacaccaac	tttgtgagcg	cactgcggt	aatggtgact	13980
gagacaccgc	aaagttaggt	gtaccagtct	ggggcagact	atTTTTtcca	gaccagtaga	14040
caaggcctgc	agaccgtaaa	cctgagccag	gctttcaaaa	acttgcaggg	gctgtggggg	14100
gtgcgggctc	ccacaggcga	ccgcgcgacc	gtgtctagct	tgctgacgcc	caactcgcgc	14160
ctgttgctgc	tgctaatagc	gcccttcacg	gacagtggca	gcgtgtcccg	ggacacatac	14220
ctaggctact	tgctgacact	gtaccgcgag	gccataggtc	aggcgcatgt	ggacgagcat	14280
actttccagg	agattacaag	tgctgacccg	gcgctggggc	aggaggacac	gggcagcctg	14340
gaggcaaccc	taaactacct	gctgaccaac	cggcgcgaga	agatccccct	gttgacacgt	14400
atgcgcgacg	aggaggagcg	cattttgcgc	tacgtgcagc	agagcgtgag	ccttaacctg	14460
ggcatgtatg	gggtaacgcc	cagcgtggcg	ctggacatga	ccgcgcgcaa	catggaaccg	14520
ggcgcgctga	cctcaaaccg	gccgtttatc	aaccgcctaa	tggactactt	gcatcgcgcg	14580
gcccgcgtga	accccgagta	tttcaccaat	gccatcttga	acccgcactg	gctaccgccc	14640
cctgggtttct	acaccggggg	attcgagggtg	cccagaggta	acgatggatt	cctctggggac	14700
gacatagacg	acagcgtggt	ttccccgcaa	ccgcagaccc	tgctagagtt	gcaacagcgc	14760
gagcaggcag	aggcggcgct	gcgaaaaggaa	agcttccgca	ggccaagcag	cttgtccgat	14820
ctaggcgctg	cggccccgcg	gtcagatgct	agtagcccat	ttccaagctt	gatagggtct	14880
cttaccagca	ctcgcaccac	ccgccccgcg	ctgctggggc	aggaggagta	cctaaacaac	14940
tcgctgctgc	agccgcagcg	cgaaaaaaac	ctgcctccgg	catttcccaa	caacgggata	15000
gagagcctag	tggacaagat	gagtagatgg	aagacgtacg	cgcaggagca	cagggacgtg	15060
ccaggccccg	gcccgcaccac	ccgtcgctcaa	aggcacgacc	gtcagcgggg	tctgggtgtgg	15120
gaggacgatg	actcggcaga	cgacagcagc	gtcctggatt	tgggagggag	tggcaaccgc	15180
tttgccgacc	ttcgccccag	gctggggaga	atgttttaaa	aaaaaaaaag	catgatgcaa	15240
aataaaaaac	tcaccaaggc	catggcacccg	agcgttggtt	ttcttgtatt	ccccctagta	15300
tgccggcgcg	ggcgatgtat	gaggaagggtc	ctcctccctc	ctacgaggtg	gtgggtgagcg	15360
cggcgccagt	ggcgggcgcg	ctgggttctc	ccttcgatgc	tccccgtggc	ccgcccgttg	15420
tgccctccgc	gtacctgcgg	cctaccgggg	ggagaaacag	catccgttac	tctgagttgg	15480
cacccctatt	cgacaccacc	cgtgtgtacc	tgggtggaaa	caagtcaacg	gatgtggcat	15540
ccctgaacta	ccagaacgac	cacagcaact	ttctgaccac	ggtcattcaa	aacaatgact	15600
acagccccgg	ggaggcaagc	acacagacca	tcaatcttga	cgaccgggtc	cactggggcg	15660
gcgacctgaa	aaccatcctg	cataccaaca	tgccaaatgt	gaacgagttc	atgtttacca	15720
ataagtttaa	ggcgcggtg	atgggtgtgc	gcttgccctac	taaggacaat	caggtggagc	15780
tgaataacga	gtgggtggag	ttcacgctgc	ccgagggcaa	ctactccgag	accatgacca	15840
tagaccttat	gaacaacgcg	atcgtggagc	actacttgaa	agtgggcaga	cagaacgggg	15900
ttctggaaag	cgacatcggg	gtaaagtttg	acaccgcgaa	cctcagactg	gggtttgacc	15960
ccgtcactgg	tcttgtcatg	cctgggggtat	atacaaaacga	agccttccat	ccagacatca	16020
ttttgtgtcc	aggatgcggg	gtggacttca	cccacagccg	cctgagcaac	ttgttgggca	16080
tcggcaagcg	gcaacccttc	caggagggct	ttaggtcac	ctacgatgat	ctggagggtg	16140
gtaacattcc	cgcactgttg	gatgtggacg	cctaccaggc	gagcttgaaa	gatgacaccg	16200
aacagggcgg	gggtggcgca	ggcggcagca	acagcagtg	cagcggcgcg	gaagagaact	16260
ccaacgcggc	agccgcggca	atgcagccgg	tggaggacat	gaacgatcat	gccattcgcg	16320
gcgacacctt	tgccacacgg	gctgaggaga	agcgcgctga	ggccgaagca	gcggccgaag	16380
ctgcgcggcc	cgctgcgcaa	cccaggtcg	agaaacccca	gaagaaaccg	gtgatcaaac	16440
ccctgacaga	ggacagcaag	aaacgcagtt	acaacctaat	aagcaatgac	agcaccttca	16500
cccagtagcg	cagctgggtac	cttgcatata	actacggcga	ccctcagacc	ggaatccgct	16560
catggaccct	gctttgcact	cctgacgtaa	cctgcggctc	ggagcaggtc	tactggctgt	16620
tgccagacat	gatgcaagac	cccgtgacct	tccgtccac	gcgccagata	agcaacttcc	16680
cgggtgggtg	cgccgagctg	ttgcccgtgc	actccaagag	ccttcaaac	gaccaggccg	16740
tctactccca	actcatccgc	cagttttacct	ctctgaccca	cgtgttcaat	cgctttcccg	16800
agaaccagat	tttggcgcg	ccgccagccc	ccaccatcac	caccgtcagt	gaaaaacgtt	16860
ctgctctcac	agatcacggg	acgctaccgc	tgcgcaacag	catcggagga	gtccagcgag	16920
tgaccattac	tgacgcgaga	cgccgcacct	gcccctacgt	ttacaaggcc	ctgggcatag	16980
tctcgcgcg	cgctcctatg	agccgcactt	tttgagcaag	catgtccatc	ccttatatgc	17040
ccagcaataa	cacaggctgg	ggcctgcgct	tcccaagcaa	gatgtttggc	ggggccaaga	17100
agcgctccga	ccaacaccca	gtgcgcgtgc	gcgggcacta	ccgcgcgccc	tggggcgcg	17160
acaaacgcgg	ccgcactggg	cgcaccaccg	tcatgacgc	catcgacgcg	gtgggtggag	17220
aggcgcgcaa	ctacacgcgc	acgcgcgcac	cagtgtccac	agtggagcgc	gccattccga	17280
ccgtgggtgc	cggagcccg	cgctatgcta	aaatgaagag	acggcgagg	cgcgtagcac	17340
gtcgccaccg	ccgcgcgccc	ggcactgcgg	tccaacgcgc	ggcgcgggcc	ctgcttaacc	17400
gcgcacgtcg	caccggccga	cgggcggcca	tgcgggccc	tccaagggct	gcccggggta	17460
ttgtcactgt	gccccccagg	tccaggcgac	gagcggccgc	cgcagcagcc	cgccgcatta	17520
gtgctatgac	tcagggtcgc	aggggcaacg	tgtattgggt	gcgcgactcg	gttagcggcc	17580
tgcgcggtgc	cgtgcgcacc	cgccccccgc	gcaactagat	tgcaagaaaa	aactacttag	17640

actcgtactg	ttgtatgtat	ccagcggcgg	cgccgcgcaa	cgaagctatg	tccaagcgca	17700
aaatcaaaga	agagatgctc	caggtcatcg	cgccggagat	ctatggcccc	-ccgaagaagg	17760
aagagcagga	ttacaagccc	cgaaaagctaa	agcgggtcaa	aaagaaaaag	aaagatgatg	17820
atgatgaact	tgacgacgag	gtggaactgc	tgacgctac	cgcgcccagg	cgacgggtac	17880
agtggaaagg	tcgacgcgta	aaacgtgttt	tgcgaccocg	caccaccgta	gtctttacgc	17940
ccggtgagcg	ctccaccgcg	acctacaagc	gcgtgtatga	tgaggtgtac	ggcgacgagg	18000
acctgcttga	gcaggccaac	gagcgctcg	gggagtttgc	ctacggaaaag	-cggcataagg	18060
acatgctggc	gttgccgctg	gacgagggca	acccaacacc	tagcctaaag	cccgtaacac	18120
tgacgacggt	gctgcccgcg	cttgaccagt	ccgaagaaaa	gcgcggccta	aagcgcgagt	18180
ctggtgactt	ggcaccacc	gtgcagctga	tggtagccaa	gcgccagcga	ctggaagatg	18240
tcttgaaaaa	aatgaccgtg	gaacctgggc	tggagcccga	ggtccgcgtg	-cggccaatca	18300
agcaggtggc	gcccggactg	ggcgtgcaga	ccgtggacgt	tcagataccc	actaccagta	18360
gcaccagtat	tgccaccgcc	acagagggca	tggagacaca	aacgtccccg	gttgccctcag	18420
cgggtggcga	tgccgcggtg	caggcggtcg	ctgcggccgc	gtccaagacc	tctacggagg	18480
tgcaaacgga	cccgtggatg	tttcgcgttt	cagccccccg	gcgcccgcgc	ggttcgagga	18540
agtacggcgc	cgccagcgcg	ctactgccc	aatatgcct	acatccttc	attgcgccta	18600
cccccggtc	tcgtggctac	acctaccgcc	ccagaagacg	agcaactacc	cgacgcgcaa	18660
ccaccactgg	aaccgcgcgc	cgccgtcgcc	gtcgccagcc	cgtgctggcc	ccgatttcgc	18720
tgccgaggg	ggctcgcgaa	ggaggcagga	ccctggtgct	gccaacagcg	cgctaccacc	18780
ccagcatcgt	ttaaaagccg	gtctttgtgg	ttcttgacga	tatggccctc	acctgcccgc	18840
tccgtttccc	ggtgcccggga	ttccgaggaa	gaatgcaccg	taggaggggc	atggccggcc	18900
acggcctgac	ggggcggcatg	cgtcgtgcgc	accaccggcg	gcggcgcgcg	tcgcaccgtc	18960
gcatgcgcgg	cggatccctg	cccctcctta	ttccactgat	cgccgcggcg	attggcgccg	19020
tgcccggaa	tgcatccgtg	gccttgacag	cgacagagac	ctgattaaaa	acaagttgca	19080
tgtggaaaaa	tcaaaataaa	aagtctggag	tctcacgctc	gcttggtcct	gtaactattt	19140
tgtagaatgg	aagacatcaa	ctttgcgtct	ctggccccgc	gacacggctc	gcgcccgctt	19200
atgggaaact	ggcaagatat	cgccaccagc	aatatgagcg	gtggcgccct	cagctggggc	19260
tcgctgtgga	gcggcattaa	aaatttcggt	tccaccgtta	agaactatgg	cagcaaggcc	19320
tggaaacagca	gcacaggcca	gatgctgagg	gataagttga	aagagcaaaa	tttccaacaa	19380
aagtggttag	atggcctggc	ctctggcatt	agcggggtgg	tggacctggc	caaccaggca	19440
gtgcaaaata	agattaacag	taagcttgat	ccccgccctc	ccgtagagga	gcctccaccg	19500
gccgtggaga	cagtgtctcc	agagggcggt	ggcgaaaagc	gtccgcgccc	cgacagggaa	19560
gaaactctgg	tgacgcaaat	agacgagcct	ccctcgtacg	aggaggcact	aaagcaaggc	19620
ctgcccacca	cccgctccat	cgcgcccatg	gctacgggag	tgctggggca	gcacacaccc	19680
gtaacgctgg	aacctgcctc	ccccgcgac	accagcaga	aacctgtgct	gccaggcccg	19740
accgcccgtg	ttgtaaccgc	tctagccgc	gcgtccctgc	gcccgcgcgc	cagcggctccg	19800
cgatcggtgc	ggcccgtagc	cagtggcaac	tggcaaaagca	cactgaacag	catcgtgggt	19860
ctgggggtgc	aatccctgaa	gcgccgacga	tgcttctgaa	tagctaaccg	gtcgtatgtg	19920
tgtcatgtat	gcgtcatgt	cgcgcgacga	ggagctgctg	agccgcgcgc	cgccgccttt	19980
ccaagatggc	tacccttcg	atgatgccgc	agtggtctta	catgcacatc	tcggggccagg	20040
acgcctcgga	gtacctgagc	cccgggctgg	tgacgtttgc	ccgcgcacac	gagacgtact	20100
tcagcctgaa	taacaagttt	agaaacccca	cgggtggccc	tacgcacgac	gtgaccacag	20160
accggtccca	gcgtttgacg	ctgcggttca	tccctgtgga	ccgtgaggat	actgcgtact	20220
cgtacaaggc	gcggttcacc	ctagctgtgg	gtgataaccg	tggtctggac	atggcttcca	20280
cgtactttga	catccgcggc	gtgctggaca	ggggccctac	ttttaagccc	tactctggca	20340
ctgctacaaa	cgccctggct	cccaaggggtg	ccccaaatcc	ttgcgaatgg	gatgaagctg	20400
ctactgctct	tgaataaaac	ctagaagaag	aggacgatga	caacgaagac	gaagttagacg	20460
agcaagctga	gcagcaaaaa	actcacgtat	ttgggcaggc	gccttattct	ggtataaata	20520
ttacaaagga	gggtattcaa	ataggtgtcg	aaggtcaaac	acctaaatat	gccgataaaa	20580
catttcaacc	tgaacctcaa	ataggagaat	ctcagtggta	-cgaaactgaa	attaatcatg	20640
cagctgggag	agtccttaaa	aagactaccc	caatgaaacc	atgttacggt	tcatatgcaa	20700
aaccacaaaa	tgaatatgga	gggcaaggca	ttcttgtaaa	gcaacaaaaat	ggaaagctag	20760
aaaagtcaagt	ggaaatgcaa	tttttctcaa	ctactgaggc	gaccgcaggc	aatgctgata	20820
acttgactcc	taaagtggta	ttgtacagtg	aagatgtaga	tatagaaacc	-ccagacactc	20880
atatttctta	catgcccact	attaaggaag	gtaactcacg	agaactaatg	ggccaacaat	20940
ctatgcccac	caggccta	tacattgctt	ttggggacaa	ttttattggt	ctaattgtatt	21000
acaacagcac	gggtaatatg	ggtgtcttgg	cgggccaagc	atcgagttg	aatgctgttg	21060
tagatttgca	agacagaaac	acagagcttt	cataccagct	tttgcttgat	tccattgggtg	21120
atagaaccag	gtacttttct	atgtggaatc	aggctgttga	cagctatgat	-ccagatgtta	21180
gaattattga	aaatcatgga	actgaagatg	aacttccaaa	ttactgcttt	ccactgggag	21240
gtgtgattaa	tacagagact	cttaccagag	taaaacctaa	aacaggtcag	gaaaaatggat	21300
gggaaaaaga	tgctacagaa	ttttcagata	aaaatgaaat	aagagttgga	aataattttg	21360

ccatggaat	caatcctaat	gccaacctgt	ggagaaattt	cctgtactcc	aacatagcgc	21420
tgtatttggc	cgacaagcta	aagtacagtc	cttccaacgt	aaaaatttct	gataacccaa	21480
acacctacga	ctacatgaac	aagcgagtgg	tggctcccgg	gttagtggac	tgctacatta	21540
accttggagc	acgctgggtcc	cttgactata	tggacaacgt	caacccattt	aaccaccacc	21600
gcaatgctgg	cctgcgctac	cgctcaatgt	tgctgggcaa	tggtcgctat	gtgcccttcc	21660
acatccaggt	gcctcagaag	ttctttgcca	ttaaaaacct	ccttctcctg	ccgggctcat	21720
acacctacga	gtggaacttc	aggaaggatg	ttaacatggg	tctgcagagc	tccctaggaa	21780
atgacctaa	gggtgacgga	gccagcatta	agtttgatag	catttgccct	tacgccacct	21840
tcttccccat	ggcccacaac	accgcctcca	cgcttgaggc	catgcttaga	aacgacacca	21900
acgaccagtc	ctttaacgac	tatctctccg	ccgcacaact	gctctaccct	atacccgcca	21960
acgctaccaa	cgtgcccata	tccatcccct	cccgcaactg	ggcggttttc	cgcggtggg	22020
ccttcacgcg	ccttaagact	aaggaaaccc	catcactggg	ctcggtgtac	gaccttatt	22080
acacctactc	tggtcttata	ccctacctag	atggaacctt	ttacctcaac	cacaccttta	22140
agaaggtggc	cattaccttt	gactcttctg	tcagctggcc	tggaatgac	cgctgtctta	22200
cccccaacga	gtttgaaatt	aagcgctcag	ttgacgggga	gggttacaac	gttgccctag	22260
gtaacatgac	caaagactgg	ttcctggtac	aaatgctagc	taactacaac	attggctacc	22320
agggcttcta	tatcccagag	agctacaagg	accgcatgta	ctccttcttt	agaaacttcc	22380
agcccatgag	ccgtcagggtg	gtggatgata	ctaaatacaa	ggactaccaa	caggtgggca	22440
tcctacacca	acacaacaac	tctggatttg	ttggctacct	tgccccacc	atgcgcgaag	22500
gacaggccta	ccctgctaac	ttccctatgc	cgcttatagg	caagaccgca	gttgacagca	22560
ttaccagaaa	aaagtttctt	tcgatcgca	ccctttggcg	catcccatte	tccagtaact	22620
ttatgtccat	gggcgcactc	acagacctgg	gccaaaacct	tctctacgcc	aactccgccc	22680
acgcgctaga	catgactttt	gaggtggatc	ccatggacga	gcccaccctt	ctttatgttt	22740
tggttgaaagt	ctttgacgtg	gtccgtgtgc	accggccgca	ccgcggcgct	atcgaaaccg	22800
tgtacctgcg	cacgcccttc	tcggccggca	acgcacaac	ataaagaagc	aagcaacatc	22860
aacaacagct	gccgccatgg	gctccagtga	gcaggaactg	aaagccattg	tcaaagatct	22920
tggttggtggg	ccatattttt	tgggcacctt	tgacaagcgc	tttccaggct	ttgtttctcc	22980
acacaagctc	gcctgcgcca	tagtcaatac	ggccggtcgc	gagactgggg	gcgtacactg	23040
gtaccccttt	gcctggaacc	cgcactcaaa	aacatgctac	ctctttgagc	cctttggctt	23100
ttctgaccag	cgactcaagc	aggtttacca	gtttgagtac	gagtcactcc	tgccgcgtag	23160
cgccattgct	tcttcccccg	accgctgtat	aacgctggaa	aagtccaccc	aaagcgtaca	23220
ggggcccaac	tcggccgcct	gtggactatt	ctgctgcatg	tttctccacg	cctttgccaa	23280
ctggcccaaa	actcccattg	atcacaaccc	caccatgaac	cttattaccg	gggtacccaa	23340
ctccatgctc	aacagtcccc	aggtacagcc	cacctgcgtg	cgcaaccagg	aacagctcta	23400
cagcttctctg	gagcgccact	cgccctactt	ccgcagccac	agtgcgcaga	ttaggagcgc	23460
cacttctttt	tgtcacttga	aaaacatgta	aaaataatgt	actagagaca	ctttcaataa	23520
aggcaaatgc	ttttattttg	acactctcgg	gtgattattt	acccccaccc	ttgccgtctg	23580
cgccgtttaa	aaatcaaagg	ggttctgccc	cgcatcgcta	tgcgccaactg	gcagggacac	23640
gttgcgatac	tggtgtttag	tgctccactt	aaactcaggc	acaaccatcc	gcggcagctc	23700
ggtgaagtgt	tcactccaca	ggctgcgcac	catcaccaac	gcgttttagca	ggtcggggcgc	23760
cgatatcttg	aatgcgcagt	tggggcctcc	gccctgcgcg	cgcgagttgc	gatacacagg	23820
gttgagcagc	tggaaacta	tcagcgccgg	gtggtgcaag	ctggccagca	cgctcttgct	23880
ggagatcaga	tcgcgctcca	ggctctccgc	gttgctcagg	gcgaacggag	tcaactttgg	23940
tagctgcctt	ccccaaaagg	gcgcgtgccc	aggctttgag	ttgcactcgc	accgtagtgg	24000
catcaaaaagg	tgaccgtgcc	cggctctggg	gttaggatac	agcgcctgca	taaaagcctt	24060
gatctgctta	aaagccacct	gagcctttgc	gccttcagag	aagaacatgc	cgcaagactt	24120
gccggaaaaac	tgattggccg	gacaggccgc	gtcgtgcaag	cagcaccttg	cgtcggtggt	24180
ggagatctgc	accacatttc	ggccccaccg	gtctttcacg	atcttggcct	tgctagactg	24240
ctccttcagc	gcgcgctgcc	cgttttcgct	cgtcacatcc	atttcaatca	cgtgctcctt	24300
atztatcata	atgcttccgt	gtagacactt	aagctcgcct	tcgatctcag	cgcagcggtg	24360
cagccacaac	gcgcagcccg	tgggctcgtg	atgctttag	gtcacctctg	caaacgactg	24420
caggtacgcc	tgcaggaatc	gccccatcat	cgctcacaaag	gtcttgttgc	tggtgaaggt	24480
cagctgcaac	ccgcggtgct	cctcgttcag	ccaggctctg	catacggcgc	ccagagcttc	24540
cacttggtca	ggcagtagtt	tgaagttcgc	ctttagatcg	ttatccacgt	ggtacttgct	24600
catcagcgcg	cgcgagcctt	ccatgccctt	ctccacgcga	gacacgatcg	gcacactcag	24660
cgggttcctc	accgtaattt	cactttccgc	ttcgtggggc	tcttccctct	cctcttgctg	24720
ccgcatacca	cgcgccactg	ggctcgtctt	attcagccgc	cgcaactgtg	gcttacctcc	24780
tttgccatgc	ttgattagca	ccggtgggtt	gctgaaaccc	accatttgta	gcgccacatc	24840
ttctctttct	tcctcgctgt	ccacgattac	ctctgggtgat	ggcgggcgct	cgggcttggtg	24900
agaagggcgc	ttctttttct	tcttgggcgc	aatggccaaa	tcgcgcgcgc	aggtcgatgg	24960
ccgcgggctg	gggtgctgcg	gcaccagcgc	gtcttctgat	gagctctctt	cgctcctcga	25020
ctcgatacgc	cgctctatcc	gcttttttgg	gggcgcgcgc	ggaggcgcg	gcgacgggga	25080

cggggacgac	acgtcctcca	tgggtggggg	acgtcgcgcc	gcaccgcgtc	cgcgctcggg	25140
ggtggtttcg	cgctgctcct	cttcccgact	ggccattttcc	ttctcctata	ggcagaaaaa	25200
gatcatggag	tcagtcgaga	agaaggacag	cctaaccgcc	ccctctgagt	tcgccaccac	25260
cgctccacc	gatgccgcca	acgcgcctac	caccttcccc	gtcgaggcac	ccccgcttga	25320
ggaggaggaa	gtgattatcg	agcaggaccc	aggttttgta	agcgaagacg	acgaggaccg	25380
ctcagtacca	acagaggata	aaaagcaaga	ccaggacaac	gcagaggcaa	acgaggaaaa	25440
agtcgggagg	ggggacgaaa	ggcatggcga	ctacctagat	gtgggagacg	acgtgctgtt	25500
gaagcatctg	cagcgccagt	gcgccattat	ctgcgacgcg	ttgcaagagc	gcagcgatgt	25560
gccccctgcc	atagcggatg	tcagccttgc	ctacgaacgc	cacctattct	caccgcgcgt	25620
accccccaaa	cgccaagaaa	acggcacatg	cgagcccaac	ccgcgcctca	acttctaccc	25680
cgtatttgcc	gtgccagagg	tgcttgccac	ctatcacatc	tttttccaaa	actgcaagat	25740
acccctatcc	tgccgtgcc	accgcagccg	agcggacaag	cagctggcct	tcgggcaggg	25800
cgctgtcata	cctgatatcg	cctcgctcaa	cgaagtgcc	aaaatctttg	agggtcttgg	25860
acgcgacgag	aagcgcgagg	caaacgctct	gcaacaggaa	aacagcgaaa	atgaaagtca	25920
ctctggagtg	ttggtggaac	tcgagggtga	caacgcgcgc	ctagcctgac	ctaaaacgcag	25980
catcgaggtc	acccactttg	cctaccggcg	acttaacct	cccccaagg	tcattgacac	26040
agtcatgagt	gagctgatcg	tgccgcgtgc	gcagcccctg	gagagggatg	caaatttgca	26100
agaacaaaca	gaggagggcc	taccgcgagt	tgccgacgag	cagctagcgc	gctggcttca	26160
aacgcgcgag	cctgcccact	tgaggagcgc	acgcaaaact	atgatggccg	cagtgcctgt	26220
taccgtggag	cttgagtcca	tcgacgggtt	ctttgctgac	ccggagatgc	agcgcaagct	26280
agaggaaaca	ttgcactaca	cctttcgaca	gggctacgta	cgccaggcct	gcaagatctc	26340
caacgtggag	ctctgcaacc	tggtctccta	ccttggaatt	ttgcacgaaa	accgccttgg	26400
gcaaaacgtg	cttcattcca	cgctcaaggg	cgaggcgcg	cgcgactacg	tcgcgcactg	26460
cgtttactta	tttctatgct	acacctggca	gacggccatg	ggcggttggc	agcagtgtct	26520
ggaggagtgc	aacctcaagg	agctgcagaa	actgtctaaag	caaaaactga	aggacctatg	26580
gacggccttc	aacgagcgct	ccgtggccgc	gcacctggcg	gacatcattt	tccecgaaacg	26640
cctgcttaaa	accctgcaac	agggctctgc	agacttcacc	agtcaaagca	tggtgcagaa	26700
cttttaggaac	tttatectag	agcgctcagg	aatcttgccc	gecacctgct	gtgacttcc	26760
tagecacttt	gtgcccatta	agtaccgcga	atgcccctcg	ccgctttggg	gccactgtct	26820
ccttctgcag	ctagccaact	accttgccct	ccactctgac	ataatggaag	acgtgagcgg	26880
tgacggtcta	ctggagtgtc	actgtcgctg	caacctatgc	accccgacc	gctccctggg	26940
ttgcaattcg	cagctgctta	acgaaagtca	aattatcggt	acctttgagc	tgacgggtcc	27000
ctgcctgac	gaaaagtccg	cggtccggg	gttgaaactc	actccggggc	tggtggacgtc	27060
ggcttacctt	cgcaaatttg	tacctgagga	ctaccacgcc	cacgagatta	ggttctacga	27120
agaccaatcc	cgcccgccaa	atgaggagct	taccgcctgc	gtcattaccc	agggccacat	27180
tcttggccaa	ttgcaagcca	tcaacaaagc	ccgccaaagag	tttctgctac	gaaagggacg	27240
gggggtttac	ttggaccccc	agtcgggcga	ggagctcaac	ccaatcccc	cgccgcgcga	27300
gccctatcag	cagcagccgc	gggcccctgc	ttcccaggat	ggcacccaaa	aagaagctgc	27360
agctgccgcc	gccacccacg	gacgaggagg	aatactggga	cagtcaggca	gaggaggttt	27420
tggaacgagga	ggaggaggac	atgatggaag	actgggagag	cctagacgag	gaagcttccg	27480
aggtcgaaga	ggtgtcagac	gaaacaccgt	caccttcggg	cgcattcccc	tcgcccggcg	27540
cccagaaatc	ggcaaccggg	tccagcatgg	ctacaacctc	cgctcctcag	gcgcgcggcg	27600
cactgcccgt	tcgcccagcc	aaccgtagat	gggacaccac	tggaaccagg	gccggttaagt	27660
ccaagcagcc	gcccgcgtta	gccaagagc	aacaacagcg	ccaaggctac	cgctcatggc	27720
gcgggcacaa	gaacgccata	gttgcttgct	tgcaagactg	tgggggcaac	atctccttcg	27780
cccgcgcgtt	tcttctctac	catcacggcg	tgcccttccc	ccgtaacatc	ctgcattact	27840
accgtcatct	ctacagccca	tactgcaccg	gcgcgcagcg	cagcggcagc	aacagcagcg	27900
gccacacaga	agcaaaggcg	accggatagc	aagactctga	caaagcccaa	gaaatccaca	27960
gcggcggcag	cagcaggagg	aggagcgctg	cgtctggcgc	ccaacgaacc	cgtatcgacc	28020
cgcgagctta	gaaacaggat	ttttccact	ctgtatgcta	tatttcaaca	gagcaggggc	28080
caagaacaag	agctgaaaat	aaaaaacagg	tctctgcgat	ccctcaccgc	cagctgcctg	28140
tatcacaaaa	gcgaagatca	gcttcggcgc	acgctggaag	acgcggaggc	tctcttcagt	28200
aaatactgcg	cgctgactct	taaggactag	tttcgcgcgc	tttctcaaat	ttaagcgcca	28260
aaactacgtc	atctccagcg	gcccagccgc	ggggcagcac	ctatcatcag	ccccattatg	28320

ttcagcctc gtcaggcaat cctaactctg cagacctcgt cctctgagcc gcgctctgga 28860
ggcattggaa ctctgcaatt tattgaggag tttgtgccat cgggtctactt taaccctctc 28920
tcgggacctc ccggccacta tccggatcaa tttattccta actttgacgc ggtaaaggac 28980
tcggcgagc gctacgactg aatgttaagt ggagaggcag agcaactgcg cctgaaacac 29040
ctgggtccact gtcgcccga caagtgttt gcccgagact ccggtgagtt ttgctacttt 29100
gaattgcccg aggatcatat cgagggcccg gcgcacggcg tccggcttac cgcccaggga 29160
gagcttgccc gtagcctgat tcgggagttt acccagcgcc ccctgctagt tgagcgggac 29220
aggggacctt gtgttctcac tgtgatttgc aactgtccta accttgatt acatcaagat 29280
ttaattaatt gccacatcct cttacacttt ttcatacatt gcccaagaat aaagaatcgt 29340
ttgtgttatg tttcaacgtg tttatttttc aattgcagaa aatttcaagt catttttcat 29400
tcagtagtat agccccacca ccacatatat taticagatc accgtacctt aatcaaacctc 29460
acagaaccct agtattcaac ctgccacctc cctcccaaca cacagagtac acagtccttt 29520
ctccccggct ggctttaaaa agcatcatat catgggtaac agacatatctc ttagggtgta 29580
tattccacac ggtttcctgt cgagccaaac gctcatcagt gatattaata aactccccgg 29640
gcagctcact taagttcatg tcgctgtcca gctgtgagc cacaggctgc tgtccaaactt 29700
gcggttgctt aacggggcggc gaaggagaag tccacgccta catgggggta gagtcataat 29760
cgtgcatcag gataggcggtg tgggtgctgca gcagcgcgag aataaactgc tgcgcgcgcc 29820
gctccgtcct gcaggaatac aacatggcag tgggtcctctc agcagtgatt cgccacggccc 29880
gcagcataag gcgccttgct ctccggggcac agcagcgac cctgatctca cttaaatacag 29940
cacagtaact gcagcacagc accacaatat tgttcaaaat cccacagtgcc aaggcgctgt 30000
atccaaagct catggcgggg accacagaac ccacgtggcc atcataccac aagcgcaggt 30060
agattaagtg gcgacccctc ataaacacgc tggacataaa cattacctct tttggcatgt 30120
tgtaattcac cacctccccg taccatataa acctctgatt aaacatggcg ccatccacca 30180
ccatcctaaa ccagctggcc aaaacctgccc cgccggctat acactgcagg gaaccgggac 30240
tggaacaatg acagtggaga gcccaggatg cgttaacctg gatcatatg ctcgcatga 30300
tatcaatgtt ggcacaacac aggcacacgt gcatacactt cctcaggatt acaagctcct 30360
cccgcgttag aaccatatcc cagggaaaca cccattcctg aatcagcgta aatccccacac 30420
tgcagggaag acctcgacg taactcacgt tgtgcattgt caaagtgtta cattcgggca 30480
gcagcggatg atccctccagt atggtagcgc gggtttctgt ctcaaaagga ggtagacgat 30540
ccctactgta cggagtgcgc cgagacaacc gagatcgtgt tggctgtagt gtcagccaa 30600
atggaacgcc ggacgtagtc atatttcctg aagcaaaacc aggtcgggg gtgacaaaca 30660
gatctgcgtc tccggtctcg ccgcttagat cgctctgtgt agtagttgta gtatatccac 30720
tctctcaag catccaggcg cccctggct tccgggttcta tgtaaacctc ttcatgccc 30780
gctgccctga taacatccac caccgcagaa taagccacac ccagccaacc tacacattcg 30840
ttctgcgagt cacacacggg aggagcggga agagctggaa gaaccatgtt ttttttttta 30900
ttccaaaaga ttatccaaaa cctcaaaatg aagatctatt aagtgaacgc gctcccctcc 30960
gggtgcgtgg tcaaactcta cagccaaaga acagataatg gcatttgtaa gatgttgac 31020
aatggcttcc aaaaggcaaa cggccctcac gtccaagtgg acgtaaaggc taaaccttcc 31080
agggtgaatc tctctataa acattccagc acctcaacc atgcccaaat aattctcctc 31140
tcgccacctt ctcaatatat ctctaagcaa atcccgaata ttaagtccgg ccattgtaaa 31200
aatctgctcc agagcgcctt ccacctcag cctcaagcag cgaatcatga ttgcaaaaaat 31260
tcaggttctt cacagacctg tataagattc aaaagcggaa cattaacaaa aataccgcga 31320
tcccgtaggt ccttcgcag ggccagctga acataatcgt gcaggctgc accgaccagc 31380
gcggccactt ccccgccagg aaccttgaca aaagaaccca cactgattat gacacgcata 31440
ctcgagcta tgctaaccag cgtagccccc aatgtagcgt tgttgcatgg gcgcgatatt 31500
aaaatgcaag gtgctgctca aaaaatcagg caaagcctcg cgcaaaaaag aaagcacatc 31560
gtagtcatgc tcatgcagat aaaggcaggt aagctccgga accaccacag aaaaagacac 31620
catttttctc tcaaacatgt ctgcccgttt ctgcataaac acaaaaataaa ataacaaaaa 31680
aacatttaaa cattagaagc ctgtcttaca acaggaaaaa caacccttat aagcataaga 31740
cggactacgg ccattgccggc gtgaccgtaa aaaaactggt caccgtgatt aaaaagcacc 31800
accgacagct cctcggtcat gtccggagtc ataatgttaag actcggtaaa cacatcaggt 31860
tgattcatcg gtcagtgtca aaaaagcgacc gaaatgccc gggggaatac ataccgcag 31920
gcgtagagac aacattacag ccccatagg aggtataaca aaattaatag gagagaaaaa 31980
cacataaaca cctgaaaaac cctcctgcct agggcaaaata gcacctccc gctccagaac 32040
aacatacagc gtttcacagc ggcagcctaa cagtcagcct taccagtaaa aaagaaaaac 32100
tattaaaaaa acaccactcg acacggcacc agctcaatca gtcacagtgt aaaaaagggc 32160
caagtgcaga gcgagtatat ataggactaa aaaatgacgt aacgggtaaa gtccacaaaa 32220
aacacccaga aaaccgcagc cgaacctacg cccagaaacg aaagccaaaa aaccacaaac 32280
ttcctcaaat cgtcacttcc gttttccac gttacgtaac tccccatttt aagaaaaacta 32340
caattcccaa cacatacaag ttactccgccc ctaaaacctc cgtcacccgc cccgttccca 32400
cgccccgcgc cacgtcacia actccacccc ctcattatca tattggcttc aatccaaaat 32460
aaggatatatt attgatgatg 32480

<210> 24
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 24
 ctcaacaatt gtggatccgt actcc 25

<210> 25
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 25
 gtgctcagca gatcttgcca ctgtg 25

<210> 26
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 26
 ggcgcgttcg gatccactct ctcc 25

<210> 27
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 27
 ctacatgcta ggcagatctc gttcggag 28

<210> 28
 <211> 1240
 <212> DNA
 <213> adenovirus

<400> 28
 ggatccactc tcttcgcgat cgctgtctgc gagggccagc tgttgggggtg agtactccct 60
 ctgaaaagcg ggcattgactt ctgcgctaag attgtcagtt tccaaaaacg aggaggattt 120
 gatattcacc tggcccgcgg tgatgccttt gaggggtggc gcatccatct ggtcagaaaa 180
 gacaatcttt ttgttggtcaa gcttggtggc aaacgaccgc tagagggcgt tggacagcaa 240
 cttggcgatg gagcgagggg tttgggtttt gtcgcgatcg gcgcgctcct tggccgcgat 300
 gtttagctgc acgtattcgc gcgcaacgca ccgccattcg ggaaagacgg tgggtgcgctc 360
 gtcgggcacc aggtgcacgc gccaaaccgc gttgtgcagg gtgacaaggc caacgctggt 420
 ggctacctct ccgcgtaggc gctcgttggc ccagcagagg cggccgcctt tgcgcgagca 480
 gaatggcggt aggggggtcta gctgcgtctc gtccgggggg tctgcgtcca cggtaaagac 540
 cccgggcagc aggcgcgcgt cgaagtagtc tatcttgcac ccttgcaagt ctacgcgctg 600

ctgccatgcg	cgggcgga	gcgcgcgctc	gtatgggttg	agtgggggac	cccatggcat	660
ggggtgggtg	agcgcgagg	cgtacatgcc	gcaaagtgcg	taaacgtaga	ggggctctct	720
gagatattcca	agatatgtag	ggtagcatct	tccaccgcgg	atgctggcgc	gcacgtaatc	780
gtatagttcg	tgcgaggag	cgaggaggtc	gggaccgagg	ttgctacggg	cgggctgctc	840
tgctcggaag	actatctgcc	tgaagatggc	atgtgagttg	gatgatatgg	ttggacgctg	900
gaagacgttg	aagctggcgt	ctgtgagacc	taccgcgtca	cgcacgaagg	aggcgtagga	960
gtcgcgcagc	ttgttgacca	gctcggcggt	gacctgcacg	tctagggcgc	agtagtccag	1020
ggtttccttg	atgatgtcat	acttatcctg	tccctttttt	ttccacagct	cgcggttgag	1080
gacaaactct	tcgcggtcct	tccagtactc	ttggatcgga	aaccgcgcgg	cctccgaacg	1140
agatccgtac	tccgcgcgg	agggacctga	gcgagtcgcg	atcgaccgga	tcggaataacc	1200
tctcgagaaa	ggcgtctaac	cagtcacagt	cgcaagatct			1240

<210> 29

<211> 8383

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV60

<400> 29

gacggatcgg	gagatctccc	gatccccctat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttggtgtgt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttaggggttag	gcgtttttg	ctgcttcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaataca	ttacgggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcg	tggtgacgg	cccaacgacc	360
ccgcgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggt	aaactgccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacggcc	cctattgacg	tcaatgacgg	taaatggccc	gectggcatt	540
atgcccagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatggg	780
gtaggcgtgt	acggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctctcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagaccgga	gcttgggtacc	900
gagctcggat	ccactctctt	ccgcacgct	gtctgcgagg	gccagctgtt	ggggtgagta	960
ctccctctga	aaagcgggca	tgacttctgc	gctaagattg	tcagtttcca	aaaacgagga	1020
ggatttgata	ttcacctggc	ccgcggtgat	gcctttgagg	gtggccgcat	ccatctggtc	1080
agaaaagaca	atctttttgt	tgtcaagctt	gggtggcaaac	gacccgtaga	gggcgttgga	1140
cagcaacttg	gcgatggagc	gcagggtttg	gtttttgtcg	cgatcggcgc	gctccttggc	1200
cgcgatgttt	agctgcacgt	attcgcgcgc	aacgcaccgc	cattcgggaa	agacgggtgt	1260
gcgctcgtcg	ggcaccaggt	gcacgcgcca	accgcggttg	tgacgggtga	caaggtcaac	1320
gctggtggct	acctctccgc	gtaggcgctc	gttggtccag	cagaggcggc	cgcccttgcg	1380
cgagcagaat	ggcggtaggg	ggtctagctg	cgctcgtcc	gggggggtctg	cgtccacggt	1440
aaagaccccg	ggcagcaggc	gcgcgtcgaa	gtagtctatc	ttgcacctt	gcaagtctag	1500
cgctgctgc	catgcgcggg	cggaagcgc	gcgctcgtat	gggttgagt	ggggaccca	1560
tggcatgggg	tgggtgagcg	cggaggcgta	catgccgaa	atgtcgtaaa	cgtagagggg	1620
ctctctgagt	attccaagat	atgtagggt	gcattctcca	ccgcggatgc	tggcgcgcac	1680
gtaatcgtat	agttcgtgcg	agggagcgag	gaggtcgga	ccgaggttgc	tacgggcggg	1740
ctgctctgct	cggaagacta	tctgcctgaa	gatggcatgt	gagttggatg	atatgggtgg	1800
acgctggaag	acgttgaagc	tggcgtctgt	gagacctacc	gcgtcacgca	cgaaggaggc	1860
gtaggagtgc	cgcagcttgt	tgaccagctc	ggcggtgacc	tgacgtctca	gggcgcagta	1920
gtccagggtt	tccttgatga	gtccatactt	atcctgtccc	tttttttct	acagctcgcg	1980
gttgaggaca	aactcttcgc	ggtctttcca	gtactcttgg	atcggaatac	cgtcgccctc	2040
cgaacgagat	ccgtactccg	ccgcgcaggg	acctgagcga	gtccgcacgc	accggatcgg	2100
aaaacctctc	gagaaaggcg	tctaaccagt	cacagtcgca	agatccaaga	tgaagcgcgc	2160
aagaccgtct	gaagatacct	tcaaccccg	gtatccatat	gacacggaaa	ccggctccctc	2220
aactgtgcct	tttcttactc	ctccctttgt	atcccccaat	gggtttcaga	agagtcctcc	2280
tggggtactc	tctttgcgcc	tatccgaacc	tctagttacc	tccaatggca	tgcttgcgct	2340
caaaatgggc	aacggcctct	ctctggacga	ggcggcaac	cttaectccc	aaaatgtaac	2400
cactgtgagc	ccacctctca	aaaaaaccaa	gtcaaacata	aacctggaaa	tatctgcaec	2460

cctcacagtt acctcagaag ccctaactgt ggctgccgcc gcacctctaa tggcgcgagg 2520
caacacactc accatgcaat cacaggcccc gctaaccgtg cacgactcca aacttagcat 2580
tgccacccaa ggacccctca cagtgtcaga aggaaagcta gccctgcaaa catcaggccc 2640
cctcaccacc accgatagca gtacccttac tatcactgcc tcaccccctc taactactgc 2700
cactggtagc ttgggcattg acttgaaaga gccattttat acacaaaatg gaaaactagg 2760
actaaagtac ggggctcctt tgcattgtaac agacgacctt aacactttga ccgtagcaac 2820
tggtccagggt gtgactatta ataatacttc cttgcaaaact aaagtacttg gagccttggg 2880
ttttgattca caaggcaata tgcaacttaa tgtagcagga ggactaagga ttgattctca 2940
aaacagacgc cttatacttg atgttagtta tccgtttgat gctcaaaacc aactaaatct 3000
aagactagga cagggccctc tttttataaa ctcagcccac aacttgga ttaactacaa 3060
caaaggcctt tacttgttta cagcttcaaa caattccaaa aagcttgagg ttaacctaa 3120
cactgccaa ggggttgatgt ttgacgctac agccatagcc attaatgcag gagatgggct 3180
tgaatttggt tcacctaatg caccaaacac aaatcccctc aaaacaaaaa ttggccatgg 3240
cctagaatgt gattcaaaca aggtatgggt tcctaaacta ggaactggcc ttagttttga 3300
cagcacagggt gcattacag taggaaacaa aaataatgat aagctaactt tggggaccac 3360
accagctcca tctcctaact gttagactaaa tgcagagaaa gatgctaaac tcactttggg 3420
cttaacaaaa tgtggcagtc aaatacttgc tacagtttca gttttggctg ttaaggcgag 3480
tttgggtcca atatctggaa cagttcaaaag tgctcatctt attataagat ttgacgaaaa 3540
tggagtgcta ctaaacaatt ccttccctgga ccagaatat tggaacttta gaaatggaga 3600
tcttactgaa ggcacagcct atacaaacgc tgttggtatt atgcctaacc tatcagctta 3660
tccaaaatct cacggtaaaa ctgccaaaag taactattgtc agtcaagttt acttaaacgg 3720
agacaaaact aaacctgtaa cactaacctt tacactaaac ggtacacagg aaacaggaga 3780
cacaactcca agtgcatact ctatgtcatt ttcattgggac tggctctggcc acaactacat 3840
taataaataa tttgccacat cctcttacac tttttcatac attgcccaag aataaaagaa 3900
gcggcgctc gagcatgcac cttagaggcc ctattctata gtgtcaccta aatgctagag 3960
ctcgctgac agcctcgact gtgccttcta gttgccagcc atctgttgtt tgccccctcc 4020
ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt cctttccctaa taaaatgagg 4080
aaattgcac gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 4140
acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg gtgggctcta 4200
tggcttctga ggcggaaaga accagctggg gctctagggg gtatccccac gcgccctgta 4260
gcggcgcat aagcgcgcg ggtgtgggtg ttacgcgcag cgtgaccgct acacttgcca 4320
gcgccctagc gcccgctcct ttcgcttctt tcccttccct tctcgccacg ttcgcccggc 4380
gtccccgta agctctaaat cggggcatcc cttaggggt ccgatttagt gctttacggc 4440
acctcgacc caaaaaactt gattagggtg atgggtcacg tagtgggcca tcgcccgtat 4500
agacggtttt tgcgcccttg acgttggagt ccacgttctt taatagtgga ctcttgttcc 4560
aaactggaac aacactcaac cctatctcgg tctattcttt tgatttataa gggattttgg 4620
ggatttggcg ctattgggtt aaaaatgagc tgatttaaca aaaatttaac gcgaattaat 4680
tgtgtggaat gtgtgtcagt taggggtggg aaagtcocca ggctccccag gcaggcagaa 4740
gtatgcaaag catgcatctc aattagtcag caaccagggtg tggaaagtc ccaggctccc 4800
cagcaggcag aagtatgcaa agcatgcatc tcaattagtc agcaaccata gtcccgcgcc 4860
taactccgcc catcccgccc ctaactccgc ccagttccgc ccattctccg ccccatggct 4920
gactaatttt ttttatttat gcagaggcgc aggcgcctc tgcctctgag ctattccaga 4980
agtagtgagg aggtttttt ggaggcctag gcttttgcaa aaagctoccg ggagcttcta 5040
tatccatttt cggatctgat caagagacag gatgaggatc gtttcgcatg attgaacaag 5100
atggattgca cgcaggttct ccggccgctt ggggtggagag gctattcggc tatgactggg 5160
cacaacagac aatcgggtgc tctgatgccg ccgtgttccg gctgtcagcg cagggggcgc 5220
cggttctttt tgtcaagacc gacctgtccg gtgcccgtga tgaactgcag gacgaggcag 5280
cgcggtctatc gtggctggcc acgacggcg ttccttgccg agctgtgctc gacgtgtgca 5340
ctgaagcggg aagggactgg ctgctattgg gcgaagtgcc ggggcaggat ctctgtcat 5400
ctcaccttgc tctgcccag aaagtatcca tcatggctga tgcaatgcgg cggctgcata 5460
cgcttgatcc ggctacctgc ccattcgacc accaagcgaa acatcgcatc gagcagcac 5520
gtactcggat ggaagccggt cttgtcgatc aggatgatct ggacgaagag catcaggggc 5580
tcgcccagc cgaactgttc gccaggctca aggcgcgcac gcccgcaggc gaggatctcg 5640
tcgtgaccca tggcgatgcc tgcttgccga atatcatggt cggaccgcta tcaggacata gcgttggcta 5700
gattcatcga ctgtggccgg ctgggtgtgg aatgggctga cggcttctc cgtctttagc 5760
cccgtgatat tgctgaagag cagcgcacgc ccttctatcg ccttcttgac gaggcttctt 5820
gtatcgccgc tcccgatctg aaatgaccga ccaagcgacg cccaacctgc catcacgaga 5880
gagcgggact ctgggggttc tctatgaaag gttgggcttc ggaatcggtt tccgggacgc 5940
tttcgattcc accgcgcct gcggggatct catgctggag ttcttcgccc accccaactt 6000
cggctggatg atcctccagc gttataatg atcacaattt acacaataa 6060
gtttattgca gcttataatg cttagttgtg tttgtccaaa ctcatcaatg tatcttatca 6120
agcatttttt tcaactgcatt

```

tgtctgtata ccgctcgacct ctagctagag cttggcgtaa tcatgggtcat agctgtttcc 6240
tgtgtgaaat tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaaagt 6300
taaagcctgg ggtgcctaata gagtgagcta actcacatta attgcgttgc gctcactgcc 6360
cgctttccag tccgggaaacc tgcctgtgcca gctgcattaa tgaatcggcc aacgcgcggg 6420
gagaggcggt ttgcgtattg ggcgctcttc cgcttccctcg ctactgact cgctgcgttc 6480
ggtcggtcgg ctgcggcgag cggatcagc tcactcaaaag gcggtaatag gggtatecac 6540
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 6600
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca 6660
caaaaatcga cgctcaagtc agaggtggcg aaaccgcaca ggactataaa gataccaggc 6720
gtttccccct ggaagctccc tcgtgcgtc tccgtttccg accctgccgc ttaccggata 6780
cctgtccggc tttctccctt cgggaagcgt ggcgctttct caatgctcac gctgtaggta 6840
tctcagttcg gtgtaggctg ttcgctccaa gctgggctgt gtgcacgaac ccccggttca 6900
gcccgaccgc tgcgccttat ccggtaaata tccgtcttgag tccaaccggg taagacacga 6960
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgagggt atgtaggcgg 7020
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatctgg 7080
tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 7140
caaacaaacc accgctggta gcggtggttt tttgtttgc aagcagcaga ttacgcgcag 7200
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggctctgacg ctcagtgga 7260
cgaaaactca cgtaagggg ttttggatc gagattatca aaaaggatct tcacctagat 7320
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 7380
tgacagttac caatgcttaa tcagtgggc acctatctca gcgatctgtc tatttcgttc 7440
atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 7500
tggccccagt gctgcaatga taccgcgaga ccacgcctca ccggctccag atttatcagc 7560
aataaaccag ccagccggaa gggccgagcg cagaagtggg cctgcaactt tatccgcctc 7620
catccagctc attaatgtt gccgggaagc tagagtaagt agttcgccat ttaatatggt 7680
gcgcaacggt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 7740
ttcattcagc tccggttccc gtccctccag cgttgtcaga agtaagttgg ccgcagtgtt 7800
aaaagcggtt agctccttcg cactgcataa ttctcttact gtcattctga gaatagtgt 7860
atcactcatg gttatggcag actcaaccaa gtcattctga gaatagtgt 7920
cttttctgtg actggtgagt caatacggga taataccgcg ccacatagca gaactttaa 8040
gagtgtctct tgcgcggcgt gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 8100
agatccagtc tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 8160
caccagcggt tctgggtgag caaaaaacagg aaggcaaaat gccgcaaaaa agggaaataag 8220
ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 8280
tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 8340
aggggttccg cgcacatttc cccgaaaagt gccacctgac gtc 8383

```

<210> 30

<211> 7960

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid pDV67

<400> 30

```

gacggatcgg gagatctccc gatccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtegct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttaggggttag gcgttttgcg ctgcttcgag atgtacgggc cagatatatc cgttgacatt 240
gattattgac tagttattaa tagtaataca ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccggc tggctgaccg cccaacgaac 360
cccgcctatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacggcc cctattgacg tcaatgacgg taaatggccc gcttggcatt 540
atgcccagta catgacctta tgggaacttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcgggttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatatacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatatata cagagactct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gctggctagc 900

```

gtttaaactt aagcttggtta ccgagctcgg atccactctc ttccgcacgc ctgtctgcga 960
ggggccagctg ttgggggtgag tactccctct gaaaagcggg catgacttct gcgctaagat 1020
tgtcagtttc caaaaacgag gaggatttga tattcacctg gcccgcggtg atgcctttga 1080
gggtggccgc atccatctgg tcagaaaaga caatcttttt gttgtcaagc ttggtggcaa 1140
acgacccgta gagggcggtg gacagcaact tggcgatgga gcgcaggggt ttggttttgt 1200
cgcgatcggc gcgctccttg gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc 1260
gccattcggg aaagacgggt gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggt 1320
tgtgcagggt gacaagggtca acgctgggtg ctacctctcc gcgtaggcgc tcgttggtcc 1380
agcagaggcg gccgcccctg cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt 1440
ccgggggggtc tgcgtccacg gtaagaccc cgggcagcag gcgcgcgtcg aagtagtcta 1500
tcttgcatcc ttgcaagtct agcgccctgt gccatgcgcg ggcggcaagc gcgcgctcgt 1560
atgggttgag tgggggaccg catggcatgg ggtgggtgag cgcggaggcg tacatgccgc 1620
aaatgtcgtg aacgtagagg ggctctctga gtattccaag atatgtaggg tagcatcttc 1680
caccgcggtg gctggcgcg cgcgtatgag acgtaatcgt atagtctgtg cgaggagcgc aggaggtcgc 1740
gaccgaggtt gctacggggc ggctgctctg ctccgaagac tatctgcctg aagatggcat 1800
gtgagttgga tgatatggtt ggacgctgga agacgttgaa gctggcgtct gtgagacctg 1860
ccgcgtcacg cacgaaggag gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga 1920
cctgcacgtc tagggcgcg tagtccaggg ttctcttgat gatgtcatat ttatctctgc 1980
cctttttttt ccacagctcg cggttgagga caaactcttc gcggtctttc cagtactctt 2040
ggatcggaat cccgtcggcc tccgaacgag atccgtactc cgcgcgcgag ggacctgagc 2100
gagtcgcgat cgaccggatc ggaaaacctc tcgagaaagg cgtctaacca gtcacagtgc 2160
caagatccaa gatgaagcgc gcaagaccgt ctgaagatag cttcaacccc gtgtatccat 2220
atgacacgga aaccggtcct ccaactgtgc cttttcttac tctctccctt gtatcccca 2280
atgggtttca agagagtcct cctggggtac tctctttgcg cctatccgaa cctctagtta 2340
cctccaatgg catgcttgcg ctcaaaatgg gcaacggcct ctctctggac gaggcgggca 2400
accttacctc ccaaaatgta accactgtga gccacactct caaaaaaacc aagtcaaca 2460
taaactgga aatatctgca cccctcacag ttacctcaga agccctaact gtggtgccc 2520
ccgcacctct aatggtcgag ggcaacacac tcaccatgca atcacaggcc ccgctaaccg 2580
tgcacgactc caaacttagc attgccaccc aaggacccct cacagtgtca gaaggaaagc 2640
tagccctgca aacatcaggc cccctcacca ccacgatag cagtaccctt actatccat 2700
cctcaccccc tctaactact gccactggta gcttgggcat tgacttgaaa gagccattt 2760
atacacaaaa tggaaaacta ggactaaagt acggggctcc tttgcatgta acagacgacc 2820
taaactctt gaccgtagca actggtccag gtgtgactat taataatact tccctgcaaa 2880
ctaaagtac tggagccttg ggttttgatt cacaaggcaa tatgcaactt aatgtagcag 2940
gaggactaag gattgattct caaaacagac gccttatact tgatgttagt tatccgttg 3000
atgtcaaaa ccaactaat ctaagactag gacagggccc tctttttata aactcagccc 3060
acaacttga tattaactac aacaaaggcc tttacttggt tacagcttca aacaattcca 3120
aaaagcttga ggttaaccta agcactgcca aggggttgat gtttgacgt acagccatag 3180
ccattaatgc aggagatggg cttgaatttg gttcacctaa tgcaccaaac acaactccc 3240
tcaaaacaaa aattggccat ggcctagaat ttgattcaaa caaggctatg gttcctaacc 3300
taggaactgg ccttagtttt gacagcacag gtgocattac agtaggaaac aaaaataatg 3360
ataagctaac tttgtggacc acaccagctc catctcctaa ctgtagacta aatgcagaga 3420
aagatgctaa actcactttg gtcttaacaa aatgtggcag tcaaatactt gctacagttt 3480
cagttttggc tgttaaaggc agtttggtc caatatctgg aacagttcaa agtgctcatc 3540
ttattataag atttgacgaa aatggagtgc tactaaacaa ttccttctcg gaccagaat 3600
attggaactt tagaaatgga gatcttactg aaggcacagc ctatacaaac gctgttggt 3660
ttatgcctaa cctatcagct tatccaaaat ctcacggtaa aactgcaaaa agtaacattg 3720
tcagtcaagt ttacttaaac ggagacaaaa aacactaacc attacactaa 3780
acggtacaca ggaaacagga gacacaactc caagtgcata ctctatgtca ttttcatggg 3840
actggtctgg ccacaactac attaatgaaa tatttgccac atcctcttac actttttcat 3900
acattgcca agaataaaaag aagcggccgc tcgagtctag agggcccggt taaacccgct 3960
gatcgcctc gactgtgcct tctagtggc agccatctgt tgtttgcccc tccccgctg 4020
cttcttgac cctggaagg gccaactcca ctgtccttcc taataaaatg caggaaattg 4080
catcgcatag tctgagtagg gtgcattcta ttctgggggg tggggtgggg caggacagca 4140
agggggagga ttgggaagac aatagcaggc atgctgggga tgcggtgggc tctatggctt 4200
ctgagcgga aagaaccagc tggggctcta gggggtatcc ccacgcgccc tgtagcggcg 4260
cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt gccagcgc 4320
tagcgcgcgc tcccttcgct ttcttccct ccttctcgc cagtttcgac ggcgttcccc 4380
gtcaagctct aaatcggggc atccctttag ggttccgatt tagtgcttta cggcacctcg 4440
accccaaaaa acttgattag ggtgatggt cagctagtg gccatcgccc tgatagacgg 4500
tttttcgccc tttgacgttg gagtccacgt tctttaatag tggactcttg ttccaaactg 4560
gaacaacact caaccctatc tcggtctatt cttttgattt ataagggatt ttggggattt 4620

cggcctattg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg 4680
gaatgtgtgt cagttagggt gtggaaagtc cccaggctcc ccaggcaggc agaagtatgc 4740
aaagcatgca tctcaattag tcagcaacca ggtgtggaaa gtccccaggc tccccagcag 4800
gcagaagtat gcaaagcatg catctcaatt agtcagcaac catagtcctcg cccctaactc 4860
cgcccatccc gccctaact cgcgccagtt ccgcccattc tccgcccatt ggctgcactaa 4920
ttttttttat ttatgcagag gccgaggccg cctctgcctc tgagctattc -cagaagtagt 4980
gaggaggctt ttttggaggc ctaggctttt gcaaaaagct cccgggagct tgtatatcca 5040
ttttcggatc tgatcagcac gtgttgacaa ttaatcatcg gcatagtata tcggcatagt 5100
ataatacgac aaggtgagga actaaacatg ggccaagtgt accagtgcgg ttccgggtgt 5160
caccgcgcgc gacgtcgccg gagcggtcga ggtctggacc gaccggctcg gggtctcccg 5220
ggacttcgtg gaggacgact tcgcccgtgt ggtccgggac gacgtgaccc tgttcacatcag 5280
cgcggtccag gaccagggtg tgccggacaa caccctggcc tgggtgtggg tgccggcct 5340
ggacgagctg tacgccgagt ggtcggaggt cgtgtccacg aacttcggg acgctcccg 5400
gccggccatg accgagatcg gcgagcagcc gtggggcggt gagtccgccc tgccgcagacc 5460
ggccggcaac tgcgtgcaat tcgtggccga ggagcaggac tgacacgtgc tacgagattt 5520
cgattccacc gccgccttct atgaaagggt gggcttcgga atcgttttcc gggacgcgg 5580
ctggatgac ctccagcgcg gggatctcat gctggagttc ttcgcccacc ccaacttgtt 5640
tattgcagct tataatggtt acaataaag caatagcatc acaatttca caaataaagc 5700
atttttttca ctgcattcta gttgtggttt gtccaaactc atcaatgtat cttatcatgt 5760
ctgtataccg tcgacctcta gctagagctt ggcgtaatca tggatcatagc tgtttcctgt 5820
gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca taaagtgtaa 5880
agcctggggt gcctaatagag tgagctaact cacattaatt gcgttcgct cactgccgc 5940
tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcgccaaac gcgcggggag 6000
aggcggtttg cgtattgggc gctcttcgc tcctcgctc actgactcgc tgcgtcgggt 6060
cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacgggt tatccacaga 6120
atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg 6180
taaaaaggcc gcgttgctgg cgtttttcca taggctccgc cccctgacg agcatcaca 6240
aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 6300
tccccctgga agctccctcg tcgctctcc tgttcgacc ctgccgctta ccggatacct 6360
gtccgccttt ctcccttcgg gaagcgtggc gctttctcaa tgctcacgct gtaggtatct 6420
cagttcgggt taggtcgtt gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 6480
cgaccgctgc gccttatccg gtaactatcg tcttgagtc aaccggtaac gacacgctt 6540
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg tagggcgtgc 6600
tacagagttc ttgaagtggg gccctaacta cggctacact agaaggacag tatttggtat 6660
ctgcgtctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatecggcaa 6720
acaaaccacc gctggtagcg gtggttttt tgtttgcaag cagcagatta ccgcagaaa 6780
aaaagatct caagaagatc ctttgatctt tctacgggg tctgacgctc agtggaacga 6840
aaactcacgt taagggattt tggatcatgag attatcaaaa aggatcttca cctagatcct 6900
tttaaatata aaatgaagtt ttaaataaat ctaaagtata tatgagtaaa cttggtctga 6960
cagttaccaaa tgcttaataca gtgaggcacc tatctcagcg atctgtctat ttcgttcac 7020
catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggtc taccatctgg 7080
ccccagtgt gcaatgatac cgcgagaccc acgctcacgg gctccagatt tatcagcaat 7140
aaaccagcca gccggaaggg ccgagcgcag aagtggctct gcaactttat ccgcctccat 7200
ccagtctatt aattgttgcc ggggaagctag agtaagtagt tcgccagtta atagtttgcg 7260
caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 7320
attcagctcc gggtcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 7380
agcggtagc tccttcggtc ctccgacgt tgtcagaagt aagttggccg cagtggtatc 7440
actcatgggt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 7500
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgatgc ggcgaccgag 7560
ttgtcttgc ccggcgtaaa tacgggataa taccgcgcca catagcagaa ctttaaaagt 7620
gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 7680
atccagttcg atgtaacca ctcgtgcacc caactgatct tcagcatctt ttactttcac 7740
cagcgtttct gggtagcaaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 7800
gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca 7860
gggttattgt ctcagagcg gatcatatt tgaatgtatt tagaaaaata aacaaatagg 7920
ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc 7960

<210> 31

<211> 30

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 31
atgggatcca agatgaagcg cgcaagaccg

30

<210> 32
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 32
cactatagcg gccgcattct cagtcattct

30

<210> 33
<211> 7989
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid pDV69

<400> 33
gacggatcgg gagatctccc gatcccttat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtegtt gagtagtgag 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggtttag gcgttttgcg ctgcttcgct atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaataca ttacgggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcg tggctgaccg cccaacgacc 360
cccggccatt gacgtcaata atgacgtatg ttcccatagt aacgcccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcgggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacecaa gctggctagc 900
gtttaaactt aagcttggtg ccgagctcgg atccactctc ttccgcctcg ctgtctgca 960
gggcccagctg ttggggtgag tactccctct gaaaagcggg catgacttct gcgctaagat 1020
tgtcagtttc caaaaacgag gaggatttga tattcacctg gccgcgggtg atgcctttga 1080
gggtggccgc atccatctgg tcagaaaaga caatcttttt gttgtcaagc ttggtggcaa 1140
acgacccgta gaggcggttg gacagcaact tggcgatgga gcgcagggtt tgggttttgt 1200
cgcgatcggc gcgtcccttg gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc 1260
gccattcggg aaagacgggt gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggg 1320
tgtgcagggt gacaagggtc acgctgggtg ctacctctcc gcgtaggcgc tcgttggtcc 1380
agcagaggcg gccgcccctg ccgagcaga atggcggtag ggggtctagc tcgctctcgt 1440
ccgggggggtc tgcgtccacg gtaaaagacc cgggcagcag gcgcgcgtcg aagtagtcta 1500
tcttgcatcc ttgcaagtct agcgcctgct gccatgcgag ggcggcaagc gcgcgctcgt 1560
atgggttgag tgggggaccc catggcatgg ggtgggtgag cgcggaggcg tactatgccg 1620
aaatgtcgta aacgtagagg ggctctctga gtattccaag atatgtaggg tagcatcttc 1680
caccgaggat gctggcgcg cagtaatcgt atagttcgtg cgagggagcg agggaggtcgg 1740
gaccgagggt gctacgggag ggctgctctg ctccgaagac tatctgcctg aagatggcat 1800
gtgagttgga tgatatggtt ggacgttgaa gctggcgtgt gtgagacctt 1860
ccgcgtcacg cacgaaggag gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga 1920
cctgcacgtc tagggcgag tagtccaggg ttcccttgat gatgtcatac ttatcctgtc 1980
cctttttttt ccacagctcg cgggtgagga caaactcttc gcggcttttc cagtactctt 2040
ggatcggaaa cccgtcggtc tccgaacgag atccgtactc cgcgcgcgag ggacctgagc 2100
gagtcggcat cgaccggatc ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg 2160

caagatccaa	gatgaagcgc	gcaagacgct	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggtcct	ccaactgtgc	cttttcttac	tectcccttt	gtatcccca	2280
atgggtttca	agagagtccc	cctgggttac	tctctttgcg	cctatccgaa	cctctagtta	2340
cctccaatgg	catgcttgcg	ctcaaaatgg	gcaacggcct	ctctctggac	gaggccggca	2400
accttacctc	ccaaaatgta	accactgtga	gcccacctct	caaaaaaacc	aagtcaaca	2460
taaacctgga	aatatctgca	cccctcacag	ttacctcaga	agccctaact	gtggctgccc	2520
ccgcacctct	aatggctcgc	ggcaacacac	tcaccatgca	atcacaggcc	ccgctaaccg	2580
tgcacgactc	caaacttagc	attgccaccc	aaggacccct	cacagtgtca	gaaggaaagc	2640
tagccctgca	aacatcaggc	cccctcacca	ccaccgatag	cagtaccctt	actatcactg	2700
cctcaccccc	tctaactact	gccactggta	gcttgggcat	tgacttgaaa	gagcccatth	2760
atacacaana	tggaaaacta	ggactaaaat	acggggctcc	tttgcatgta	acagacgacc	2820
taaacacttt	gaccgtagca	actggtccag	gtgtgactat	taataatact	tccttgcaaa	2880
ctaaagttag	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcac	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gcaggggccc	tctttttata	aactcagccc	3060
acaacttgga	tattaactac	aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaacctta	agcactgcca	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcacctaa	tgcaccaaac	acaaatcccc	3240
tcaaaaacaaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttcctaaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	ggtccaaaac	cagaagccaa	ctgcataatt	gaatacggga	3420
aacaaaaccc	agatagcaaa	ctaactttaa	tccttgtaaa	aaatggagga	attgttaatg	3480
gatattgaac	gctaattgga	gcctcagact	acgttaacac	cttatttaaa	aacaaaatg	3540
tctccattaa	tgtagaacta	tactttgatg	ccactgggtca	tattattacca	gactcatctt	3600
ctcttaaaac	agatctagaa	ctaaaataca	agcaaaccgc	tgacttttagt	gcaagaggtt	3660
ttatgccaaag	tactacagcg	tatccatttg	tccttcctaa	tgccgggaaca	cataatgaaa	3720
attatatttt	tgggtcaatgc	tactacaaag	caagcgatgg	tgcccttttt	ccgttggaag	3780
ttactgttat	gcttaataaa	cgctcgccag	atagtcgcac	atcctatggt	atgacttttt	3840
tatggctcct	gaatgctggg	ctagctccag	aaactactca	ggcaaccctc	ataacctccc	3900
cattttacct	ttcctatatt	agagaagatg	actgattttt	aagaagcggc	cgctcgagtc	3960
tagagggccc	gtttaaaccc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	4020
tggtgtttgc	ccctcccccg	tgcttccctt	gacctggaa	ggtgccactc	ccactgtcct	4080
ttcctaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	4140
gggtgggggtg	gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	4200
ggatgcggtg	ggctctatgg	cttctgaggg	ggaaagaacc	snccntagct	ggggctctag	4260
ggggatcccc	cacgcgccct	gtagcggcgc	attaagcgcg	gcgggtgtgg	tgggtacggc	4320
cagcgtgacc	gctacacttg	ccagcgccct	agcgcccgct	cctttcgctt	tcttcccttc	4380
ctttctcgcc	acgttcgccc	gctttccccg	tcaagctcta	aatcggggca	tcctttagg	4440
gttccgattt	agtgttttac	ggcacctcga	ccccaaaaaa	cttgattagg	gtgatggttc	4500
acgtagtggg	ccatcgccct	gatagacggg	ttttcgccct	ttgacgttgg	agtcacggtt	4560
ctttaatagt	ggactcttgt	tcctaaactg	aacccaactc	aacctatctt	cggtctatc	4620
ttttgattta	taagggaatt	tggggatttc	ggcctattgg	ttaaaaaatg	agctgattta	4680
acaaaaattt	aacgcgaatt	aattctgtgg	aatgtgtgtc	agttagggtg	tggaaagtcc	4740
ccagggtccc	caggcaggca	gaagtatgca	aagcatgcat	ctcaattagt	cagcaaccag	4800
gtgtggaaaag	tccccaggct	ccccagcagg	cagaagtatg	caaagcatgc	atctcaatta	4860
gtcagcaaac	atagtcgccg	ccctaactcc	gccccatccc	cccctaactc	cgccagtttc	4920
cgcccatctt	ccgccccatg	gctgactaat	tttttttatt	tatgcagagg	ccgaggccgc	4980
ctctgcctct	gagctattcc	agaagtatg	aggaggcttt	tttgaggggc	taggcttttg	5040
caaaaagctc	ccgggagctt	gtatatccat	tttcggatct	gatcagcacg	tgttgacaat	5100
taatcatcgg	catagtatat	cggcatagta	taatacgaca	aggtgaggaa	ctaaaccatg	5160
gccaagttag	ccagtgcctg	tccgggtgtc	accgcgcgcg	acgtcgccgg	agcggctcgag	5220
ttctggaccg	accggctcgg	gttctcccg	gacttcgtgg	aggacgactt	cgccggtgtg	5280
gtccgggacg	acgtgaccct	gttcatcagc	gcgggtccagg	accaggtggg	gccggacaac	5340
accctggcct	gggtgtgggt	gcgcggcctg	cagcagctgt	acgcggagtg	gtcggaggtc	5400
gtgtccacga	acttcgggga	ccctccggg	ccggccatga	ccgagatcgg	cgagcagccg	5460
tgggggcccgg	agttcgccct	gcgcgacccg	gccggcaact	gcgtgcactt	cgtggccgag	5520
gagcaggact	gacacgtgct	acgagatttc	gattccaccg	ccgccttcta	tgaagggttg	5580
ggcttcggaa	tcgttttccg	ggacgcggcg	tggatgatcc	tcacgcggcg	ggatctcatg	5640
ctggagttct	tcgcccaccc	caacttggtt	attgcagctt	ataatgggta	caaataaage	5700
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcatcttag	ttgtgggttg	5760
tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	cgacctctag	ctagagcttg	5820
cgtaaatcat	ggcatagctt	gtttcctgtg	tgaattgttt	atccgctcac	aattccacac	5880


```

aacatacagag ccggaagcat aaagtgtaaa gcctgggggtg cctaatagagt gagctaactc 5940
acattaattg cgttgcgctc actgcccgtt ttccagtcgg gaaacctgtc gtgccagctg 6000
cattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggag ctcttccgct 6060
tctcgtctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac 6120
tcaaaggcgg taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga 6180
gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat 6240
aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac 6300
ccgacaggac tataaagata ccaggcggtt cccctggaa gctccctcgt gcgctctcct 6360
gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg 6420
ctttctcaat gctcacgctg taggtatctc agttcggtgt aggtcggtcg ctccaagctg 6480
ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt 6540
cttgagtcca acccggttaag acacgactta tcgccactgg cagcagccac tggtaacagg 6600
attagcagag cgaggtatgt aggcgggtgt acagagttct tgaagtgggt gcctaactac 6660
ggctacacta gaaggacagt atttgggtatc tgcgctctgc tgaagccagt taccttcgga 6720
aaaagagttg gtagctcttg atccggcaaa caaacaccgg ctggtagcgg tgggtttttt 6780
gtttgcaagc agcagattac ggcgagaaaa aaaggatctc aagaagatcc tttgatcttt 6840
tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga 6900
ttatcaaaaa ggatcttcac ctagatcctt ttaaatataa aatgaagttt taaatcaatc 6960
taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct 7020
atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata 7080
actacgatac gggagggcctt accatctggc cccagtgtcg caatgatacc gcgagacca 7140
cgctcacccg ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgaga 7200
agtggtcctg caactttatc cgctccatc cagttatta attgttgccg ggaagctaga 7260
gtaagtagtt cgccagttaa tagtttgccg aacgttggtg ccattgctac aggcacgtg 7320
gtgtcacgct cgctcgtttg tatgggttca ttcagctccg gttcccaacg atcaaggcga 7380
gttacatgat cccccatggt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt 7440
gtcagaagta agttggccgc agtggttatca ctcatgggta tggcagcact gcataattct 7500
cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca 7560
ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtaaat acgggataat 7620
accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga 7680
aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaaccac ccgtgcaccc 7740
aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg 7800
caaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc 7860
ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg atacatat 7920
gaatgtattt agaaaaataa acaaataggg gttccgcgca catttcccg aaaagtgcc 7980
cctgacgctc

```

<210> 34

<211> 7607

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid GRE5-E1-SV40-Hygro

<400> 34

```

tctagaagat ccgctgtaca ggatgttcta gctactttat tagatccgct gtacaggatg 60
ttctagctac tttattagat ccgctgtaca gctactttat tagatccgct 120
gtacaggatg ttctagctac tttattagat ccgctgtaca gatgttctag ctactttatt 180
agatcgatct cctggcggtt cgggggtcaaa aaccagggtt ggctataaaa ggggggtggg 240
gcgcgttcgt cctcactctc ttccgcatcg ctgtctgcga gggccaggat cgatcctgag 300
aacttcaggg tgagtttggg gacccttgat tgttctttct ttttcgctat tgtaaaaattc 360
atgttatatg gagggggcaa agttttcagg gtgtgttga gaatgggaag atgtcccttg 420
tatcaccatg gaccctcatg ataattttgt ttctttcact ttctactctg ttgacaacca 480
ttgtctcttc ttattttctt ttcattttct gtaacttttt cgttaaactt tagcttgcac 540
ttgtaacgaa tttttaaatt cactttttgt tatttgtcag attgtaagta ctttctctaa 600
tcaacttttt ttcaaggcaa tcagggtata ttatatgtga cttcagcaca gttttagaga 660
acaattgtta taattaaatg ataaggtaga atatttctgc atataaaattc tggctggcgt 720
ggaaatatte ttattggtag aaacaactac atcctgggtc tcatcctgcc tttctcttta 780
tggttacaat gatatacact gtttgagatg aggataaaat actctgagtc caaacggggc 840
ccctctgcta accatgttca tgccctcttc ttttccctac agctcctggg caacgtgctg 900
gttattgtgc tgtctcatca ttttggtgaaa gaattagatc taagcttctg cagctcgagg 960

```

actcgggtcga ctgaaaatga gacatattat ctgccacgga ggtgttatta ccgaagaaat 1020
ggccgccagt cttttggacc agctgatcga agaggtagctg gctgataatc ttccacctcc 1080
tagccatttt gaaccaccta cccttcacga actgtatgat ttagacgtga cggcccccca 1140
agatcccaac gaggaggcgg ttttcgcagat ttttcccgac tctgtaatgt tggcgggtgca 1200
ggaagggtt gacttactca cttttccgcc ggcccccggg tctccggagc cgcctcacct 1260
ttcccggcag cccgagcagc cggagcagag agccttgggt ccggtttcta tgccaaacct 1320
tgtaccggag gtgatcgatc ttacctgcca cgaggctggc tttccacca gtgacgacga 1380
ggatgaagag ggtgaggagt ttgtgttaga ttatgtggag caccocgggc acggttgag 1440
gtcttgtcat tatcaccgga ggaatacggg ggaccagat attatgtgt cgctttgcta 1500
tatgaggacc tgtggcatgt ttgtctacag taagtgaata ttatgggag tgggtgatag 1560
agtgggtggg ttgggtgggt aatttttttt ttaattttta cagttttgtg gtttaagaa 1620
ttttgtattg tgattttttt aaaaggtcct gtgtctgaac ctgagcctga gcccgagcca 1680
gaaccggagc ctgcaagacc taccgcctt cctaaaaatgg cgcctgctat cctgagagcg 1740
ccgacatcac ctgtgtctag agaatgcaat agtagtacgg atagctgtga ctccggtcct 1800
tctaaccacac ctccctgagat acaccgggtg ttcccgctgt gcccattaa accagtggc 1860
gtgagagttg gtgggcgtcg ccaggctgtg gaatgtatcg aggacttgct taacgagcct 1920
gggcaacctt tggacttgag ctgtaaacgc cccaggccat aagggtgtaa cctgtgattg 1980
cgtgtgtggg taacgccttt gtttgctgaa tgagttgatg taagttaat aaagggtgag 2040
ataatgttta acttgcattg cgtgttaaat atctgacctt gggagtggtt ggaagatttt 2100
cgtgggttaa tcttgggtac atctgacctt tggagggctt gggagtgttt ggaagatttt 2160
tctgctgtgc gtaacttgct ggaacagagc tctaacagta cctcttggtt ttggaggttt 2220
ctgtggggct catcccaggc aaagtttagt tgcagaatta aggaggatta caagtgggaa 2280
tttgaagagc ttttgaatc ctgtgggtgag ctgtttgatt ctttgaatct gggctcaccg 2340
gcgcttttcc aagagaaggt catcaagact ttggattttt ccacacggg gcgctgtgcg 2400
gctgctgttg cttttttgag ttttataaag gataaatgga gcgaagaaac ccatctgagc 2460
gggggggtacc tgctggattt tctggccatg catctgtgga gagcggttgt gagacacaag 2520
aatcgccctgc tactgttgtc ttccgtccgc ccggcgataa taccgacgga ggagcagcag 2580
cagcagcagg aggaagccag gcggcggcgg caggagcaga gccatggaa cccgagagcc 2640
ggcctggacc ctccgggaatg aatgtgtac aggtgggtga actgtatcca gaactgagac 2700
gcattttgac aattacagag gatgggcagg ggctaaaggg ggtaaagagg gagcgggggg 2760
cttgtgaggg tacagaggag gctaggaatc tagcttttag cttaatgacc agacaccgtc 2820
ctgagtgtat tacttttcaa cagatcaagg ataattgcgc taatgagctt gatctgtctg 2880
cgcagaagta ttccatagag cagctgacca ctactggct gcagccaggg gatgattttg 2940
aggaggctat taggtatat gcaaagggtg cacttaggcc agattgcaag tacaagatca 3000
gcaaacttgt aaatatcagg aattgttgc acatttctgg gaacggggcc gaggtggaga 3060
tagatacggg ggatagggtg gccttttagat gtatcatgat aaatatgtgg cgggggggtc 3120
ttggcatgga cggggtgggt attatgaatg taaggtttac tggcccaatg tttagcgtga 3180
cggttttcct ggccaatacc aaccttatcc tacacgggtg aagcttctat ggggttaaca 3240
atacctgtgt ggaagcctgg accgatgtaa gggttcgggg ctgtgccttt tactgctgct 3300
ggaagggggg ggtgtgtgcg cccaaaagca gggcttcaat taagaaatgc ctctttgaaa 3360
ggtgtacctt gggatatcct tctgagggtg actccagggt gcgccacaat ttggcctccg 3420
actgtgggtt ctctatgcta gtgaaaagcg tggctgtgat taagcataac atggtatgtg 3480
gcaactgcga ggacagggcc tctcagatgc tgacctgctc ggacggcaac tgtcacctgc 3540
tgaagaccat tcacgtagcc agccactctc gcaaggcctg gccagtgttt gagcataaca 3600
tactgaccgg ctgttccttg catttgggta acagggggg ggtgttcceta ccttatccat 3660
gcaatttgag tcacactaag atattgcttg agcccagag catgtccaag gtgaacctga 3720
acgggggtgt tgacatgacc atgaagatct ggaagggtgt gaggtacgat gagaccgca 3780
ccagggtgcag accctgcgag ttgtggcggt aacatattag gaaccagcct gtgatgctgg 3840
atgtgaccga ggagctgagg cccgatcact tgggtgctggc ctgcacccgc gctgagtttg 3900
gctctagcga tgaagataca gatttgaggt ctgaaatgtg tggcggtggc ttaagggtgg 3960
gaaagaatat ataagggtgg ggtcttatgt agttttgtat ctgttttgca gcagccgccc 4020
ccgcatgag caccaactcg tttgatggaa gcattgtgag ctcatatttg acaacgcgca 4080
tgcccccctg ggccgggggt cgtcagaatg tgatgggctc cagcattgat ggtcgccccc 4140
tctgccccgc aaactctact accttgacct acgagaccgt gtctggaaag ccgttgagga 4200
ctgcagcctc cgccgcgctg tcagccgctg cagccaccgc ccgcgggatt gtgatgact 4260
ttgttttctt gagcccgctt gcaagcagtg cagcttccc ttcatccgc ccgatgaca 4320
agttgacggc tcttttggca caattggatt ctttgaccgg ggaacttaat gtcgtttctc 4380
agcagctgtt ggatctgcgc cagcaggttt ctgcccgtga ggcttctccc cctcccaatg 4440
cggtttaaaa cataaataaa aaaccagact ctgtttggat ttggatcaag caagtgtctt 4500
gctgtctcag ctgactgctt aagtcgcaag ccgaattgga tccaattcgg atcgatctta 4560
ttaaagcaga acttgtttat tgcagcttat aatggttaca aataaagcaa tagcatcaca 4620
aatttcacaa ataaagcatt ttttctactg cattctagtt gtgggtttgtc caaactcatc 4680


```

aatgtatctt atcatgtctg gtcgactcta gactcttccg ctctctcgct cactgactcg 4740
ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 4800
ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 4860
gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg ccccccctgac 4920
gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 4980
taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt 5040
accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc 5100
tgtaggtatc tcagttcggg gttaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 5160
cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caaccgggta 5220
agacacgact tatcgccact ggcagcagcc actggttaaca ggattagcag agcgaggat 5280
gtaggcgggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca 5340
gtatttggta tctgcgctct gctgaagcca gttacctcgc gaaaaagagt tggtagctct 5400
tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt 5460
acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 5520
cagtggaaacg aaaactcacg ttaagggat ttggtcatga gattatcaaa aaggatcttc 5580
acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtaa atatagtaa 5640
acttggctcg acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta 5700
tttcgttcat ccatagttgc ctgactcccc gtctgttaga taactacgat acgggagggc 5760
ttaccatctg gccccagtg cgcgagacc cagctcacc ggctccagat 5820
ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtgggcc tgcaacttta 5880
tccgcctcca tccagtctat taattgttgc cggaagctca gagtaagtag ttccgagtt 5940
aatagtttgc gcaacgttgt tgccattgct acaggcatcg tgggtgcacg ctctgctgtt 6000
ggtagtggctt cattcagctc cggttcccaa cgatcaaggc gagttacatg atccccatg 6060
ttgtgcaaaa aagcgggttag ctcttcgggt cctccgatcg ttgtcagaag taagtgggc 6120
gcagtgttat cactcatggt tatggcagca ctcttaatt ctcttactgt catgccatcc 6180
gtaagatgct tttctgtgac tggtagtac tcaaccaagt cattctgaga atagtgtatg 6240
cggcgaccga gttgtctctg cccggcgctc ataccgggata ataccgcgc acatagcaga 6300
actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta 6360
ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct 6420
tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480
ggaataaggg cgacacggaa atgttgaata ctcatactct tcctttttca atattattga 6540
agcattttatc agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat 6600
aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc 6660
attattatca tgacattaac ctataaaaaat aggcgtatca cgaggccccct ttcgtctcgc 6720
gcgtttcggg gatgacgggtg aaaacctctg acacatgcag ctcccggaga cggtcacagc 6780
ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttgg 6840
cgggtgtcgg ggctggctta actatcgggc atcagagcag attgtactga gagtgcacca 6900
tatgcgggtg gaaataccgc acagatgcgt aaggagaaaa taccgcatac ggaattgtta 6960
agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac 7020
caataggccg aaatcggaac aatcccttat aaatcaaaag aatagaccga gatagggttg 7080
agtgtgttgc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa 7140
gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt 7200
tttttggggg cgaggtggcg taaagcacta aatcggaacc ctaaaaggag cccccgattt 7260
agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggagaa agcgaaagga 7320
gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcc 7380
gcgttaaatg cgccgctaca gggcgctcc cattcgccat tcaggctgag caactgttgg 7440
gaagggcgat cgggtcggggc ctcttcgcta ttacgcagc tggcgaaagg gggatgtgct 7500
gcaaggcgat taagttgggt aacgccaggg ttttccagc cagcagcttg taaaaacgacg 7560
gccagtgaat tgtaatacga ctactatag ggcgaattaa ttcgggg 7607

```

<210> 35

<211> 11600

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid MMTV-E2a-SV40-Neo

<400> 35

```

gaattccgca ttgcagagat attgtattta agtgcctagc tcgatacaat aaacgccatt 60
tgaccattca ccacattggg gtgcacctcc aagcttgggg agaaatgggt gaactcccga 120

```

gagtgtccta cacctagggg agaagcagcc aaggggttgt ttcccaccaa ggacgacccg 180
tctgcgcaca aacggatgag cccatcagac aaagacatat tcattctctg ctgcaaacctt 240
ggcatagctc tgctttgcct ggggctattg ggggaagtgt cgggtcgtgc tcgcaggggt 300
ctcacccttg actcttttaa tagctcttct gtgcaagatt acaatctaaa caattcggag 360
aactcgacct tcctcctgag gcaaggacca cagccaactt cctcttacia gcccgcacga 420
ttttgtcctt cagaaataga aataagaatg cttgctaana attatatttt taccaataag 480
accaatccaa taggtagatt attagttact atgttaagaa atgaatcatt atcttttagt 540
actattttta ctcaaattca gaagttagaa atgggaatag aaaatagaaa gagacgctca 600
acctcaattg aagaacaggt gcaaggacta ttgaccacag gcctagaagt aaaaaaggga 660
aaaaagagtg tttttgtcaa aataggagac aggtggtggc aaccagggac ttatagggga 720
ccttacatct acagaccaac agatgcccc caatggctat aaagtgttat atagatccct cccttttcgt 840
tgggataggt ggggtacagt acctccttgg tgtatgtgt ctcaagaaga aaaagacgac 900
gaaagactcg ccagagctag aggtacatga ttatatattat ctaggaaacag gaatgcactt ttgggggaaag 960
atgaaacaac ccaaggagggt gacagtggct ggactaatag aacattatct tgcaaaaact 1020
catggcatga gttattatga atagccttta ttggcccaac cttgcgggtc ccagggctta 1080
agtaagtgtt ttggtacaaa ctgttcttaa aacgaggatg tgagacaagt ggtttcctga 1140
cttggtttgg tatcaaaggt tctgatctga gctctgagtg ttctattttc ctatgttctt 1200
ttggaattta tccaaatctt atgtaaatgc ttatgtaaac caagatataa aagagtgtctg 1260
attttttgag taaacttgca acagtccctc cactcacctc ttgtgtgttt gtgtctgttc 1320
gccatccgt ctccgctcgt cacttatcct tcactttcca gaggggtccc ccgcagaccc 1380
cggcgacct caggtcggcc gactcggcca gctggcgccc gaacagggac cctcggataa 1440
gtgaccttg tctctatttc tactatttgg tgtttgtctt gtattgtctc ttctctgtct 1500
ggctatcatc acaagagcgg aacggactca ccatagggac caagctagcg cttctcgtcg 1560
cgtccaagac cctcaaagat ttttggcact tcgttgagcg aggcgatatc aggtatgaca 1620
gcgcctgccc gcaaggccag ctgtttgtcc gctcggctgc ggttggcagc gcaggatagg 1680
ggtatcttgc agttttggaa aaagatgtga taggtggcaa gcacctctgg cacggcaaat 1740
acggggtaga agttgaggcg cgggttgggc tgcgatgtgc cgttttcttg gcgtttgggg 1800
ggtacgcgcg gtgagaatag gtggcgctcg taggcaaggg tgacatccgc tatggcgagg 1860
ggcacatcgc tgcgctcttg caacgcgctc cagataatgg cgcactggcg ctgcagatgc 1920
ttcaacagca cgtcgtctcc cacatctagg tagtcgccat gcctttcgtc cccccgccg 1980
acttgttctt cgtttgcctc tgcgttgtcc tggctcttgc ttttatcctc tgttgggtact 2040
gagcgttctt cgtcgtcttc gcttacaaaa cctgggtcct gctcgataat cacttctctc 2100
tcctcaagcg ggggtgcctc gacggggaag ctgttggcg cgttggggc atcgttggag 2160
gcggtggtgg cgaactcaga gggggcggtt aggtgtcct tcttctcgac tgactccatg 2220
atctttttct gcctatagga gaaggaaatg gccagtcggg aagaggagca gcgcgaaacc 2280
accccgagc gcggacgcgg tgccggcgga cgtcccccac ccatggagga cgtgtcgtc 2340
cgtcccggt cgccgcggcc tccccggcg ccccaaaaa agcggatgag acccggtatc 2400
gagtcagagg acgaggaaga ccatcacaa gacgcgctgg tgcgcgcac acccagccc 2460
cggccatcga cctcggcgcc ggatttggcc atttgcgcca agaagaaaaa gaagcgccct 2520
tctcccaagc ccgagcgccc gccatcacca gaggtaatcg tggacagcga ggaagaaaga 2580
gaagatgtgg cgctacaaat ggtgggttct agcaaccac cgggtgctaat caagcatggc 2640
aaaggaggta agcgcacagt gcggcggtg aatgaagacg acccagtggt cgttgggtatg 2700
cggacgcaag aggaagagga agagcccagc gaagcggaaa gtgaaattac ggtgatgaac 2760
ccgctgagtg tgccgatcgt gtctcgtgg gagaaggcca tggaggctgc gcgcgcgtg 2820
atggacaagt accacgtgga taacgatcta aaggcgaact tcaaactact gcctgaccaa 2880
gtggaagctc tggcgccgt atgcaagacc tgggtgaac aggagcaccg cgggttgag 2940
ctgaccttca ccagcaaaa gacctttgtg acgatgatgg ggcgattcct gcaggcgtag 3000
ctgcagctgt ttgcagaggt gacctacaag catcacgagc ccacgggctg cgcgttgtgg 3060
ctgcaccgct gcgctgagat cgaaggcgag cttaagtgtc tacacggaag cattatgata 3120
aataaggagc acgtgattga aatggatgtg acgagcgaaa acgggacagc cgcgctgaag 3180
gagcagctca gcaaggccaa gctcgtgaa aaccggtggg gccgaaatgt ggtgcagatc 3240
tccaacaccg acgcaagggt ctgcgtgcac gacgggctt gtccggccaa tcagttttcc 3300
ggcaagtctt gcggcatgtt cttctctgaa ggcgcaagg ctcaggtggc ttttaagcag 3360
atcaaggctt ttatgcaggg gctgtatcct aacgcccaga ccgggcacgg tcacctttt 3420
atgccactac ggtgcgagtg caactcaaag cctgggcagc cgccctttt gggaaggcag 3480
ctaccaagtg tgactccgt gacctgagc aacgcggagg accctggagc ggatctgatc 3540
tccgacaaga gcgtgctggc cagcgtgcac caccggcgcc tgatagtgtt ccagtgtgc 3600
aaccctgtgt atcgcaatc gcgcgcgcag ggcggaggcc ccaactgcga cttcaagata 3660
tcggcgcccc acctgctaaa cgcgttgggt atggtgcgca gcctgtggag tgaaaacttc 3720
accgagctgc cgcggatgg tgtgcctgag gcactaaca ccagtatcgc ccagtatcgc 3780
aacgtgtccc tgccagtggc gctatagcat gcgcggcaga accccttga tttttaaacg 3840

gcgcagacgg	caaggggtggg	ggtaaataat	cacccgagag	tgtacaaata	aaagcatttg	3900
cctttattga	aagtgtctct	agtacattat	ttttacatgt	ttttcaagtg	acaaaaagaa	3960
gtggcgctcc	taatctgcgc	actgtggctg	cggaagtagg	gcgagtgccg	ctccaggaag	4020
ctgtagagct	gttcctgggt	gcgacgcagg	gtgggctgta	cctggggact	gttgagcatg	4080
gagttgggta	ccccggtaat	aaggttcatg	gtgggggtgt	gatccatggg	agtttggggc	4140
cagttggcaa	aggcgtggag	aaacatgcag	cagaatagtc	cacaggcgcc	cgagttgggc	4200
ccctgtacgc	tttgggtgga	ctttccagc	gttatacagc	ggtcggggga	agaagcaatg	4260
gcgctacggc	gcaggagtga	ctcgtactca	aactggtaaa	cctgcttgag	tcgctgggtca	4320
gaaaagccaa	agggctcaaa	gaggtagcat	gtttttgagt	gcgggttcca	ggcaaaggcc	4380
atccagtgtg	cgccccaggt	ctcgcgaccg	gccgtattga	ctatggcgca	ggcgagcttg	4440
tgtggagaaa	caaagcctgg	aaagcgcttg	tcataggtgc	ccaaaaata	tggcccaaaa	4500
ccaagatcct	tgacaatggc	tttcagttcc	tgctcactgg	agcccatggc	ggcagctgtt	4560
gttgatgttg	cttgcttctt	tatgttgtgg	cgttgccggc	cgagaagggc	gtgcgcaggt	4620
acacggtttc	gatgacgccg	cggtgcggcc	ggtgcacacg	gaccagctca	aagacttcaa	4680
acaaaacata	aagaaggggt	ggctcgtcca	tgggattccat	atatagggcc	cgggttataa	4740
ttacctcagg	tcgacctcga	gggatctttg	tgaaggaaacc	ttacttctgt	gggtgtgacat	4800
aattggacaa	actacctaca	gagatttaaa	gctctaaggt	aaatataaaa	tttttaagtg	4860
tataatgtgt	taaactactg	attctaattg	tttgtgtatt	ttagattcca	acctatggaa	4920
ctgatgaatg	ggagcagtg	tggaaatgcct	ttaatgagga	aaacctgttt	tgctcagaag	4980
aaatgccatc	tagtgatgat	gaggctactg	ctgactctca	acattctact	cctccaaaaa	5040
agaagagaaa	ggtagaagac	cccaaggact	ttccttcaga	attgctaagt	tttttgagtc	5100
atgctgtgtt	tagtaataga	actcttgctt	gctttgctat	ttacaccaca	aaggaaaaag	5160
ctgcactgct	atacaagaaa	attatggaaa	aatattctgt	aacctttata	agtaggcata	5220
acagttataa	tcataacata	ctgttttttc	ttactccaca	caggcataga	gtgtctgeta	5280
taataaacta	tgctcaaaaa	ttgtgtacct	ttagcttttt	aatttgtaaa	ggggtttaata	5340
aggaatat	gatgtatagt	gccttgacta	gagatcataa	tcagccatac	cacatttgta	5400
gaggttttac	ttgcttttaa	aaacctccca	cacctcccc	tgaacctgaa	acataaaatg	5460
aatgcaattg	ttgttggtta	cttgtttatt	gcagcttata	atggtttaca	ataaagcaat	5520
agcatcacaa	atttcacaaa	taaagcattt	ttttcactgc	attctagttg	tggtttgtcc	5580
aaactcatca	atgtatctta	tcattgtctg	atccggctgt	ggaatgtgtg	tcagttaggg	5640
tgtggaaagt	ccccaggctc	cccagcaggc	agaagtatgc	aaagcatgca	tctcaattag	5700
tcagcaacca	ggtgtggaaa	gtccccaggc	tccccagcag	gcagaagtat	gcaaagcatg	5760
catctcaatt	agtcagcaac	catagtcccg	cccctaactc	cgcccatccc	gccccctaac	5820
ccgcagctt	ccgcccattc	tcgcgcccat	ggctgactaa	ttttttttat	ttatgcagag	5880
gccgagcccg	cctcgccctc	tgagctattc	cagaagtagt	gaggaggctt	ttttggaggc	5940
ctaggctttt	gcaaaaagct	tcacgctgcc	gcaagcactc	agggcgcaag	ggctgtctaaa	6000
ggaagcggaa	cacgtagaaa	gccagtccgc	agaaacgggt	ctgaccccg	atgaatgtca	6060
gctactgggc	tatctggaca	agggaaaaac	caagcgcaaa	gagaaagcag	gtagcttgca	6120
gtgggcttac	atggcgatag	ctagactggg	cggttttatg	gacagcaagc	gaaccggaat	6180
tgccagctgg	ggcgccctct	ggtaagggtg	ggaagccctg	caaagtaaac	tggatggctt	6240
tcttgccgcc	aaggatctga	tggcgcagg	gatcaagatc	tgatcaagag	acaggatgag	6300
gatcgtttcg	catgattgaa	caagatggat	tgcaagcagg	ttctccggcc	gcttgggtgg	6360
agaggctatt	cggctatgac	tgggcacaac	agacaatcgg	ctgctctgat	gccgcgctgt	6420
tcgggtgtgc	agcgcagggg	cgcccggttc	tttttgtcaa	gaccgacctg	tcgggtgcc	6480
tgaatgaact	gcaggacgag	gcagcgcgcc	tatcgtggct	ggccacgacg	ggcgctcctt	6540
gcgcagctgt	gctcgacgtt	gtcactgaag	cggaaggga	ctggctgcta	ttgggcgaag	6600
tgccggggca	ggatctcctg	tcactctacc	ttgctcctgc	cgagaaagta	tccatcatgg	6660
ctgatgcaat	gcggcggtcg	catacgtttg	atccggctac	ctgcccattc	gaccaaccaag	6720
cgaacatcg	catcgagcga	gcacgtactc	ggatggaagc	cggtcttgct	gatcaggatg	6780
atctggacga	agagcatcag	gggctcgccg	cagccgaact	gttcgcccagg	ctcaaggcgc	6840
gcattgcccga	cggcgaggat	ctcgtcgtga	cccatggcga	tgctgcttg	ccgaatatca	6900
tggtggaaaa	tggccgcttt	cttggtatca	tcgactgtgg	ccggctgggt	gtggcggacc	6960
gctatcagga	catagcgttg	gctacccgtg	atatgtgtga	agagcttggc	ggcgaatggg	7020
ctgaccgctt	cctcgtgctt	tacggtatcg	ccgctcccga	ttcgcagcgc	atcgccctct	7080
atcgcttctt	tgacgagttc	ttctgagcgg	gactctgggg	ttcgaaatga	ccgaccaagc	7140
gacgcccac	ctgccatcac	gagatttcga	ttccaccgcc	gccttctatg	aaagtttggg	7200
cttcggaatc	gttttcgggg	acgcgggtcg	gtgatctctc	cagcgggggg	atctcatgct	7260
ggagttcttc	gcccaccccg	ggctcgatcc	cctcgcgagt	tggttcagct	gctgcttgag	7320
gctggacgac	ctcgcggagt	tctaccggca	gtgcaaatcc	gtcggcatcc	aggaaaccag	7380
cagcggctat	ccgcgcaccc	atgcccccca	actgcaggag	tggggaggga	cgatggccgc	7440
tttggctccc	gatctttgtg	aaggaaacct	acttctgtgg	tgtgacataa	ttggacaaac	7500
tacctacaga	gatttaagac	tctaaggtaa	atataaaatt	tttaagtgta	taatgtgtta	7560

aactactgat	tctaattggt	tgtgtatgtt	agattccaac	ctatggaact	gatgaatggg	7620
agcagtgggt	gaatgccttt	aatgaggaaa	acctgttttg	ctcagaagaa	atgccatcta	7680
gtgatgatga	ggctactgct	gactctcaac	attctactcc	tccaaaaaag	aagagaaagg	7740
tagaagaccc	caaggacttt	ccttcagaat	tgctaagttt	tttgagtcac	gctgtgttta	7800
gtaatagaac	tcttgcttgc	tttgctatgt	acaccacaaa	ggaaaaagct	gcactgctat	7860
acaagaaaat	tatggaaaaa	tattctgtaa	cctttataag	taggcataac	agttataatc	7920
ataacatact	gttttttctt	actccacaca	ggcatagagt	gtctgctatt	aataactatg	7980
ctcaaaaatt	gtgtaccttt	agctttttta	tttgtaaagg	ggttaataag	gaatatttga	8040
tgtatagtgc	cttgactaga	gatcataatc	agccatacca	catttgtaga	ggttttactt	8100
gctttaaaaa	acctcccaca	cctcccctg	aacctgaaac	ataaaatgaa	tgcaattggt	8160
gttgtaact	tgtttattgc	agcttataat	ggttacaaat	aaagcaatag	catacacaaat	8220
ttcacaaata	aagcattttt	ttcactgcat	tctagtgtgt	gtttgtccaa	actcatcaat	8280
gtatcttatc	atgtctggat	ccccagggaag	ctcctctgtg	tcctcataaaa	ccctaaccctc	8340
ctctacttga	gaggacattc	caatcatagg	ctgcccattc	accctctgtg	tcctcctggt	8400
aattaggtca	cttaacaaaa	aggaaaattg	gtaggggttt	ttcacagacc	gctttctaag	8460
ggtaatttta	aaatatctgg	gaagtccctt	ccactgctgt	gttccagaag	tggtggtaaa	8520
cagcccacaa	atgtcaacag	cagaaacata	caagctgtca	gctttgcaca	agggcccaac	8580
accctgctca	tcaagaagca	ctgtggttgc	tggtgttagta	atgtgcaaaa	caggaggcac	8640
attttcccca	cctgtgtagg	ttccaaaata	tctagtgttt	tcatttttac	ttggatcagg	8700
aaccagcac	tccactggat	aagcattatc	cttatccaaa	acagccttgt	ggtcagtgtt	8760
catctgctga	ctgtcaactg	tagcattttt	tggggttaca	gtttgagcag	gatatttggt	8820
cctgtagttt	gctaacacac	cctgcagctc	caaagggttc	ccaccaacag	caaaaaaatg	8880
aaaatttgac	ccttgaatgg	gtttccagc	accattttca	tgagtttttt	gtgtccctga	8940
atgcaagtgt	aacatagcag	ttaccccaat	aacctcagtt	ttaacagtaa	cagcttccca	9000
catcaaaata	tttccacagg	ttaagtccct	atttaaatta	ggcaaaggaa	ttcttgaaga	9060
cgaaagggcc	tcgtgatagc	cctattttta	taggttaaat	tcagtataat	aatggtttct	9120
tagacgtcag	gtggcacttt	tcggggaaat	gtgcgcggaa	cccctatttg	tttatttttc	9180
taaatacatt	caaataatga	tcgcgtcatg	agacaataac	cctgataaat	gcttcaataa	9240
tattgaaaaa	ggaagagtat	gagtattcaa	caattccgtg	tcgcccctat	tccttttttt	9300
gcggcatttt	gccttcctgt	ttttgtcac	ccagaaacgc	tggtgaaagt	aaaagatgct	9360
gaagatcagt	tgggtgcacg	agtgggttac	atcgaactgg	atctcaacag	cggtaagatc	9420
cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	9480
tggtggcggg	tattatcccc	tggtgacgcc	gggcaagagc	aactcggctg	ccgcatacac	9540
tattctcaga	atgacttggt	tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	9600
atgacagtta	gagaattatg	cagtgtctgc	ataacatga	gtgataaacac	tcgggccaac	9660
ttacttctga	caacgatcgg	aggaccgaag	gagctaaccg	cttttttgca	caacatgggg	9720
gatcatgtaa	ctgccttga	tcgttgggaa	ccggagctga	atgaagccat	cccaaacgac	9780
gagcgtgaca	ccacgatgcc	tgacgcaatg	gcaacaacgt	tgcgcaaaact	attaactggc	9840
gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	ggatggaggc	ggataaagtt	9900
gcaggaccac	ttctgcgctc	ggcccttccg	gctggctggt	ttattgtctga	taaatctgga	9960
cgcggtgagc	gtgggtctcg	cggtatcatt	gcagcactgg	ggccagatgg	taagccctcc	10020
cgatctcgtg	ttatctacac	gacggggagt	caggcaacta	tggtgaaacg	aaatagacag	10080
atcgctgaga	taggtgcctc	actgattaag	catttggaac	tgtcagacca	agtttactca	10140
tatatacttt	agattgattt	aaaacttcat	ttttaattta	aaaggatcta	gggtgaagatc	10200
ctttttgata	atctcatgac	caaaatccct	taacgtgagt	tttcgttcca	ctgagcgtca	10260
gaccccgtag	aaaagatcaa	aggatcttct	tgagatccct	tttttctgcg	cgtaactctgc	10320
tgcttgcaaa	caaaaaaacc	accgctaoca	gcgggtggtt	gtttgccgga	tcaagagcta	10380
ccaactcttt	ttccgaaggt	aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	10440
ctagtgtagc	cgtagttagg	ccaccacttc	aagaactctg	tagcaccgcc	tacataacctc	10500
gctctgctaa	tcctgttacc	agtggctgct	gccagtggcg	ataagtcgtg	tcttaccggg	10560
ttggactcaa	gacgatagtt	accggataag	cgcgagcggg	cgggctgaac	gggggggttcg	10620
tgacacacagc	ccagcttggg	gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	10680
ctatgagaaa	gcgccacgct	tcccgaaggg	agaaaggcgg	acaggtatcc	ggtaagcggc	10740
agggctcgga	caggagagcg	cacgagggag	cttccagggg	gaaacgcctg	gtatctttat	10800
agtcctgtcg	ggtttcgcca	cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	10860
gggcggagcc	tatggaaaaa	cgccagcaac	gcggcctttt	tacggttcct	ggccttttgc	10920
tggccttttg	ctcacatggt	ctttcctgcg	ttatcccttg	attctgtgga	taaccgtatt	10980
accgcctttg	agtgagctga	taccgctcgc	cgcagccgaa	cgaccgagcg	cagcgagtca	11040
gtgagcgagg	aagcggaaga	gcgcctgatg	cggatatttc	tccttacgca	tctgtgcggg	11100
atttcacacc	gcataatggt	cactctcagt	acaattctgt	ctgatgcgcg	atagttaagc	11160
cagtatctgc	tccttgcttg	tgtgttggag	gtcgtgagt	agtgccgcgag	caaaatttaa	11220
gctacaacaa	ggcaaggctt	gaccgacaat	tgcatagaga	atctgcttag	ggttaggcgt	11280

tttgcgctgc ttcgcgatgt acgggccaga tatacgcgta tctgagggga ctaggggtgtg 11340
tttaggcgaa aagcggggct tcggttgtag gcggttagga gtcccctcag gatatagtag 11400
tttcgctttt gcatagggag ggggaaatgt agtcttatgc aatacacttg tagtcttgca 11460
acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc 11520
gattgtgga agtaagggtg tacgatcgtg ccttattagg aaggcaacag acgggtctga 11580
catggattgg acgaaccact 11600

<210> 36
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 36
gtcactcgag gactcggctg actgaaaatg agacatatta tctgccacgg acc 53

<210> 37
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 37
cgagatcgat cacctccggt acaagggttg gcatag 36

<210> 38
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 38
catgaagatc tggaagggtg tgaggtacga tgagacc 37

<210> 39
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 39
gcgacttaag cagtcagctg agacagcaag acatttgctt gatccaaatc c 51

<210> 40
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 40
cacgaattcg tcagcgcttc tcgtcgcgtc caagaacc 38

<210> 41
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 41
caccgccggg aggcggcgcc gacggggacg gg

32

<210> 42
<211> 7231
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid pDV80

<400> 42
ctgctccctg cttgtgtgtt ggaggtcgt gagtagtgcg cgagcaaaat ttaagctaca 60
acaaggcaag gcttgaccga caattgcatg aagaatctgc ttaggggttag gcgttttgcg 120
ctgcttcgcg atgtacgggc cagatatacg cgttgacatt gattattgac tagttattaa 180
tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg cgttacataa 240
cttacggtaa atggcccgcc tggctgaccg cccaacgacc ccgcccatt gacgtcaata 300
atgacgtatg ttcccatagt aacgccaaata gggactttcc attgacgtca atgggtggac 360
tatttacggt aaactgccc cttggcagta catcaagtgt atcatatgcc aagtacgccc 420
cctattgacg tcaatgacgg taaatggccc gcctggcatt atgccagta catgacctta 480
tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac catggtgatg 540
cggttttggc agtacatcaa tggcggtgga tagcgttttg actcacgggg atttccaagt 600
ctccacccca ttgacgtcaa tgggagtgtg ttttggcacc aaaatcaacg ggactttcca 660
aaatgtcgt acaactccgc cccattgacg caaatggcg gtaggcgtgt acggtgggag 720
gtctatataa gcagagctct ctggctaact agagaacca ctgcttactg gcttatcgaa 780
attaatacga ctactatag ggagacccaa gctggctagc gtttaaaactt aagcttggta 840
ccgagctcgg atccactctc ttccgcattc ctgtctgcga gggccagctg ttggggtgag 900
tactccctct gaaaagcggg catgactctt gcgctaagat tgtcagtttc caaaaacgag 960
gaggatttga tattcacctg gcccgcggtg atgcctttga ggggtggcgc atccatctgg 1020
tcagaaaaga caatctttt gtgtcagac ttggtggcaa acgaccgta gagggcggtg 1080
gacagcaact tggcgatgga gcgcaggggt tggttttgt cgcgatcggc gcgctccttg 1140
gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc gccattcggg aaagacgggtg 1200
gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggg tgtgcagggt gaccaaggta 1260
acgctggtgg ctacctctcc gcgtaggcgc tcgttggctc agcagaggcg gccgcccttg 1320
cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt ccggggggtc tgcgtccacg 1380
gtaaagacc cgggcagcag gcgcgcgtcg aagtagtcta tcttgcatcc ttgcaagtct 1440
agcgctgct gccatgcgcg ggcggcaagc gcgcgctcgt atgggttagg tgggggaccc 1500
catggcatgg ggtgggtgag cgcggaggcg tacatgccgc aaatgtcgt aacgtagagg 1560
ggctctctga gtattccaag atatgtagg tagcatctc caccgcggat gctggcgcgc 1620
acgtaatcgt atagtctgt cgagggagcg aggaggtcgg gaccgaggtt gctacggggc 1680
ggctgctctg ctcggaagac tatctgcctg aagatggcat gtgagttgga tgatagggtt 1740
ggacgctgga agacgttgaa gctggcgtct gtgagacctt ccgcgtcacg cacgaaggag 1800
gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga cctgcacgtc tagggcgag 1860
tagtccagggt tttccttgat gatgtcatac ttatcctgtc cctttttttt ccacagctcg 1920
cggttgagga caaactcttc gcggtctttc cagtactctt ggatcggaat cccgtcggcc 1980
tcggaacgag atccgtact cgcgcgcgag ggacctgagc gactccgcat cgaccggatc 2040
ggaaaacctc tcgagaaagg gctctaacca gtcacagtcg caagatccaa gatgaaggag 2100
gcccgcacca gcgaagatga cttcaacccc gtctacccct atggctacgc gcggaatcag 2160
aatatccctt tcctcactcc cccctttgtc tcctccgatg gattcaaaaa ctccccctt 2220
gggtactgt cactcaaact ggtgatcca atcaccatta ccaatgggga tgatccctc 2280
aaggtgggag gtggtctcac tttgcaagat cgaagccta ctgtaaaccc taaggatcca 2340
ctgcaagtta atactgataa aaaacttgag cttgcatatg ataaccatt tgaaagtagt 2400
gctaataaac ttagtttaaa agtaggacat ggattaaaag tattagatga aaaaagtgtc 2460

gcggggttaa aagatttaatt tggcaaaactt gtgggttttaa caggaaaagg aataggcact 2520
gaaaatttag aaaatacaga tggtagcagc agagggaattg gtataaatgt aagagcaaga 2580
gaaggggtga catttgacaa tgatggatac ggaacccaaa gtatgacacg 2640
cgacacttt ggacaacacc agacacatct ccaaactgca caattgctca agataaggac 2700
tctaaactca ctttggtagt tacaaagtgt ggaagtcaaa tattagctaa tgtgtctttg 2760
atttgtgtcg caggaaagta ccacatcata aataataaga caaatccaaa aataaaaagt 2820
tttactatta aactgctatt aagtggaaat ggagtgttt tagacaactc aaatcttggg 2880
aaagcttatt ggaacttttag aagtggaaat tccaatgttt cgacagctta tgaaaaagca 2940
attgggtttta tgcctaattt ggtagcgtat ccaaaaccca gtaattctaa aaaatatgca 3000
agagacatag tttatggaac tatatatctt ggtggaaaac ctgatcagcc agcagtcatt 3060
aaaactacct ttaaccaaga aactggatgt gaattttgaa accactctt ttaccttctc ctatattgcc 3120
tccaaaacct atgaaaatgt tgaattttgaa accactctt ttaccttctc ctatattgcc 3180
caagaatgaa agagcggccg ctgcagctta gagggcccgt ttaaaccgcg tgatcagcct 3240
cgactgtgcc ttctagtgtc cagcatctcg ttgtttgccc ctcccccggt ccttccctga 3300
ccctgggaagg tgcactccc actgtccttt cctaataaaa tgaggaaatt gcatcgcatt 3360
gtctgagtag gtgtcattct attctggggg gtgggtggg gcaggacagc aagggggagg 3420
attgggaaga caatagcagg catgctgggg atgctgtggg ctctatggct tctgaggcgg 3480
aaagaaccag ctggggctct aggggggtatc ccacgcgcgc ctgtagcggc gcattaagcg 3540
cggcgggtgt ggtgggttacg cgcagcgtga cgcctacact tgccagcgcc cttagcgccc 3600
ctcctttcgc tttcttccct tcctttctcg ccacgttctc cggctttccc cgtcaagctc 3660
taaactcggg catcccttta gggttccgat ttagtgttt acggcacctc gaccccaaaa 3720
aacttgatta ggggtgatggg tcacgtagtg ggccatcgcc ctgatagacg gtttttegcc 3780
ctttgacgtt ggagtcacg ttctttaata ttgtactctt gttccaaact ggaacaacac 3840
tcaaccctat ctcggtctat tcttttgatt tataagggat ttggggatt tcggcctatt 3900
ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa ttaattctgt ggaatgtgtg 3960
tcagttagggt tgtggaaagt ccccaggctc cccaggcagg cagaagtatg caaagcatgc 4020
atctcaatta gtcagcaacc aggtgtggaa agtccccagg ctccccagca ggcagaagta 4080
tgcaaagcat gcatctcaat tagtcagcaa ccatagtccc gccctaaact cgcgccatcc 4140
cgccctaac tccgcccagt tccgcccatt ctccgcccc tggctgacta atttttttta 4200
tttatgcaga ggccgaggcc gcctctgcct ctgagctatt ccagaagtag tgaggaggct 4260
tttttgagg cctaggcttt tgcaaaaagc tcccgggagc ttgtatatcc attttcggat 4320
ctgatcagca cgtgttgaca attaatcacc ggcatagtat atcggcatag tataatacga 4380
caagtgagg aactaaacca ttggccaagt gaccagtgc gttccgggtc tcaccgcgcg 4440
cgacgtcgcc ggagcggctc agttctggac cgaccggctc gggttctccc gggacttcgt 4500
ggaggacgac ttccgcccgtg tggctccggg cgacgtgacc ctgttcatca gcgcggteca 4560
ggaccagggt gtgcccggaca acaccctggc ctgggtgtgg gtgcccggcc tggacgagct 4620
gtacgcccag tggctggagg tegtgtccac gaacttccgg gacgcctccg ggcggccat 4680
gaccgagatc ggcgagcagc cgtgggggag ggagttcgcc ctgcccagac cggccggcaa 4740
ctgctgcac ttctgtggcc tatgaaaggt tgggcttcgg ctacgagatt tcgattccac 4800
cgccgcttc tatgaaaggt tgggcttcgg aatcgttttc cgggacgcgc gctggatgat 4860
ctccagcgc ggggatctga tegtggagtt cttcgccac cccaactgt ttattgcagc 4920
ttataatggt tacaaaataa gcaatagcat cacaaatttc acaaataaag catttttttc 4980
actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg tctgtatacc 5040
gtcgacctct agctagagct tggcgtaatc atggtcatag ctgtttctgt tgtgaaattg 5100
ttatccgctc acaattccac acaacatacg agccggaagc ataaagtga aagcctgggg 5160
tgctaataga gtgagctaac tcacattaat tgcgttgcgc tccactgccc ttctccagtc 5220
gggaaacctg tegtgcagc tgcattaatg aatcgcccaa cgccggggga gaggcgggtt 5280
gcgtattggg cgtcttccg cttoctcgt cactgactcg ctgcgctcgg tctgtccggct 5340
gcgcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcaggggg 5400
taacgcagga aagaacatgt gagcaaaaag ccagcaaaaag gccaggaacc gtaaaaaggc 5460
cgcttgcgt gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg 5520
ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg 5580
aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtocgcctt 5640
tctcccttcg ggaagcgtgg cgttttctca atgctcacgc tgtaggtatc tcagttcggg 5700
gtagttcgtt cgctccaagc tgggtgtgt gcacgaaccc cccgttcagc ccgaccgtg 5760
cgcttatcc ggtaactatc gtcttgagtc caaccgggta agacacgact tatcgccact 5820
ggcagcagcc actggtaaca ggattagcag agcgagggtg gtaggcgggt ctacagagtt 5880
cttgaagtgg tggcctaact acggtacac tagaaggaca gtatttggt tctgcgctct 5940
cgtgaagcca gttacctcg gaaaagagat tgtagctct tgatccggca aacaaaaccac 6000
cgctggttagc ggtggttttt ttgtttgcaa cgacagatt acgcgcgaaa aaaaaggatc 6060
tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaaag aaaaactcac 6120
ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaatta 6180


```

aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca 6240
atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 6300
ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtg 6360
tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 6420
agccggaagg gccgagcgca gaagtgggtcc tgcaacttta tccgcctcca tccagtctat 6480
taattgttgc cggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 6540
tgccattgct acaggcatcg tgggtgtcacg ctcgctcgtt ggtatggctt cattcagctc 6600
cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcgggttag 6660
ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 6720
tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 6780
tggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 6840
cccggcgctca atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 6900
tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 6960
gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc 7020
tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 7080
atgttgaaata ctcatactct tcctttttca atattattga agcatttata aggggttattg 7140
tctcatgagc ggatacatat ttgaatgtat ttgaaaaaat aaacaaatag ggggtccgcg 7200
cacatttccc cgaaaagtgc cacctgacgt c. 7231

```

<210> 43
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 43
 tgtcttgat ccaagatgaa gcgcgccgc cccagcgaag atgacttc 48

<210> 44
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 44
 aaacacggcg gccgctcttt cattcttg 28

<210> 45
 <211> 17
 <212> PRT
 <213> Ad 37 N-terminus

<400> 45
 Met Ser Lys Arg Leu Arb Val Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
 1 5 10 15

<210> 46
 <211> 6
 <212> PRT
 <213> artificial sequence

<400> 46
 Lys Arg Ala Arg Pro Ser
 1 5

<210> 47
 <211> 17

<212> PRT

<213> Ad5 modified N-terminus

<400> 47

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro Tyr
1 5 10 15

<210> 48

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 48

ggatccatgg gatacttggt agca

24

<210> 49

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 49

gcaactcgag tcattcttgg gcaatatagg

30

<210> 50

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 50

cgcgctgact cctaaggact agtttc

26

<210> 51

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 51

gcgcttaatt aacatcatca ataataacc ttatattt

37



100



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/083729 A3

(51) International Patent Classification: C12N 15/861,
A61K 48/00, A61P 27/02

(21) International Application Number: PCT/EP01/04863

(22) International Filing Date: 30 April 2001 (30.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/562,934 1 May 2000 (01.05.2000) US

(71) Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35,
CH-4056 Basel (CH). THE SCRIPPS RESEARCH IN-
STITUTE [US/US]; 10550 North Torrey Pines Road, La
Jolla, CA 92037 (US).

(71) Applicants and

(72) Inventors: NEMEROW, Glen, R. [US/US]; 462 Cerro
Street, Encinitas, CA 92024 (US). VON SEGGERN,
Daniel, J. [US/US]; Apartment 30, 5175 Luigi Terrace,
San Diego, CA 92122 (US). FRIEDLANDER, Marty
[US/US]; 1720 Zapo Street, Del Mar, CA 92014 (US).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate In-
tellectual Property, Patent & Trademark Dept., CH-4002
Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
19 September 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/083729 A3

(54) Title: VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY

(57) Abstract: Adenovirus vector-based gene therapy methods for treating ocular disorders are provided. Adenovirus vectors for therapy of ocular diseases and methods of treatment using the vectors are provided. Compositions, kits, and methods of preparation and use of the vectors for gene therapy are provided.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/04863

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/861 A61K48/00 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, BIOSIS, MEDLINE, EMBASE, SCISEARCH, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BENNETT J. (REPRINT) ET AL: "Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse" GENE THERAPY, (SEP 1998) VOL. 5, NO. 9, PP. 1156-1164. PUBLISHER: STOCKTON PRESS, HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND. ISSN: 0969-7128., XP001064828 UNIV PENN, DEPT OPHTHALMOL, SCHEIE EYE INST, FM KIRBY CTR, SCH MED, 310 STELLAR CHANCE LABS, PHILADELPHIA, PA 19104 (Reprint) page 1156 abstract page 1157, left-hand column, paragraph 1 page 1158; figure 2 page 1159, right-hand column, paragraph 2 page 1160; figure 6 -/-	1-7
Y		8-33



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

11 April 2002

Date of mailing of the international search report

15/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/04863

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 48027 A (UNIV FLORIDA) 29 October 1998 (1998-10-29) page 2, line 22 -page 3, line 5 page 3, line 33 -page 4, line 33	1
A	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TSUBOTA, KAZUO ET AL: "Adenovirus-mediated gene transfer to the ocular surface epithelium" retrieved from STN Database accession no. 130:177282 HCA XP002195798 abstract & EXP. EYE RES. (1998), 67(5), 531-538 ,	8
A	ABRAHAM N G ET AL: "Adenovirus-mediated heme oxygebase-1 gene transfer into rabbit ocular tissues" INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 36, no. 11, 1 October 1995 (1995-10-01), pages 2202-2210, XP002086227 ISSN: 0146-0404 page 2203, right-hand column, paragraph 3 -page 2204, left-hand column, paragraph 2 page 2204, left-hand column, paragraph 4 -right-hand column, paragraph 1 page 2206, right-hand column, paragraph 2 -page 2207, right-hand column, paragraph 2	8
A	WO 96 13276 A (GENENTECH INC) 9 May 1996 (1996-05-09) page 6, line 2 -page 18, line 6	8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 01/04863

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 10-33 (all partially, insofar as they concern in vivo methods) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
information on patent family members

International Application No

PCT/EP 01/04863

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9526409	A	05-10-1995	FR 2718150 A1	06-10-1995
			AU 2142595 A	17-10-1995
			CA 2184755 A1	05-10-1995
			EP 0753067 A1	15-01-1997
			WO 9526409 A1	05-10-1995
			JP 9510621 T	28-10-1997
			ZA 9502563 A	21-12-1995
WO 9822609	A	28-05-1998	US 5877011 A	02-03-1999
			AU 732220 B2	12-04-2001
			AU 5455298 A	10-06-1998
			EP 0946742 A1	06-10-1999
			JP 2001505054 T	17-04-2001
			WO 9822609 A1	28-05-1998
WO 9848027	A	29-10-1998	AU 735788 B2	12-07-2001
			AU 7140698 A	13-11-1998
			AU 7467598 A	13-11-1998
			BR 9808606 A	23-05-2000
			EP 0977841 A2	09-02-2000
			EP 0977880 A2	09-02-2000
			JP 2001523959 T	27-11-2001
			JP 2001527399 T	25-12-2001
			US 6225291 B1	01-05-2001
			WO 9848009 A2	29-10-1998
WO 9613276	A	09-05-1996	US 5827702 A	27-10-1998
			CA 2203374 A1	09-05-1996
			EP 0789592 A1	20-08-1997
			JP 10508025 T	04-08-1998
			US 6204251 B1	20-03-2001
			WO 9613276 A1	09-05-1996

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/04863

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>page 1161, right-hand column, paragraph 3 -page 1162, left-hand column, paragraph 1 page 1162, left-hand column, paragraph 4 -page 1162, right-hand column, paragraph 2</p> <p>---</p>	
X	<p>WO 95 26409 A (ABITBOL MARC ;MALLET JACQUES (FR); REVAH FREDERIC (FR); ROUSTAN PA) 5 October 1995 (1995-10-05) page 1, line 3 - line 7 page 4, line 26 -page 5, line 26 page 6, line 1 - line 23 page 10, line 10 - line 19 claims 1,11-24</p> <p>---</p>	1-7
Y	<p>HUANG SHUANG ET AL: "A single amino acid in the adenovirus type 37 fiber confers binding to human conjunctival cells" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 4, April 1999 (1999-04), pages 2798-2802, XP002139782 ISSN: 0022-538X the whole document</p> <p>---</p>	8-33
A	<p>ARNBERG NIKLAS ET AL: "Fiber genes of adenoviruses with tropism for the eye and the genital tract" VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 227, no. 1, 1997, pages 239-244, XP002139781 ISSN: 0042-6822 page 239 abstract page 242; figure 2 page 244, left-hand column</p> <p>---</p>	
A	<p>WO 98 22609 A (ARMENTANO DONNA E ;GREGORY RICHARD J (US); GENZYME CORP (US); SMIT) 28 May 1998 (1998-05-28) page 6, line 16 -page 7, line 28</p> <p>---</p>	
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994 GOURAS PETER ET AL: "Reporter gene expression in cones in transgenic mice carrying bovine rhodopsin promoter/lacZ transgenes." Database accession no. PREV199598013526 XP002195797 abstract & VISUAL NEUROSCIENCE, vol. 11, no. 6, 1994, pages 1227-1231, ISSN: 0952-5238</p> <p>---</p>	1
	<p>---</p> <p>-/--</p>	